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1. LIST OF ABBREVIATIONS 
aBMD areal Bone Mineral Density 
AD Autosomal dominant 
ADL Activity of daily living 
AMI Acute myocardial infarction 
AR Autosomal recessive 
BMD Bone mineral density 
BMP1 Bone morphogenetic protein 1 
BV Bone volume 
CI Confidence interval 
COL1A1 Collagen type 1 alpha 1 
COL1A2 Collagen type 1 alpha 2 
COPD Chronic obstructive pulmonary disease 
CPR Danish Civil Registration Register 
CREB3L1 cAMP responsive element binding protein 3 like 1 
CRTAP Cartilage associated protein 
CSA Cross-sectional area 
CT Computed tomography 
DI Dentinogenesis imperfecta 
DNA Deoxyribonucleic acid 
DNPR Danish National Prescription Register 
DXA Dual energy x-ray absorptiometry 
ECG Electrocardiogram 
EDR Excess death rate 
EF Ejection fraction 
FEV1 Forced expiratory volume in 1 second 
FEV1/FVC 
Ratio of Forced expiratory volume in 1 second to Forced vital ca-
pacity 
FKBP10 FK506 binding protein 10  
FVC Forced vital capacity 
HA Hydroxylapatite 
HRQoL Health-related quality of life 
HR Hazard ratio 
HRpQCT High-resolution peripheral quantitative computed tomography 
ICD-X 
 
World Health Organisation International Classification of Disease 
Version X 
IFITM5 Interferon induced transmembrane protein 5 
IQR Interquartile range 
IRR Incidence rate ratio 
LEPRE1 leucine proline-enriched proteoglycan 
LX Lumbar vertebral number X 
MBTPS2 Membarne bound transcription factor peptidase, site 2 
MR Mortality ratio 
NPR Danish National Patient Register 
NSAID Non-steroidal anti-inflammatory drugs 
NYHA New York Heart Association Functional Classification 
OI Osteogenesis imperfecta 
OR Odds ratio 
P3H1 Prolyl 3-hydroxylase 1 
pCO2 Carbon dioxide tension 
PLOD2 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
PLS3 Plastin 3 
pO2 Oxygen tension 
PPIB Peptidylprolyl isomerase B 
pQCT Peripheral quantitative computed tomography 
PTH Parathyroid hormone 
RANKL Receptor activator of nuclear factor kappa-B ligand 
RCT Randomised controlled trial 
SD Standard deviation 
SERPINF1 Serpin family F member 1 
SERPINH1 Serpin family H member 1 
SHR Sub-hazard ratio 
SP7 Sp7 transcription factor  
SpO2 Oxygen saturation, as measured by pulse oximetry 
Tb.1/N.SD Standard deviation of (1/trabecular number) 
Tb.N Trabecular number 
Tb.Sp Trabecular spacing 
Tb.Th Trabecular thickness 
ThX Thoracic vertebra number X 
TLC Total lung capacity 
TMEM38B Transmembrane protein 38B 
TV Tissue volume 
VO2max Maximal oxygen uptage 
vBMD Volumetric bone mineral density 
VO2peak The plateau of oxygen uptake 
WHO World Health Organization 
WNT1 Wnt family member 1 
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2. Background 
2.1 PREVALENCE AND INCIDENCE OF OI 
Osteogenesis imperfecta (OI), or brittle bone disease, is a pheno-
typically heterogeneous, rare connective tissue disorder that af-
fects 10.6 per 100,000 persons in Denmark (5). Patients with OI 
usually present with blue sclera, varying degree of bone deformi-
ties, and frequent fractures. OI is most often due to dominantly 
inherited variants to the COL1A1 and COL1A2 genes (6). The dis-
ease may be classified according to Sillence’s classification into 
four groups: type I (clinical severity: mild), type II (lethal), type III 
(severe) and type IV (moderate) (7). The clinical heterogeneity is 
illustrated in Figure 1. During the recent decades several recessive 
forms, X-linked forms, and an autosomal dominant form of OI due 
to mutations in a non-collagen gene have been reported (8). 
These newly discovered forms of OI follow the same nomencla-
ture and are called OI type V-XVI (moderate to severe) (9).  
 
 
Figure 1. Clinical heterogeneity of OI Shows whole-body DXA scan 
pictures of patients with different subtypes of OI illustrating the 
clinical heterogeneity of OI. Inspired by Reeder and Orwoll (10).  
 
Based on data on all newborn (live births and stillbirths after the 
28th week of gestation) in the Danish county of Funen from 1970 
to 1984, Andersen and Hauge (5) estimated the incidence of OI to 
be 21.8 per 100,000. In a Brazilian population over the same time 
period, the incidence of OI was estimated to be 4.3 per 100,000 
births (11). This is in line with other authors from the US and Fin-
land, where the prevalence of OI is reported as 4.0-6.7 per 
100,000 births (9, 12, 13). Andersen et al. (14) used a chart review 
of orthopaedic-, paediatric- and obstetric- patient charts to iden-
tify all patients with OI born during the period of observations, 
the authors furthermore evaluated all radiograph-diagnosis to 
identify patients with typical OI findings on the radiographs. Clini-
cal information was then sought on every identified patient (14). 
The higher incidence found in Denmark could be due to the au-
thors included information on all births on Funen, which had not 
previously been done (14). Lastly the increased incidence found 
by Andersen et al. (14) could be due to a high geographical con-
centration of families with many children.  Based on all patients 
registered with an OI diagnosis in the Danish National Patient 
Register (NPR) from 1977 to 2013, we have estimated the inci-
dence of OI in Denmark to be 15 [range 5-24] per 100,000 births 
(1) (Figure 2).  According to our data, the population prevalence 
of OI in Denmark was 10.3 per 100,000, with 575 patients regis-
tered with an OI diagnosis in the NPR and alive at the end of 2012 
and a total population of 5,602,628 persons at the end of 2012 (1, 
15). 
 
 
Figure 2. Incidence of OI in Denmark The figure shows the inci-
dence of patients with OI born in Denmark from 1977-2013 per 
100,000 births.  These numbers will be influenced by the time to 
diagnosis, which may well vary in OI. The full line indicates the trend 
in incidence over time. Using a linear regression model, this trend 
was not significant (β-coefficient 0.17 [95% CI: -0.66-1.01], 
p=0.674). We used data supplied from Statistics Denmark, Division 
of Research, as described in detail in the attached publications, Pa-
per I (1), II (2), and IV and in Chapter 8.1 of this thesis.  
 
In 1983 the population prevalence was estimated at 10.6 per 
100,000 inhabitants (48 patients in a population of 453,921 per-
sons) and about 85% of patients had non-lethal forms of OI (5). As 
a result of early prenatal diagnostics (and pregnancy termination 
leading to fewer cases) the non-lethal forms of OI now constitute 
more than 95% of children born with OI in the US (16).  
2.2 DIAGNOSIS AND CLINICAL PRESENTATION OF OI 
Figure 3 shows the time from birth until an OI diagnosis is regis-
tered in the Danish National Patient Register (NPR) for patients 
born in Denmark since 1977. The median time to diagnosis from 
birth was 2.8 (range 0-33) years. 
 
 
Figure 3. The diagnostic delay from birth of the OI diagnosis The 
figure shows the time to diagnosis in patients registered with OI in 
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the NPR, born after 1977. Due to low numbers of individuals diag-
nosed over the age of 16, we have grouped these together to en-
sure sufficient patient confidentiality. The median time from birth 
to first registration in the NPR (indicating the time of diagnosis) was 
2.8 years (interquartile range, IQR: 0.5-10.7 years), and 90% of all 
patients with OI were diagnosed by 16.6 years of age. We 
acknowledge that some patients may not yet have been diagnosed 
with OI, but more than half of the patients born after 2009 will have 
been diagnosed prior to the end of 2012 (the latest available up-
dated version of the NPR at the time of data extraction i.e. 27th July 
2014), and more than a quarter of the patients born in January 
2012 will have been diagnosed at the time of data extraction from 
the NPR. The Y-axis shows the total number of patients (N), and the 
X-axis shows the age at OI diagnosis for each individual. The dashed 
lines show the 25% and 75% IQR, the median and the 90% percen-
tile.    
2.1.2 Diagnosis and care of patients with OI 
Molecular tests, such as analysis of the structure and quantity of 
type I collagen synthesised in vitro by cultured dermal fibroblasts 
or DNA sequence analysis, can give valuable information about 
phenotype and clinical severity and even provide the diagnosis in 
most cases (12, 16, 17). Abnormalities in type 1 collagen are found 
in 98% of individuals with type II OI, about 90% of patients with 
type I OI, and 84% of patients with type III and IV when analysing 
cultured dermal fibroblasts (18). The best practice guidelines for 
the laboratory diagnosis of OI published in 2012 by the European 
Molecular Genetics Quality Network working group (16) state that 
patients with suspected OI should have sequence analysis and 
quantitative analysis of COL1A1 and COL1A2 genes on genomic 
DNA (16). Such genetic testing will identify over 90% of correctly 
diagnosed patients with COL1A1 and COL1A2 disease-causing gene 
variants (16). If no causative variants in the COL1A1 or COL1A2 
genes are found, the working group recommends a new clinical as-
sessment to re-evaluate the clinical OI diagnosis 16. If the diagnosis 
is upheld, the working group then recommends sequencing of all 
known recessive genes that cause OI (16).  
 
The diagnosis of OI is, however, often based on clinical traits such 
as blue sclera, family history, and frequent fractures resulting from 
little or no precipitating trauma.  
 
The spectrum of disease severity varies between OI centres due to 
different indications for hospital follow-up and varying population 
case mix. The diagnosis of specific OI types is somewhat subjective 
and can depend on the amount of available clinical information 
and the patient age as the diagnosis of OI type VI requires histolog-
ical analysis of bone tissue, and hyperplastic callus diagnostic for 
OI type V may not be present in children (19). 
 
Care of adult patients with OI in Denmark is centred in four highly 
specialised centres (Aarhus University Hospital, Odense University 
Hospital, Copenhagen University Hospital in Hvidovre, and 
Rigshospitalet). Care of paediatric patients with OI is centred in two 
highly specialised units for rare diseases at Aarhus University Hos-
pital and Rigshospitalet. There may be differences in how patients 
are diagnosed with OI at these centres, but the diagnosis is often 
made clinically and supported by either collagen analysis and/or 
DNA tests.  
 
2.2.2 Clinical phenotypes and genetic variants 
Mutations causing haplotype insufficiency more often resulted in 
a quantitative collagen type 1 deficiency than did helical mutations 
arising from missense mutations that resulted in qualitative colla-
gen type 1 defects (20). Collagen type 1 is a heterotrimer that con-
tains two α1-chains and one α2-chain. Procollagen undergoes a va-
riety of post-translation modification and folding processes, closely 
regulated by key proteins that facilitate the folding and chaperone 
the procollagen molecules into the collagen fibrils (12). Mutations 
to any of the genes involved in this process may cause specific 
forms of OI. The clinical phenotypes and genetic variants of the dif-
ferent types of OI are described in Table 1. The OI subtypes can be 
grouped into five clinical syndromes, based on the patient’s clinical 
features irrespective of the genotype (6). 
 
Sillence 
type 
Mode of in-
heritance 
Associated 
gene 
Effect on collagen OI syndrome name Clinical Seve-
rity 
I AD COL1A1 / 
COL1A2 
Defects in collagen syn-
thesis, structure or pro-
cessing 
Non-deforming OI 
with blue sclera 
Mild 
II AD COL1A1 / 
COL1A2 
Defects in collagen syn-
thesis, structure or pro-
cessing 
Perinatally lethal Lethal 
III AD COL1A1 / 
COL1A2 
Defects in collagen syn-
thesis, structure or pro-
cessing 
Progressively defor-
ming 
Severe 
IV AD COL1A1 / 
COL1A2 
Defects in collagen syn-
thesis, structure or pro-
cessing 
Common variable OI 
with normal sclera 
Moderate 
V AD IFITM5 Defects in bone minerali-
sation 
OI with calcification 
in intraosseous mem-
branes 
Moderate 
VI AR SERPINF1 Defects in bone minerali-
sation 
Progressively defor-
ming 
Severe 
VII AR CRTAP Defects in collagen modi-
fication 
Common variable OI 
with normal sclera 
Moderate 
VIII AR LEPRE1/P3H1 Defects in collagen modi-
fication 
Perinatally lethal Lethal 
IX AR PPIB Defects in collagen modi-
fication 
Common variable OI 
with normal sclera 
Moderate 
X AR SERPINH1 Defects in collagen fold-
ing and cross-linkage 
Progressively defor-
ming 
Severe 
XI AR FKBP10 Defects in collagen fold-
ing and cross-linkage 
Progressively defor-
ming 
Severe 
XII AR SP7 Defects in osteoblast de-
velopment with collagen 
insufficiency 
Common variable OI 
with normal sclera 
Moderate 
XIII AR BMP1 Defects in collagen syn-
thesis, structure or pro-
cessing 
Progressively defor-
ming 
Severe 
XIV AR TMEM38B Defects in collagen modi-
fication 
Progressively defor-
ming 
Severe 
XV AR WNT1 Defects in osteoblast de-
velopment with collagen 
insufficiency 
Progressively defor-
ming 
Severe 
XVI AR CREB3L1 Defects in osteoblast de-
velopment with collagen 
insufficiency 
Progressively defor-
ming 
Severe 
Bruck 
Syn-
drome 
 
AR PLOD2 Defects in collagen fold-
ing and cross-linkage 
Progressively defor-
ming 
OI with con-
tractions of 
large joints 
X-linked X-Linked PLS3/MBTPS2 
(21) 
No known collagen ef-
fect. 
- 
PLS3 may be involved in 
mechanosensing of oste-
ocytes 
Common variable OI 
with normal sclera 
Moderate 
The table shows the OI type using Sillence’s Classification (originally 
1979, updated 2014), the mode of inheritance, the affected genes, 
the clinical phenotype characteristics and the clinical syndromes of 
OI. AD, Autosomal dominant, AR, Autosomal recessive. Adapted 
from Forlino and Marini (2015) (9) (12)and van Dijk and Sillence 
(2014) (6). 
 
The non-deforming OI with blue sclera, or Sillence OI type I, is re-
garded as the mildest phenotype of OI (18). It is the most common 
form and accounted for 71% of OI cases on Funen in 1983 (5). The 
patients have relatively low fracture rates and few severe bone de-
formities. The bone deformities rarely progress over time.  
 
Common variable OI with normal sclera is a moderately severe 
phenotype and comprises the autosomal dominant OI type IV, the 
autosomal recessive forms VII, IX, and XII as well as the X-linked 
PLS3-mutated form of OI (6). The patients will have recurrent frac-
tures and variable degrees of deformity of long bones and spine 
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(6). Thirty per cent of OI type IV patients will have basilar impres-
sion (22). OI type IV accounted for 6% of all OI cases on Funen in 
1983 (5). No data are available on the distribution of the recessive 
forms of OI in Denmark, but the recessive and X-linked forms of OI 
account for less than 10% of all OI cases.  
 
OI with calcification in the interosseous membranes (OI type V) is a 
moderate to severe phenotype with an autosomal dominant pat-
tern of inheritance and white sclera. The most pronounced fea-
tures are hyperplastic callus, progressive calcification of the inter-
osseous membranes and coarse mesh-like lamellation of bone in 
bone biopsies (6, 12).  
 
The progressively deforming OI subgroup comprises the autosomal 
dominant type III OI that accounted for 12% of all cases of OI on 
Funen in 1983 (5) and the recessive forms OI type VI-VIII, IX-XI, XIII-
XVI, and Bruck Syndrome (OI with joint contractions) (6). Patients 
are born with multiple fractures and will continue to suffer frac-
tures, thus developing progressive bone deformities and severe 
length growth retardation (6). Most patients become immobile 
and wheelchair-bound.  
 
The perinatal lethal OI subtypes comprise OI type II that accounted 
for 12% of all identified cases on Funen in 1983 (5). Perinatal lethal 
forms of the autosomal recessive forms OI type VII, VIII and IX have 
also been reported (12).  
 
In a Canadian study including 598 patients (from 487 families) who 
were clinically diagnosed with either mild OI (OI type I) or moder-
ate to severe OI (OI type III, IV, V, VI, VII or Cole Carpenter Syn-
drome), a disease-causing gene variant could be found in 585 pa-
tients (98%) (19). In the mild OI group, 86% had mutations to the 
COL1A1 gene, 11% had mutations to the COL1A2 gene, and no mu-
tations could be found in 3% of patients (19). In the moderate to 
severe OI group, 39% had mutations to the COL1A1 gene, 38% had 
mutations to the COL1A2 gene, and 12% had mutations to reces-
sive OI genes (of which mutations to SERPINF1 (4%) and CRTAP 
(2.9%) were the most common) (19). Moderate to severe pheno-
types of OI can thus more often be associated with other mutations 
than COL1A1 and COL1A2, possibly as much as 20% of all cases, at 
least in the children followed through the Shriners Hospital for Chil-
dren in Montreal.  
 
In a Danish cross-sectional study of 85 patients with OI, including 
58 patients clinically diagnosed with OI type I, 12 patients clinically 
diagnosed with OI type III and 15 patients clinically diagnosed with 
OI type IV, identified 68 OI causing mutations (20). In 4 patients no 
mutations to either COL1A1, COL1A2 or 11 other genes associated 
with OI (20). The mutations causing OI type I were more often lo-
cated to COL1A1 than COL1A2 (46 out of 55 mutations) (20). In 
both patients with OI type III and OI type IV the mutations were 
evenly distributed across the two genes (20). 
2.2.3 Skeletal manifestations and fractures in OI 
Skeletal fragility is a hallmark of OI and results in frequent frac-
tures. Moreover, many patients have bowing deformities of the 
long bones and, depending on clinical severity, have growth defi-
ciency (12). In a study of 95 adults with OI types I, III and IV, 47% 
had upper extremity deformities, 63% had lower extremity de-
formities, and 21% had upper and lower extremity deformities, 
scoliosis and/or kyphosis (23). Other skeletal features depend on 
both age and clinical severity and include macrocephaly, flat mid-
face and triangular facies, basilar impression, and chest-wall de-
formities such as pectus excavatum, pectus carinatum, or barrel 
chest (12). Regardless of clinical phenotype, the incidence of scoli-
osis has been reported as 39-80% (24, 25). Wormian bones (intra 
sutural bone) are common in OI, and approximately 35% of pa-
tients with OI type I, 78% of patients with OI type IV, and 96% of 
patients with OI type III present with wormian bones (26).  
2.2.4 Non-skeletal manifestations of OI 
Protein account for 20% of the human body mass, 30% of the pro-
teins found in the human body is collagen and 90% of all collagen 
is collagen type 1 (27). The skeleton accounts for 14% of the total 
body weight. In the bone 10-30% is organic material, and of this 
90-95% is collagen and mostly collagen type 1 – however less then 
20% of the total body collagen type 1 is found in the bone tissue. 
 
Among 88 patients with OI, 26% had dentinogenesis imperfecta 
(DI) where the teeth are yellow and appear transparent, and be-
come prone to increased wear and breakage (28).  
 
Pre-senile hearing loss due to otosclerosis is frequently reported in 
OI (29). In a Danish study comprising 173 patients with OI, 50% had 
hearing loss with 3% anacusis, 8% sensorineural, 12% conductive, 
and 27% mixed causes of hearing loss (29). Thirty-two (19%) of the 
patients had undergone stapedectomy due to otosclerosis, with 
excessive growth of the bones of the middle ear, or fractures and 
callus formation to the bones of the inner ear (18, 29).  
 
The central corneal thickness has been found to be decreased in 
children with OI aged 10.1±2.5 years of age, compared with 15 
healthy age- and gender-matched controls (30). Similarly, Hald et 
al. showed that corneal thickness is lower than expected in adult 
patients with OI, and most profoundly in patients with type I OI 
(31). Also, OI is associated with low ocular rigidity (32). Finally, OI 
may be associated with open angle glaucoma may also be (32). 
 
In a Finnish retrospective patient-record study of 47 patients with 
OI (64% type I, 21% type IV or VI, and 15% type III) aged 1-19 years, 
70% of patients had joint hypermobility (33). Adults with OI often 
report hypermobility, but the prevalence and severity are un-
known.  
 
Two-thirds of patients with OI report easy bruising (34). Studies of 
thrombocyte aggregations have shown abnormal platelet func-
tions (34, 35). Exposed collagen from the blood vessel wall after 
vessel damage will normally attract platelets and further platelet 
aggregation. It has been speculated that the defective collagen 
seen in OI can result in defects in the platelet plug formation, caus-
ing increased bleeding time and bruising (36). Further research, ho-
wever, is needed to elucidate this.  
2.2.5 Cardiovascular manifestations in of OI 
Collagen type 1 is an important constituent of various parts of the 
cardiovascular system, including the heart valves, chordae 
tendineae, fibrous rings of the heart, interventricular septum, 
aorta, and most other arteries (37, 38). In two murine models 
(Aga2-mouse and OIM-mouse), the mutations introduced to the 
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COL1A1 or COL1A2 genes have caused the homozygote mice to 
present skeletal, cardiovascular, and pulmonary phenotypes (39-
41). There seems to be increased prevalence of cardiovascular dis-
ease in OI, but the literature is mostly cross-sectional studies or 
case series and case reports (42).  
2.2.6 Causes of Death and life expectancy in OI 
Prior to the studies comprised in this PhD thesis, little was known 
about the life expectancy and causes of death in patients with OI. 
One study have shown that in patients with more severe pheno-
types the main cause of death was due to respiratory tract infec-
tions (43).  
2.3 CURRENT TREATMENT OPTIONS IN OI 
Treatment of OI focuses on three elements: prevention of frac-
tures, correction of bone deformities, and treatment of other com-
plications such as hearing loss, dental problems, and pain manage-
ment.  
2.3.1 Prevention of fractures 
Many different drugs, such as e.g. calcitonin (44), fluoride (45) and 
strontium ranelate (8), aimed at preventing fractures in osteopo-
rosis have been tested for fracture prophylaxis in patients with OI 
without success. Since the late 1990s, patients with OI have fre-
quently been treated with bisphosphonates (8). This may lower the 
risk of fracture although the effect has been questioned (46, 47). 
Where most of the treatment trials report positive effects on BMD, 
it must be kept in mind that these effects do not automatically 
translate into a reduced fracture risk.  
 
In the latest Cochrane review of bisphosphonate treatment in pa-
tients with OI, twelve trials enrolled 709 children, and two trials 
enrolled 110 adults (47). All trials assessing BMD reported statisti-
cally significant increases with oral or iv bisphosphonates (47). In 
six of the trials evaluating the effect of oral bisphosphonates com-
pared to placebo there was no difference in the number of patients 
that reported at least one fracture during follow-up, but the frac-
ture rates and risks were lower in the bisphosphonate treated 
groups at 1 and 2 years of intervention (47). The three studies that 
evaluated the effects of iv bisphosphonates versus placebo could 
not detect any effects on the number of patients suffering a frac-
ture nor the fracture rates or fracture risk between the treated and 
non-treated participants (47).    
 
A recent systematic review that included six randomised controlled 
trials (RCTs) evaluating the effect of bisphosphonates compared 
with placebo in patients with OI included a meta-analysis of the 
fracture prevention of bisphosphonates in OI (46). The study re-
ported a trend towards a reduction in fracture rates in bisphospho-
nate-treated patients (risk ratio = 0.79 [95% CI: 0.62-1.01], p=0.07, 
I2=0%) (46). Similarly, bisphosphonates tended to reduce the pro-
portion of patients who experienced fractures (risk ratio = 0.84 
[95% CI: 0.69-1.01], p= 0.06, I2=0%) (46).  
 
In our study (Paper II) we had no data on bisphosphonate use in 
the patients with OI, but we saw no period effect when we entered 
calendar year into our Poisson model, as would be expected had 
the prognosis of fractures suddenly improved with the more wide-
spread prophylactic use of bisphosphonates in the late 1990s. In 
the Norwegian study of 97 adults with OI, there was no significant 
difference in the number of reported fractures between bisphos-
phonate users and non-users (48). In the Canadian study of 86 chil-
dren with OI type I, 48 children were not treated with bisphospho-
nates at the study start, but 25 of these patients subsequently 
started on intravenous bisphosphonates, and the average number 
of annual fractures decreased from 0.77 per patient to 0.44 frac-
tures per patient (49). This reduction in fracture rate was, however, 
non-significant (p=0.2) (49). The effect of bisphosphonates as frac-
ture prevention in patients with OI is questionable.     
 
A single RCT, including adult patients with type I, III or IV OI, has 
tested the effect of teriparatide (biosynthetic human parathyroid 
hormone 1-34) versus placebo on fracture risk and BMD (50). The 
study showed significant BMD increase in both hip and spine in all 
phenotypes, but the largest effect was seen in the milder pheno-
type (50). There was no effect on self-reported fracture rates be-
tween the treated patients and placebo group (50).  
 
A Danish investigator-initiated clinical trial is currently ongoing, 
and patients are being recruited to the study. The TREAT-OI study 
is a double-blinded placebo controlled RCT testing the effect of 
treatment with teriparatide (PTH) and zoledronic acid in adult pa-
tients with OI (51). One-third of the patients will have zoledronic 
acid and placebo PTH injections for two years, followed by one year 
of zoledronic acid; one-third will have PTH and placebo zoledronic 
acid injections for two years, followed by one year of zoledronic 
acid; and one-third will have placebo PTH and placebo zoledronic 
acid injections for three years. The study will evaluate changes in 
bone mass, bone geometry, and bone microarchitecture using 
DXA, HRpQCT, and in a subset of patients transiliac bone biopsies. 
Other studies evaluating the effects on fracture risk and fracture 
rates of PTH injections followed by zoledronic acid compared to 
standard care are currently being planned. One study with adult 
UK patients will be the first with sufficient power to evaluate 
whether combined PTH and zoledronic acid can prevent fractures 
in OI.  
 
Denosumab, a RANKL antibody, resulted in a significant increase in 
BMD after 48 weeks of treatment in a single-arm safety trial includ-
ing 10 children with OI (52). Data on long-term follow-up, treat-
ment in adults, or fracture prevention are not currently available. 
According to ClinicalTrials.gov, there are no current studies on 
denosumab in OI (August 2016).  
 
Preclinical studies in the Brtl/+ mouse, a murine model for OI, have 
tested sclerostin antibody treatment and showed increased corti-
cal bone formation, long bone mass, and long bone strength with-
out increasing the brittleness in growing mice (53). Romosozumab, 
a monoclonal antibody that binds sclerostin, has a dual effect on 
bone by increasing bone formation and reducing bone resorption 
and thus has favorable effects in both aspects of bone volume reg-
ulation in patients with osteoporosis, and have been tested in 
phase II trials and are currently undergoing phase III investigation 
as a fracture preventing drug for the treatment of osteoporosis 
(54). Preparations are underway for a industry-initiated, interna-
tional, multicentre double-blinded RCT using recombinant human-
ised monoclonal antibody against human sclerostin in patients 
with OI type I, III or IV. 
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2.3.2 Surgical treatment  
Non-surgical fracture management is generally preferred in OI, but 
is not always appropriate. The main reasons for choosing surgical 
treatment are to treat fractures, to prevent fractures and to cor-
rect bone deformities. When surgery is considered, the risk of non-
union and the need for subsequent revision procedures must be 
kept in mind (55). Furthermore, anaesthesia and peri-operative 
management can be challenging in patients with OI. Careful posi-
tioning is needed to avoid fractures, and airway management may 
be difficult as overextension of the cervical spine can lead to 
odonto-axial dislocation or fractures. Bleeding and bruising 
tendencies are also well described in OI, and clotting abnormalities 
usually exist at the stage of platelet plug formation and may cause 
excessive bleeding during surgery. Lastly, patients with OI have in-
creased risk of metabolic acidosis, hypercapnia, muscle rigidity, 
and progressively increasing body temperature during anaesthesia 
(36). The cause of the “malignant hyperthermia-like” syndrome 
seen in some patients with OI during anaesthesia may be due to 
other mechanisms than those seen in inherited malignant hyper-
thermia (56). In a single-centre chart-review study from Italy, Chi-
arello et al. (57) had treated 29 patients with OI with a reported 
mean age of 8.0±8.3 [sic!] years. Of the 245 procedures performed, 
166 were for 110 fractures, and 79 were for correction of deformity 
(57). Common surgical complications regarding fracture care were 
non-union or delayed union (11.4%), malunion (5.7%), and implant 
loosening (6.1%) (57). Surgically implanted intramedullary rodding 
of the lower limb long bones have been shown to improve function 
and ambulation in children with OI (58, 59). The correction of fore-
arm deformities with rodding has also improved functional ability 
in children with OI evaluated by the Pediatric Evaluation of Disabil-
ity Inventory (60). Telescopic rods are often used in pediatric pa-
tients allowing for vertical height gain, but non-telescoping rods 
have been used with success. In a Danish trial including 9 children, 
who underwent a total of 16 surgical procedures with intra medul-
lar rods, the stabilisation of deformities in the lower extremities 
decreased the rate of fractures and allowed most formerly non-
ambulatory patients to walk (61).  
2.3.3 Pain management in OI 
In children, bisphosphonate treatment has increased the lumbar 
spine BMD and improved vertebral height (8, 62). It has been 
claimed that bisphosphonate treatment could reduce bone pain. A 
systematic review by Rijks et al. (63) identified five studies where 
evaluation of bone pain was an outcome. In one of these, bone 
pain improved significantly with bisphosphonate therapy (63). In 
another study, bone pain was significantly less after 24 months of 
treatment compared to baseline, but the same change was seen in 
the placebo group. This was not reproduced in the other studies 
included in the review (63). There is little evidence to support the 
claim that bisphosphonate treatment will reduce bone pain in all 
patients with OI, but it may have an effect in some patients.  
 
Non-pharmacological treatment in OI often includes physiotherapy 
and occupational therapy and aims at reducing pain and improving 
ambulation. A Dutch study evaluating the effect of training and 
physical therapy on fatigue and health-related quality of life 
(HRQoL) included 34 (22 girls) children with type I or IV OI, who 
were randomised to either 30 sessions of 45 minutes exercise or 
no intervention over a period of 12 weeks (64). The study used the 
subscale “subjective fatigue” of the self-reported Checklist Individ-
ual Strength-20 questionnaire and assessed HRQoL using the Child 
Health Questionnaire Parent-Form 50 (64). After 12 weeks of su-
pervised training, subjective levels of fatigue were reduced, but no 
effect was seen on HRQoL (64). 
2.4 GAPS IN CURRENT KNOWLEDGE REGARDING OI 
While the bone phenotypes and genotypes in OI are well de-
scribed and fast evolving, less is known about other aspects of the 
disease that may be associated with the quantitative or qualita-
tive defect of collagen type 1 seen in OI. Only a very few studies 
have focused on life expectancy and causes of death in patients 
with OI and population based studies are lacking. Causes of death 
can be viewed as a pseudo-marker of the burden of disease dur-
ing life. We need more knowledge about which diseases are asso-
ciated with OI, and how the burden of these diseases may influ-
ence patients’ quality of life and longevity. The important role of 
collagen type 1 plays in the function and structure of the heart 
makes it biologically plausible that patients with OI will have in-
creased risk of cardiovascular diseases. It is difficult to draw any 
conclusions on causality from cross-sectional studies but a longi-
tudinal population based study with statistical power to correct 
for confounders for cardiovascular diseases could elaborate on 
the relationship between OI and the risk of cardiovascular dis-
eases. Where the increased fracture rates seen in patients are 
well described, and are close to a diagnostic criterion of the dis-
ease, less is known about the exact differences in fracture rates 
between patients with OI and the general population. Further-
more, little is known about the changes in the fracture rates over 
time. Whole-bone strength depends on the amount of bone, the 
spatial distribution of the bone mass (geometry), microarchitec-
ture of the bone, and the intrinsic properties of the materials that 
form the bone (65). HRpQCT is designed for in vivo assessment of 
volumetric bone mineral density, bone geometry, and bone mi-
croarchitecture at the distal radius and tibia. At the time of the 
planning of this thesis no other studies were available using 
HRpQCT in the evaluation of patients with OI. 
3. HYPOTHESIS, STUDY OBJECTIVES AND SEARCH STRATEGIES 
3.1 HYPOTHESES 
Figure 4 summarises the main hypotheses of this thesis. 
 
We hypothesise that OI will, through different mechanisms, influ-
ence the risk of death in patients with OI and will result in a short-
ened lifespan compared to the general population.  
Studies have shown excess death in relation to osteoporotic frac-
tures, for both major osteoporotic fractures such as hip and verte-
bral fractures but also for non-hip and non-vertebral fractures (66). 
We hypothesise that patients with OI will have increased risk of 
death due to fractures compared to the general population. Colla-
gen type 1 is an important constituent of different parts of the car-
diovascular system (37, 38).  Cardiovascular disease is a leading 
cause of death, and increased prevalence of cardiovascular disease 
will increase the risk of premature death. We hypothesise that pa-
tients with OI will have increased risk of death due to cardiovascu-
lar diseases compared to the general population as a consequence 
of the quantitative or qualitative defect of collagen type 1 in OI. 
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The prevalence of scoliosis can increase the risk of restrictive pul-
monary disease, and thus the risk of pulmonary infections. We hy-
pothesise that patients with OI will have increased risk of death due 
to respiratory diseases.  
 
Bone strength is determined by bone geometry, bone microstruc-
ture, bone mass, and the quality of the bone matrix (67). Several 
studies in children and adults have shown that BMD is lower in pa-
tients with OI than in healthy controls (3). The bones are ‘brittle’ 
and absorb less energy before fracturing (68). This results in in-
creased risk of fractures in patients with OI. We hypothesise that 
patients with OI will have increased fracture rates compared to the 
general population, but that the relative risk of fractures will de-
crease with increasing age. We further hypothesise that the frac-
ture pattern seen in OI (i.e. which bones fracture at which stages 
of life) will mimic that of the general population. Lastly, we hypoth-
esise that patients with OI will have altered bone microarchitec-
ture, lower bone mass, and different bone geometry to healthy 
non-OI individuals that may explain some of the increased fracture 
risk seen in patients with OI.   
 
The heart valves, chordae tendineae, annuli fibrosis, interventricu-
lar septum, aorta and most other arteries contain collagen type 1 
(37, 38). The collagen fibres in the ventricular myocardium contrib-
ute to the tensile stiffness and maintain the architecture of the my-
ocytes (40). In the OIM mouse model, the collagen area fraction 
and fibre density in the heart was 35-38% lower in the homozygote 
mice compared to the wild-type mice (41), indicating that collagen 
type 1 plays an important role in heart function. 
 
We hypothesise that patients with OI will have increased risk of 
aorta and mitral valve insufficiency, increased risk of heart failure 
(due to enlargement of the ventricles that dilate due to the quan-
titative or qualitative defect of collagen type 1), increased risk of 
atrial fibrillation (due to dilatation of the atria caused by the 
quantitative or qualitative defect of collagen type 1) and increase 
the risk of vessel dissection and aneurisms, even after correction 
for non-collagen related causes of these conditions. 
 
 
 
Figure 4. Main hypotheses The figure is theory-driven and shows 
the multifactorial causes of premature death in OI. We hypothesise 
that the decreased amount of collagen type 1 seen in OI increases 
the risk of cardiovascular diseases that in turn will increase the risk 
of premature death. OI also alters the bone matrix quality, increas-
ing the risk of fractures that may be associated with increased risk 
of death, but may also cause immobilisation. The increased frac-
ture risk may also lead to lower physical activity as a fracture pre-
vention technique. Immobilisation and reduced physical activity in-
crease the risk of cardiovascular disease through ischaemic 
cardiovascular disease. Fractures of the spine may cause scoliosis, 
while hyperlaxity in spinal ligaments causes scoliosis and/or kypho-
sis that increase the risk of restrictive and obstructive pulmonary 
diseases. This increases the risk of respiratory tract infections that 
also increase the risk of premature death in OI. Restrictive pulmo-
nary disease can also increase the risk of cardiovascular disease. 
There may also be other, as yet unknown factors leading to prem-
ature death in OI such as clinical severity and phenotype, gender 
and ageing, but these are not shown for the sake of simplicity. Full 
lines indicate a direct relationship; dashed lines indicate an indirect 
relationship. OI: Osteogenesis imperfecta, CVD: cardiovascular dis-
ease, Rest. pulm.: restrictive pulmonary, Obst. pulm.: obstructive 
pulmonary disease.  
3.2 STUDY OBJECTIVES 
The study objectives were: 
 
1) to evaluate the risk of death and causes of death in patients with 
OI and to calculate median survival  time in OI compared to the 
general population (Paper I) (1) 
 
2) to evaluate fracture rates and the pattern of fractures through-
out life in patients with OI and compared to the general population 
(Paper II) (2) 
 
3) to evaluate the bone mineral density, bone geometry, and bone 
microarchitecture in patients with OI type I compared to a non-OI 
matched reference group, and to explore the causes of the in-
creased fracture rates in OI (Paper III) (3) 
 
4) to evaluate the risk of cardiovascular disease in patients with OI 
compared to the general population (Paper IV)  
3.3 SYSTEMATIC SEARCH AND NARRATIVE REVIEW 
3.3.1 Search strategy 
A series of systematic searches and reviews of current literature 
was conducted in PubMed, Embase classic, Embase, and the 
Cochrane Library for the four main themes of this thesis (1: Risk of 
death, cause of death and life expectancy in OI, 2: Fracture risk and 
fracture rates in OI, 3: BMD, bone geometry, and bone microarchi-
tecture in OI, 4: Cardiovascular diseases in OI). All included publi-
cations were hand-searched for any relevant references that were 
missed with the search strategy. 
 
The search strategy, specific search strings, dates of the searches, 
and the search results are shown in Appendix 1.1 – 1.4.  
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3.3.2 Eligibility criteria for studies 
Randomised controlled trials, cohort, case-control or cross-sec-
tional studies, and case series including patients with OI were in-
cluded in this review. The search was limited to literature in Dan-
ish, Norwegian, and English.  
 
Reviews, case reports or case series with under 10 patients, com-
mentaries, publications based on secondary data, conference pa-
pers, non-peer reviewed publications, publications only including 
foetal, neonatal or autopsy data or pregnancy outcome, non-OI 
publications only identified through the author names of Lobstein 
or Bruck (these are also names of OI subtypes), publications with 
only non-human data, studies reporting novel OI mutations (unless 
they included more than 10 patients and covered one of the main 
themes of the thesis), and publications that evaluated pharmaco-
logical or surgical treatment and did not have a non-OI reference 
group were excluded.  
3.3.3 Data extraction 
One author (LF) extracted data from the included studies on study 
design and size, participant age, gender, and phenotype, and 
characteristics of the reference group or material if present or 
used in the studies. Information on phenotype was extracted 
from the publications and presented as described by the authors 
if present. Values and data were presented as in the original pub-
lications.  
4. CAUSES OF DEATH AND LIFE EXPECTANCY IN OI 
This chapter evaluates the current literature on causes of death 
and life expectancy in OI. Little is currently known about the risk of 
death in patients with OI.  
 
We performed a register-based cohort study using data extracted 
from Statistics Denmark Division of Research, which administers 
the health registers used in the study. Statistics Denmark is a state 
institution under the Ministry of Social Affairs and the Interior. We 
included all patients with OI registered in the NPR and compared 
their risk of death, primary causes of death, and median survival to 
a reference population, as described in Paper I (1).  
 
We defined patients as all persons registered with an OI diagnosis 
in the National Patient Register (NPR) from 1977 (the start of the 
register) and until the latest updated version of the NPR at the time 
of data extraction (summer 2014). For the general population ref-
erence group, we randomly selected five individuals matched by 
gender, birth year, and birth month to each identified OI patient. 
To minimise the risk of misclassification, the controls could not be 
patients or first or second-degree relatives to any of the identified 
patients. The reference population was generated from the Danish 
Civil Registration Register (which administers the unique identifi-
cation number (CPR) given to all inhabitants of Denmark and Dan-
ish citizens) and was supplied by Statistics Denmark Division of Re-
search without any involvement of the study team in choosing or 
determining the eligibility of the chosen participants.  
 
We extracted data from the NPR on surgery and discharge diagno-
sis from hospital stays, outpatient clinics, and emergency depart-
ments. We extracted data on dispensed prescriptions from the 
Danish National Prescription Register (DNPR), information on mi-
gration from the CPR, and data on time of death, place of death, 
and cause of death from the Causes of Death Register.  
 
While case series and cross-sectional studies can provide detailed 
clinical information about each participant, a nationwide cohort 
study using register data is (in Denmark) representative of the en-
tire population with no loss to follow-up. The nationwide coverage 
ensures a larger patient sample for conditions with low incidence 
such as OI, and the cohort design increases generalisability to the 
OI population. The limitations to this design are described in detail 
in Paper I (1) and in section 8.1 of this thesis.  
4.1 LITERATURE SEARCH 
The literature search was conducted as described in section 3.3 
(inclusion and exclusion criteria) and Appendix 1.1 (search dates, 
search strings and search results) and aimed to identify all studies 
evaluating the risk of death, causes of death, and life expectancy 
in OI. A flow diagram of the study selection can be seen in Figure 
5. Of the 435 publications initially identified, 242 were from Em-
base, 129 from PubMed and 64 from the Cochrane Library. After 
removal of 46 duplicate records, 389 titles and abstracts were 
screened. The 19 articles that fulfilled at least one inclusion crite-
rion and no exclusion criteria were then screened by full text, and 
five publications were found to be eligible for data extraction. The 
extracted data are presented in Table 2. 
 
 
Figure 5. Flow diagram of study selection for studies covering risk 
and causes of death in OI 
 
 DANISH MEDICAL JOURNAL   9 
 
 
 
 
Table 2. Studies on causes and risk of death in OI included in this review 
Author 
(year) 
Study Design Total Pa-
tients 
(Women) 
[Risk of 
death] 
Patient years 
of observa-
tion 
Reference popula-
tion 
(women) 
Observa-
tion pe-
riod 
Mild Phenotype 
(women) 
[Risk of death] 
Moderate Phenotype 
(women) 
[Risk of death] 
Severe Phenotype 
(women) 
[Risk of death] 
Most Severe Phenotype 
(women) 
[Risk of death] 
Folkestad, 
(2016) (1) 
Registry based 
Cohorts study 
687 (379) 
 
[HR: 2.90, 
95% CI: 
2.31-3.64] 
25,615 3435 (1895) 1977-
2013 
- - - - 
Singer 
(2001) (69)  
National Sur-
vey study 
743 (412) 
- 
6970 Life tables for Eng-
land and Wales in 
1981 
1980-
1993 
383 (272) 
 
[108% EDR] 
237 (130) 
 
[193% EDR] 
123 (70) 
 
[2400% EDR] 
- 
Paterson 
(1996) (70) 
National Sur-
vey study 
743 (412)* 
- 
6970 Life tables for Eng-
land and Wales in 
1981 
1980-
1993 
* 
[MR 1.08, 
95% CI: 0.64-1.81] 
* 
[MR 1.93, 
95% CI: 1.17-3.13] 
* - 
McAllion 
(1996) (43) 
National Sur-
vey study 
79 (?) 
- 
- National mortality 
statistics 1995 
1980-
1995 
411 
- 
- 38 - 
Shapiro 
(1985) (71) 
Case series 
from one cen-
tre 
85 (43) 
- 
- - 1938-
1983 
212 
[0 of 21 patients died 
during median follow-up 
of 17.5 years] 
213 
[0 of 21 patients died 
during median follow-up 
of 17.7 years] 
27 
[2 of 27 patients died 
during median follow-up 
of 18.9 years] 
16 
[15 of 16 patients died 
during median follow-up 
of 6 weeks] 
Spanger 
(1982) (72) 
Cross-sectio-
nal study 
47 (?) 
- 
- - 15 years 214 
[3 of 21 patients died 
during median follow-up 
of 18 months] 
- 95 
[1 of 9 patients died dur-
ing median follow-up of 
5 months] 
176 
[15 of 17 patients died 
during median follow-up 
of 2 weeks] 
* Same population as reported in Singer et al.(69). 1) Including patients with clinical type I and IV, 2) Including patients with first fracture 
in childhood after they began to walk, 3) Including patients with first fracture in childhood before they could walk, 4) Neonates with clinical 
severity score under 2.0, 5) Neonates with clinical severity score of 2.0-2.6, 6) Neonates with clinical severity score above 2.7. HR: Hazard 
Ratio, CI: Confidence interval, EDR: Excess Death Rate, MR: Mortality Ratio
4.2 RISK OF DEATH IN OI 
The absolute risk of death is the same in all individuals, obviously. 
When using the term risk of death in this segment it refers to the 
differences between patients with OI and non-OI individuals during 
the observation period on a group level. This may be based on the 
all cause HR, the cause specific SHR, the Excess Death Rate or Mor-
tality Ratio between the different groups included in the different 
studies.     
 
In our study (Paper I) we identified 687 patients with OI, of whom 
112 died during the observation period. The all-cause mortality 
hazard ratio for death (HR) was 2.9 [95% CI: 2.3-3.6] in patients 
with OI compared to the reference population (1). For men, the HR 
was 3.7 [95% CI: 2.6-5.2] and for women 2.4 [95% CI: 1.8-3.3] when 
compared to the reference population (1). Children with OI had in-
creased all cause mortality, where 15 patients died before the age 
of 1, and a total of 19 patients with OI died prior to the age of 6 
years and in total 26 patients with OI died prior to age 18 (fewer 
than 3 participants in the reference population died prior to age 
18) (1). The low number of childhood deaths in the reference pop-
ulation resulted in an HR of 66.1 [95% CI: 15.7-278.7] for patients 
with OI aged less than 18 years (1).  
 
Singer et al. (69) and Paterson et al. (70) reporting on the same 
study population included 743 patients with OI (383 with type I OI 
without dentinogenesis imperfecta (DI), 77 with type I OI with DI, 
123 with type III OI, and 160 with type IV) from England and Wales 
in a study of life expectancy in OI. The observation period com-
prised 13 years (from1980 to 1993). During 6940 patient years of 
observation, 57 patients died (69). The authors estimated the 
 
  
mortality ratio (MR) between the OI patients and the predicted 
mortality using data from the Office of Population Censuses and 
Surveys, Mortality Statistics and Review and the 1981 Life tables 
for England and Wales. An MR of 100% would indicate no differ-
ence between the observed and predicted mortality, while an MR 
above  
 
100% would indicate increased mortality in patients with OI. The 
MR for patients with OI type I without DI was 140% in men and 85% 
in women. The MR for a combined group of OI type I with DI AND 
OI type IV was 295% in men and 133% in women. The MR for pa-
tients with type III OI was 1130% in men and 2400% in women (69). 
The authors found increased childhood mortality for all groups i.e. 
MR of 128% for patients with type I OI without DI, 335% in the 
combined group of OI type I with DI and type IV OI, and 26,000% in 
patients with type III OI (69). Singer et al. (69) and Paterson et al. 
(70) used data from a survey of patients in England and Wales (69, 
70) who were recruited through the British OI patient society. The 
authors did not provide information about the number of patients 
with OI living in England and Wales or about the response rate and 
selection bias was possible.  
 
Shapiro (71) reviewed the charts of 85 patients who had been di-
agnosed with OI at a children’s hospital in Boston from 1938 to 
1983. The patients were divided into four groups according to clin-
ical severity: OI congenita A (the most severe phenotype, diag-
nosed at birth), OI congenita B (moderate to severe phenotype di-
agnosed at birth), OI tarda A (milder phenotype, not diagnosed at 
birth, without DI), and OI tarda B (milder phenotype, not diagnosed 
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at birth, with DI) (71). All but one of the 16 patients with the most 
severe phenotype had died, with a median survival time of 6 
months (range: stillborn – 3 years and 9 months) (71). Two patients 
with the moderate to severe phenotype had died at the time of the 
publication, both due to respiratory problems prior to their 6th 
month of life (71). None of the patients with the milder phenotypes 
had died during a median follow-up of 17.6 years (71). The study is 
a single-centre case series, and may be subject to selection bias, 
thus, the results may only hold true for the specific population. The 
results illustrate a clear difference in mortality risk between differ-
ent phenotypes of OI, but do not evaluate the risk of death in the 
general OI population compared to non-OI individuals. 
 
Spanger et al. (72) aimed to generate a clinical severity score based 
on radiographic findings in newborns with OI and used data from a 
bone dysplasia register at the Children’s Hospital, University of 
Mainz and the Red Cross Children’s Hospital, University of Cape 
Town. The authors evaluated clinical severity in 47 neonates with 
OI diagnosed at birth using a scoring system of skeletal pathologies 
to evaluate the risk of death in OI (72). Fifteen of the 17 patients 
with the highest clinical severity scores died within two weeks of 
birth; one of the 9 patients with medium high clinical severity 
scores died within one month of birth; and three of the 21 patients 
with the lowest clinical severity scores had died at the time of pub-
lication, younger than 6 months (72). It is unknown how the pa-
tients were selected for entry into the register and for evaluation, 
and selection bias may limit the results. The authors concluded, in 
concordance with other studies, that 88% of patients with the most 
severe phenotypes (i.e. with the highest clinical severity score) 
would die shortly after birth, but that 90% of patients with lower 
severity scores would survive (72).  
 
Our own study and the literature confirm our hypothesis that the 
risk of death is increased in OI. The risk of death in OI is associated 
with male gender and young age. Clinical severity is reported in 
many studies as associated with an increased risk of death in the 
most severe phenotypes compared to patients with milder dis-
ease. This is however a circular argument as to some degree the 
patients were grouped according to their risk of their outcome i.e. 
patients with OI type II will by definition be lethal and thus have a 
much higher risk of death than patients with OI type I. 
4.3 LIFE EXPECTANCY IN OI 
As shown in Figure 6, in our study (Paper I) we found a median sur-
vival for men with OI to be 72.4 years [95% CI: 68.8-77.7] vs. 81.9 
years [95% CI: 79.3-84.3] for men in the reference population 
(p<0.001) (1). The median survival for Danish women with OI was 
77.4 years [95% CI: 74.6-79.8] vs. 84.5 years [95% CI: 83.0-86.2] in 
the reference population (1).  
 
Paterson et al. (70) used data from the same database as Singer et 
al. (69) to calculate life expectancy in OI. The life expectancy in pa-
tients with type I OI without DI was equal to that of the general 
population (78.4 years for women and 73.6 years for men). In the 
combined group of patients with OI type I with DI AND patients 
with OI type IV, life expectancy was 72.0 [95% CI: 67.2-76.8] years 
in women and 68.8 [95% CI: 62.4-75.6] years in men. The confi-
dence intervals indicate that the life expectancy was shorter than 
expected in women. In patients with type III OI, life expectancy was 
markedly reduced. Twenty-six patients had died during the obser-
vation period, and 19 of them prior to their 10th birthday. Life ex-
pectancy at birth was 28.8 [95% CI: 16.0-41.6] years for females 
and 43.2 [95% CI: 22.4-64.0] years for males. Due to the increased 
neonatal mortality, the remaining life expectancy for patients after 
their 1st birthday was 33.6 [95% CI: 23.2-44.0] years for females 
and 48.0 [95% CI: 33.6-62.4] years for males.  
 
 
Figure 6. Kaplan Meier estimates of survival in OI The figure shows 
the KM plots in men and women with OI compared to the reference 
population. Y-axis shows the present remaining in the populations 
and the X-axis the population age. There is increased neonate mor-
tality in patients with OI, especially in men. The dashed lines indi-
cate the reference population, the solid line the OI population. 
 
The starting point for calculating life expectancy is the age-specific 
death rates of a population. Paterson et al. (70) estimated life ex-
pectancy based on 6970 patient years and 57 deaths. For small 
populations with few deaths, it is possible to adjust a known life 
table derived from a larger population by multiplying this life table 
by the age and gender specific standardized mortality rates for the 
population (e.g. patient population) of interest. Peterson et al. (70) 
used this approach to calculate life expectancy in patients with OI 
as they had calculated the mortality ratios for each group of inter-
est, but this pragmatic approach may be prone to bias as it assumes 
that the mortality ratios are constant between the groups. In 
smaller populations, the estimation of life expectancy is prone to 
overestimation, and a population size of at least 5000 individuals 
has been recommended to estimate a population life expectancy 
with accuracy (73). For a low-mortality population, a total popula-
tion exposure time should supersede 15,000 patient years at risk 
to allow accurate calculation of life expectancy (74). According to 
the American Centre for Disease Control, a reliable life table can-
not be generated if the number of deaths in the total population 
(e.g. small municipalities or small ethnic groups) is under 700, and 
thus life expectancy cannot be estimated with adequate statistical 
certainty (75). Neither approach was suitable for our data, as we 
included births from 1899 to 2013 and has left-truncated the data 
as a patient had to be alive at least until 1977 to appear in the reg-
isters, and patients with OI could have died prior to entering the 
registers – thus introducing survival bias to our data. This is illus-
trated by the relatively higher than expected median survival time 
in the reference population. We acknowledge that our estimates 
of survival time are probably too high compared to that expected 
in the Danish population covering individuals born from 1899, but 
the comparison with the OI group should still illustrate the reduced 
median survival time seen in OI.   
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Our study (Paper I) and the literature confirm our hypothesis that 
life expectancy in patients with OI is lower than in the general pop-
ulation.  
4.4 CAUSES AND RISK FACTORS FOR DEATH IN OI 
4.4.1 Clinical severity 
Sillence’s classification of OI is based on both clinical features and 
mode of inheritance (6, 7). Due to the lack of clinical information 
and information on genotype in the Danish health registers, it is 
not possible to identify the different phenotypes of the disease 
through these data sources (1). Severe phenotypes of OI have in-
creased risk of death, and the risk of neonatal death is especially 
associated with clinical severity (43, 69-72). This is, however, a cir-
cular argument as the grouping of patients is done according to 
clinical severity. This ‘bias by indication’ must be kept in mind when 
evaluating the between group differences. It could be argued that 
a genotype to mortality risk correlation study would reduce ‘the 
clinical (often subjective) grouping of patients’-bias into account.   
4.4.2 Gender 
Female gender favours longevity in patients with OI. In our study, 
we found that the HR for early death was higher in men than in 
women (1). In British patients with OI the mortality ratio for pa-
tients with type I OI without DI was 140% in men and 85% in 
women (69). Similarly, the mortality ratio for patients with type I 
OI with DI AND patients with type IV OI was 295% in men and 133% 
in women (69). Among those with OI type III, however, female pa-
tients had shorter life expectancy and higher mortality ratio than 
male patients (69). The Paterson et al. (70) and Singer et al. (69) 
studies included data on the same 123 (70 women) patients with 
OI type III, of whom 26 (19 women) died during the observation 
period. The expected number of deaths was 0.6 among the men 
and 0.4 among the women (69). This could explain the difference 
in mortality ratio between the genders in the most severe pheno-
types, as the mortality ratio is defined as the relative difference 
between the observed and expected number of deaths.  
4.4.3 Trauma 
In our study, 4.5% of deaths were due to external causes of mor-
bidity and mortality (i.e. trauma), which was more frequent than 
the 1.9% in the reference population (1). This is in line with the 
findings of McAllion and Paterson (43), who reported that 13.2% 
of patients with type III OI died due to trauma, compared to 2.7% 
of the general population. These authors (43) evaluated the causes 
of death in patients with OI who had participated in a survey in 
1980-1995 that was distributed through the Brittle Bones Society, 
and 68 of the 1297 participants had died during the observation 
period. There was no information about the response rate or the 
degree of coverage of the British OI population (43), so selection 
bias of participants cannot be ruled out. The authors had clinically 
evaluated 37 of the patients, and gathered clinical data on the re-
maining participants from questionnaires sent to the patients 
while they were still alive or a chart review (43), which may give 
some information bias to the clinical data. Whereas all specific 
causes of death were gathered through the Danish Causes of Death 
register in our cohort study, McAllion and Paterson identified the 
primary cause of death using a variety of sources such as death 
certificates, autopsy reports, medical records, hospital consultants, 
relatives, and the Brittle Bone Society (43). This approach is more 
prone to recall bias than our register-based approach.  
 
We included national data that included all patients with an ICD-8 
or ICD-10 diagnosis for OI and assume that the phenotype distribu-
tion is the same as that previously reported for the Danish OI pop-
ulation, where the mild phenotypes outnumber the more severe 
phenotypes (5). In the McAllion and Peterson study (43), 50% of  
patients had OI type III or IV.  
 
Short-term mortality is increased after osteoporotic fractures (66), 
and we speculate that death associated with fractures or trauma 
might be underreported in our study. If a patient dies shortly after 
suffering a fracture, the physician is likely to register the cause of 
death as fracture-related, but if the patient dies from complica-
tions associated with the fracture, e.g. a pulmonary embolism, sev-
eral weeks after the fracture event, then the primary cause of 
death might not illustrate the underlying cause (the fracture) (1). 
As patients with OI have more fractures than non-OI individuals (2), 
the risk of fracture-related death is higher in the OI population as 
a result of frequent exposure.  
4.4.4 Pulmonary diseases 
In our study (Paper I) we found that patients with OI had an in-
creased risk of death due to respiratory diseases with an SHR of 3.1 
[95% CI: 1.4-6.9] (1).  
 
Even in mild to moderate cases, scoliosis can cause pulmonary dys-
function including reduced vital capacity and exercise capacity, and 
recurrent respiratory infections (76). Kyphoscoliosis is frequently 
seen in OI, and six studies have evaluated pulmonary function in 
patients with OI using spirometry (24, 25, 39, 77-79). The studies 
evaluated total lung capacity, forced expiratory volume in 1 second 
(FEV1), forced vital capacity (FVC), and the FEV1/FVC ratio in pa-
tients with type I, III or IV OI and compared these results to pre-
dicted values according to age, gender, and height. The studies 
found that patients with OI type I often reach the predicted values 
of lung function, but the results for severe phenotypes were more 
diverse (24, 25, 39, 77-79).  
 
The FEV1/FVC ratio is used to distinguish between an obstructive 
and a restrictive pattern of pulmonary function. An FEV1/FVC ratio 
below 70% is interpreted as an obstructive pattern of pulmonary 
function (80), while an FEV1/FVC ratio above 80% is interpreted as 
a restrictive pattern (80). The FEV1/FVC ratio can be falsely ele-
vated in OI due to low values of both FEV1 and FVC (24). Studies 
have consistently shown elevated HR for mortality associated with 
both restrictive and obstructive pulmonary function (81). In a Nor-
wegian cross-sectional study, Wekre et al. (25) included 97 adult 
patients with either OI type I, IV or III and found two patients with 
an obstructive pulmonary function pattern, four patients with a re-
strictive pattern when using actual height to predict the pulmonary 
function values, and two further patients when using arm-span as 
a proxy for vertical height. Scoliosis was negatively correlated to 
pulmonary function in six studies (24, 25, 39, 77-79). The degree of 
scoliosis varied by clinical severity and age, thus in the Norwegian 
study 46% of adult patients were scoliotic – 36% of those with OI 
type I and 100% of those with OI type III had significant scoliosis 
(25). In a longitudinal study of German patients with type III and IV 
OI, 78.3% of patients developed scoliosis during the observation 
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period from birth to young adulthood, and patients with lower air-
way obstruction had more severe scoliosis than those without 
lower airway obstruction (39). Pulmonary function declined signif-
icantly with age for all patients – from nearly normal at age 4 to 
about half of the predicted values by age 20, even in patients with 
only mild scoliosis (39). Kyphosis showed no significant correlation 
with FVC, FEV1 or TLC in adults with OI (24).  
 
Arterial pO2 and pCO2 was reported within normal ranges in chil-
dren with OI regardless of phenotype (79), but this study was small 
and included 11 patients with OI recruited through a single OI 
treatment centre. The pO2 and pCO2 values were compared to ref-
erence range values, and comparison to a matched reference 
group of non-OI individuals would have enabled the authors to 
evaluate whether pO2 and pCO2 were significantly different from 
non-OI individuals (even within normal reference ranges). Another 
study found that patients with OI type III had a drop in oxygen sat-
uration (SpO2) at night, the average SpO2 being 91.9±12.2% with a 
nadir of 85.4±8.1%, and SpO2 was below 95% for 18% of the night 
(77). In patients with type IV OI, the average SpO2 was 96.8±2.4% 
with a nadir of 87.7±7.3%, and SpO2 was below 95% for 8% of the 
night (77). These results do not seem to be normally distributed 
based on the standard distribution, and it may have been more ap-
propriate to report median (range) values. The authors used a two 
way Analysis of Variance (ANOVA) to evaluate the difference be-
tween groups. There is no requirement for the data to be normally 
distributed using this model, but the residuals, are assumed to 
have a normal distribution – there was no indication if the authors 
evaluated this in their analysis. SpO2 is not expected to drop in non-
OI individuals during sleep. When compared to healthy age- and 
gender-matched reference participants, patients with OI type III 
and IV had significantly lower tidal volume in both supine and 
seated positions, and their respiration rate was significantly higher 
(77). 
 
The main causes of death in OI in the McAllion and Paterson study 
were pulmonary disease and respiratory tract infections (43). How-
ever, the study was not population-based and did not include the 
expected distribution of clinical phenotypes in an OI population, as 
half of their patients had more severe OI (43). Based on the preva-
lence of different phenotypes reported by Andersen and Hauge (5), 
we would expect that under 30% of the OI population would have 
type III or IV OI. Clinical severity is an important predictor of re-
duced pulmonary function. Severe phenotypes are associated with 
more respiratory morbidity and thus higher risk of death due to 
respiratory diseases.   
4.4.5 Neurological diseases 
The absolute risk of death due to neurological diseases, as given in 
death certificates and registered in the causes of death register, 
was low in our study, with 4 out of 112 deaths registered as caused 
by neurological diseases, and the relative risk compared to the ref-
erence population was non-significant with a SHR of 2.1 [95% CI: 
0.6-6.6] (1).  
 
Basilar impression or invagination (infolding of the occipital con-
dyles and elevation of the clivus and posterior cranial fossa) results 
in the cervical spine migrating upwards into the foramen magnum 
(82). The prevalence of basilar impression or invagination is 25% 
regardless of OI phenotype, but only a few of the patients with bas-
ilar impression show neurological symptoms (22). In the McAllion 
and Paterson study (43), three patients died due to compression of 
the brain caused by basilar invagination. Deaths related to neuro-
logical diseases accounted for 12.2% (5 of 38) of deaths in OI type 
I and IV patients, while only 2.6% of deaths in the general popula-
tion were due to neurological diseases during the same time period 
(43).  
4.4.6 Gastrointestinal diseases 
We found an increased risk of death from diseases of the gastroin-
testinal system in our study, with 9 (1.3%) deaths compared to 8 
(0.2%) deaths in the reference population, resulting in a SHR of 4.2 
[95% CI: 1.6-10.8] (1). The level of detail in the Danish Causes of 
Death Register limits the information on specific gastrointestinal 
diseases, and the precise causes of this increased risk are unclear. 
One hypothesis is increased NSAID use due to pain in patients with 
OI, who had higher use of prescription NSAIDs compared to the 
reference population (57% vs. 47%, p<0.001). Low-dose NSAID is 
sold over the counter (ibuprofen 200mg tablets) in Denmark and 
are thus not included in the Danish Prescription registries at indi-
vidual level. There is also a risk of underestimating the NSAID use 
in the reference population – they may buy more over-the-counter 
drugs than the OI population, who are likely to be followed more 
closely by medical staff and thus have a larger proportion of their 
drugs prescribed and thus registered in the Danish prescription da-
tabase. 
 
The causes of death in OI are summarised in Figure 7. 
 
 
Figure 7. Causes of death in OI The figure shows the factors that 
influence the risk of early death in patients with OI, based on data 
from the studies included in this thesis. OI most often causes qual-
itative or quantitative collagen type 1 defects, and the lack of 
available collagen alters the bone matrix quality that in turn in-
creases the risk of bone fractures even with minor trauma. 
Trauma can also cause fractures that increase the risk of death. 
Fractures can also lead to scoliosis (as can the collagen type 1 de-
fect). Scoliosis can lead to respiratory tract infections and thus in-
creased risk of death. The collagen defect influence the risk of de-
veloping basillaris invagination that can cause neurological 
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conditions that increase the risk of death. Through an unexplained 
pathway, patients with OI have higher mortality from gastrointes-
tinal disorders. Men have higher risk of death than women, at 
least for milder phenotypes. Cardiovascular diseases and malig-
nancies were frequent causes of death in patients with OI, but the 
risk of death was similar to that of the general population and is 
therefore not featured in this figure.    
 
Our study (Paper I) and the literature confirm our hypotheses that 
patients with OI have increased risk of death from respiratory dis-
ease and trauma causing fractures. We also found that patients 
with OI had increased risk of death due to gastrointestinal and neu-
rological diseases. We could not confirm the hypothesis that pa-
tients with OI had increased risk of death from cardiovascular dis-
eases compared to the general population, even though the 
absolute risk of death due to these diseases was high in our cohort 
study. (1).  
4.5 CONCLUSION 
Based on current knowledge, we conclude that patients with OI 
have increased risk of death compared to the general population. 
Their increased risk of death from trauma, respiratory diseases, 
neurological diseases and gastrointestinal diseases seems related 
to clinical severity and male gender. Studies are needed to evalu-
ate the causes and severity of respiratory tract diseases in OI 
compared to the general population and to evaluate the causes of 
the increased risk of gastrointestinal death. Population-based lon-
gitudinal studies with information about genotype and clinical 
characteristics would greatly add to present knowledge. 
5.  FRACTURES IN OI 
This chapter evaluates the current literature on several aspects of 
fractures in OI: the risk of fractures in patients with OI compared 
to non-OI individuals, fracture rates in patients with OI, typical frac-
ture sites, and the pattern (i.e. changes in fracture rates and sites) 
of fractures over the lifespan of a patient with OI. 
 
The bone fragility seen in OI leads to increased fracture risk, and 
most patients with OI will experience multiple fractures through-
out life. Although fracture rates are not part of the diagnostic cri-
teria for the phenotypes in Sillence’s classification, clinical severity 
is partly based on the number of fractures experienced. There is 
some clinical overlap between Sillence’s subtypes, and the pheno-
types are heterogeneous. Patients with OI often report more fre-
quent fractures during childhood and early adulthood, fewer frac-
tures in adulthood, and increasing fracture rates in old age. 
Patients furthermore describe that the causal trauma differs 
throughout life – at younger ages, the trauma causing a fracture is 
often very minor and the fracture comes as a surprise, whereas 
fractures in later life are caused by more severe trauma and are 
more anticipated. Most of the treatment of OI is focused on frac-
ture prevention. Little is however known about which patients to 
treat, for what duration and how to monitor patients during treat-
ment. The effect of bisphosphonates as primary fracture preven-
tion in patients with OI (of all ages) is questionable.  
We performed a register-based cohort study using the same cohort 
as in Papers I (1) and IV (i.e. including all patients registered with 
an OI diagnosis in the NPR) and compared the fracture rates and 
sites to those in a reference population of non-OI individuals ran-
domly selected from the central persons register and matched 5:1 
for age and gender to the patients with OI. We counted all frac-
tures registered in the NPR from 1995 until the end of 2012. We 
acknowledge that by using register data we only identify fractures 
that need hospital attention, and that patients with OI may to 
some extent treat smaller fractures at home with immobilisation 
and analgesia. Our data may thus reflect the fracture burden to the 
health care system and not necessarily that experienced by the pa-
tient. Our data also reflect current standards of care for OI and 
would probably be different if the condition remained untreated. 
The design of the study is described in detail in Paper II (2) and dis-
cussed in section 8.1 of this thesis.  
5.1 LITERATURE SEARCH 
The literature search was conducted as described in section 3.3 (in-
clusion and exclusion criteria) and Appendix 1.2 (search dates, 
search strings and search results) and aimed to identify all studies 
evaluating fracture risk and fracture burden in patients with OI. A 
flow diagram of the study selection can be seen in Figure 8. A total 
of 1423 publications were found via Embase, 1232 via PubMed, 
and 102 via Cochrane Library. After excluding 574 duplicates, 2183 
titles and/or abstracts were screened for eligibility and resulted in 
35 publications for full-text screening. One article was identified 
through a manual search of the references included in this chapter, 
leading to 19 publications being included in the review. Data from 
Paper II (2) are also included in the review. The study characteris-
tics can be seen in Table 3 and 4.  
  
 
Figure 8. Flow diagram of study selection for studies on fractures 
in OI 
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Table 3. Studies on fractures in OI  
 Total OI population Reference population OI type I OI Type III OI Type IV Other OI types Reported fracture outcome 
Author  
(Year) 
Total 
Number 
(women) 
Age 
(range 
or ±SD) 
Total 
Number 
(women) 
Age Total 
Number 
(women) 
Age Total 
Number 
(women) 
Age Total 
Number 
(women) 
Age Total 
Number 
(women) 
Age N
 Previous 
IRR 
Age at 1
st  
Sites 
Fx/year 
  Pattern 
  
Folke-
stad 
(2016) 
(2) 
644 (358) 15 
(0-71)1 
3361 
(1855) 
15 
(0-81) 
2 
- - - - - - - - - Y - Y Y Y 
Hald  
(2016) 
(20) 
85 
(49) 
- - - 58 
(34) 
46.5 
±16.6 
12 
(5) 
38.8 
±13.5 
15 
(8) 
43.5 
±12.4 
- - Y - - - - - 
Patel  
(2015) 
(83) 
544 (304) 12.6 
(0-67) 
- - 244 (131) 13.6 
(0-67) 
100 (58) 11.4 
(0-54) 
147 (82) 12.0 
(0-63) 
53 
(33)3 
1-
33 
- - - - Y - 
Lindahl  
(2015) 
(84) 
222 (101) - - - 151 (65) 17.51 
±13.94 
29 
(21) 
17.72 
±14.08 
42 
(15) 
17.32 
±10.61 
- - Y - - Y4 Y - 
Diacinti 
(2015) 
(85) 
58 
(25) 
7.0 
(1-18) 
- - 44 
(?) 
- 4 
(?) 
- 10 
(?) 
- - - - - - Y4 - - 
Brizola 
(2014) 
(86) 
62 
(32) 
8 
(2-14) 
- - 31 
(15) 
8 
(2-15) 
9 
(5) 
8 
(2-13) 
22 
(12) 
11 
(7-14) 
- - - - Y Y - - 
Wekre 
(2014) 
(25) 
97 
(56)5 
44±12 - - 75 
(47) 
45±13 9 
(3) 
35±7 11 
(2) 
47±7 - - - - - Y4 - - 
Ben 
Amor 
(2013) 
(49) 
86 
(50) 
13.3 
±13.9 
- - 86 
(50) 
13.3 
±13.9 
- - - - - - Y - - Y Y - 
Aglan 
(2012) 
(87) 
43 
(26) 
5.7 
(0-20.0) 
- - 11 
(9) 
6.6 
(3.3-
12.5) 
22 
(11) 
5.5 
(1.4-
17.8) 
9 
(5) 
10.0 
(3.9-
20.0) 
1 
(1)6 
0.5 - - Y Y Y - 
Wekre 
(2011) 
(48) 
97 
(56)5 
44±12 - - 75 
(47) 
45±13 9 
(3) 
35±7 11 
(2) 
47±7 - - Y - - - Y - 
McKier-
nan 
(2005) 
(88) 
111 (78) 20-70 - - 111 (78) 20-70 - - - - - - Y7 - - Y - - 
Moore 
(1998) 
(89) 
12 
(7) 
7.35 
(4.5-
16.9) 
- - - - - - - - - - Y - - - Y - 
Davie 
(1994) 
(90) 
9 
(6) 
11±3 132 (75) 5-13 - - - - - - - - Y - - Y Y - 
Vetter  
(1992) 
(91) 
127 
(?) 
0-108 - - 40 
(?) 
0-107 39 
(?) 
0-108 49 
(?) 
0-108 - - - - - Y Y Y 
Paterson 
(1987) 
(92) 
78 
(?) 
20.7 
±16.13 
100 
(?) 
9.12 
±2.139 
- - - - 78 
(?) 
20.7 
±16.13 
- - Y - Y Y Y - 
Andersen 
(1986) 
(14) 
17 (9) 0-12 - - 12 (7) 2-12 2 
(1) 
3-12 1 
(1) 
6 2 
(2)10 
- Y - - - - - 
Paterson 
(1984) 
(93) 
65 
(45) 
M: 59.9 
±10.9 
F: 60.5 
±7.6 
- - 53 
(40) 
- 2 
(1) 
- 11 
(5) 
- - - - - - Y Y Y 
Paterson 
(1983) 
(94) 
166 
(?) 
0-40 - - 166 
(?) 
0-40 - - - - - - - - - Y Y Y 
Sillence 
(1979) 
(7) 
154 
(?) 
-   127 
(?) 
- 21 
(?) 
- 8 
(?) 
 14 
(?)6 
- - - Y - - - 
Bauze 
(1975) 
(95) 
42 
(24) 
2-65 - - 25 
(16) 
4-65 17 
(11) 
2-56 3 
(2) 
4-43 - - Y - Y - - - 
Falvo 
(1974) 
(96) 
90 
(54) 
0.2-75 - - 35 
(22)11 
1-65 12 
(7)12 
0.2-18 48 
(25)13 
0.5-75 - - Y - Y Y Y - 
 
The table shows the included studies, the number of participants and the distribution of different phenotypes in each publication. We 
identified 20 publication through our literature search excluding our own publication (Paper II), the review includes 21 publications in 
total. The reported fracture outcomes are: The total number of fractures (N previous), the risk of fractures in patients with OI (IRR), age 
at first fracture (age at 1st), fracture rates per person year (Fx/year) and the pattern of fracture rates over time (Pattern). 1) Age at the 
start of the fracture register used to calculate fracture rates and incidence rate ratios. Total person-time at risk 10137.2 years. 2) Age at 
the start of the fracture register used to calculate fracture rates and incidence rate ratios. Total person-time at risk 53328.2 years. 3) 
Group comprising OI type V (16 (11)), type VI (11 (5)) and type VII (5 (5)) and unclassified and others (21 (12)). 4) Indicating the number 
or rate of vertebral fractures. 5) Spine X-ray only available in 92 of the 97 participants. 6) OI type II 7) Including information about previ-
ous fractures and number of fractures suffered after the age of 18 years of age. 8) Patients followed from birth until 10 years old. 9) Ref-
erence population matched to 23 of the patients, 10) patients with OI type II, both died early in life, 11) OI tarda II (mild), 12) OI congeni-
tal (severe), 13) OI tarda I (moderate) 
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5.2 RISK OF FRACTURES IN PATIENTS WITH OI  
By including a reference population, we were able to calculate the 
incidence rate ratio (IRR) for fractures between the OI and refer-
ence populations (2). The overall IRR was 8.1 [95% CI: 7.5-8.8]. Fig-
ure 9 shows the IRR between patients and the reference popula-
tion for different fracture sites. 
 
 
Figure 9. Incidence rate ratio according to fracture site, for men 
and women The IRR compares fracture rates in patients with OI 
and the reference population. The circles indicate the IRR, the error 
bars show 95% CI, and the arrows indicate wider CI or higher IRR 
than the figure scale allows. The vertical line indicates a value of 
1.00; if the CI crosses this line, the fracture rate for patients and 
reference population is not significantly different. 
 
Only one other study has compared fracture rates in patients with 
OI and healthy non-OI participants. This study included 23 patients 
with OI type IV without DI aged 5-11 years and a reference popu-
lation of otherwise healthy schoolchildren who were randomly re-
cruited though local schools (92). The patients had experienced an 
average of 16.7 fractures per person and the reference individuals 
0.22 fractures per person. While 34.8% of the OI patients had had 
a skull fracture, only 1% of the reference individuals had experi-
enced this (92). As the participants’ parents were interviewed at 
home about the fracture history, and information about fractures 
was based on a questionnaire, the results may be subject to recall 
bias. Selection bias may also be present, as the patients with OI 
may not have been representative of the British OI population.  
 
The lifetime number of fractures per individual in an otherwise 
healthy general population is unknown. In a British epidemiologi-
cal study of childhood fractures, one-third of boys and girls had at 
least one fracture before 17 years of age (97). The combined risk 
of having a common osteoporotic fracture for a women aged 50 
years during the remainder of her life is 30-40% (98). The inci-
dence rate for any fracture in Denmark in 2011 was 191 (95% CI: 
190-120) per 10,000 person years in people older than 20 years 
(99). In children, the peak fracture incidence is 1.5% in girls aged  
 
 
 
11, and 3% in boys aged 14 years (97). It is thus likely that the av-
erage number of fractures throughout life in an otherwise healthy 
general population is below one fracture per individual. The num-
ber of fractures in the OI population is much higher, as summa-
rised in Table 4. 
Table 4. Number of fractures reported in OI studies 
Author 
(year) 
Number of parti-
cipants 
(women) 
Age of partici-
pants 
Clinical Severity 
(OI type) 
Number of fractures per individual 
reported by Author 
Hald 
(2016)  
(20) 
58 (34) 47±17 I 10  
(range: 0-60) 
Hald 
(2016)  
(20) 
12 (5) 39±14 III 51  
(range: 15-150) 
Hald 
(2016)  
(20) 
15 (8) 44±12 IV 10  
(range: 0-25) 
Lindahl 
(2015)  
(84) 
151 (65) 23±17* I 11±12* 
Lindahl 
(2015)  
(84) 
29 (21) 23±19* III 48±40* 
Lindahl 
(2015)  
(84) 
42 (15) 20±12* IV 21±17* 
Wekre 
(2011)  
(48) 
74 (47) 45±12 I (range: 1-170) 
Wekre 
(2011)  
(48) 
9 (6) 35±7 III (range: 25-250) 
Wekre 
(2011)  
(48) 
11 (2) 47±7 IV (range: 4-300) 
McKier-
nan 
(2005)  
(88) 
111 (78) 41  
(range: 20-70) 
I, III, IV 31 
Moore  
(1998)  
(89) 
12 (7) 7  
(IQR: 6-15) 
- 8  
(IQR: 4-12) 
Davie  
(1994)  
(90) 
9 (3) 11±3 I 5  
(IQR:5-8) 
Andersen  
(1986)  
(14) 
12 (7) (range: 2-12) I (range: 1-13) 
Andersen  
(1986)  
(14) 
2 (2) - II >20 
Andersen  
(1986)  
(14) 
2 (1) (range: 3-12) III (range: 18-34) 
Andersen  
(1986)  
(14) 
1(1) 6 IV 0 
Bauze  
(1978)  
(95) 
22 (16) 25  
(range: 4-65) 
Mild 8  
(range: 1-25) 
Bauze  
(1978)  
(95) 
3 (2) 20  
(range: 4-43) 
Moderate 22  
(range: 7-30) 
Bauze  
(1978)  
(95) 
17 (6) 24  
(range: 2-56) 
Severe 43  
(range: 6-100) 
Falvo 
(1974)  
(96) 
43 (25) (range: 0.5-75) OI tarda II 7  
(range:1-23) 
Falvo 
(1974)  
(96) 
35 (22) (range:1-65) OI Tarda I 24  
(range: 1-105) 
Falvo 
(1974)  
(96) 
12 (7) (range:0.2-18) OI Congenita 70  
(range: 6-325) 
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  * Data are presented as mean±SD, but the standard deviation in-
dicates that the data are NOT normally distributed, and median 
(range) would have been more appropriate for presenting the data.  
Although the number of fractures experienced by patients with OI 
varies in these studies, nearly all patients with OI had experienced 
a fracture prior to study enrolment regardless of age, and the num-
ber of reported fractures far supersedes that expected in a non-OI 
individual.  
 
Andersen et al. (14) recorded the fracture history in the children 
identified through their epidemiological study of OI incidence and 
reported that patients with OI type I had between 1-13 fractures 
during the first 12 years of life, the two patients with OI type III had 
suffered 18 and 34 fractures whereas the one patient with OI type 
IV had not experienced any fractures at 6 years of age. The study 
was population based, but there were few patients with the more 
severe phenotypes included in the study. Two other studies on 
fractures in children reported a median of 5 and 8 fractures among 
children with median age of 11 and 8 years, respectively (89, 90). 
Both studies were very small, and the results may not apply to all 
children with OI. Moore et al. (89) included patients referred for 
evaluation due to multiple fractures, thus biasing the results by in-
dication. Davie et al. (90) included patients with OI and a positive 
family history of OI, and it can be argued that hospital-recruited 
participants represent the most severely affected patients. Even 
with these caveats, we must assume a higher fracture risk in chil-
dren with OI compared to the general population.  
 
In a group of 33 men aged 20-70 with mild (67%), moderate (30%), 
or severe (3%) OI, a median of 36 fractures was reported prior to 
study participation (88). The 78 women in the study had experi-
enced on average 28.5 fractures per participant (88). A Norwegian 
study of 97 adults with OI showed a varying number of previous 
fractures according to phenotype, where patients with type I OI re-
ported 1-170 fractures, patients with type IV reported 4-300 frac-
tures, and patients with type III reported 25-100 fractures; age did 
not differ significantly between these groups (48). A Swedish study 
also found that clinical phenotype was significantly associated with 
the number of fractures experienced up until the end of the obser-
vation period (84). Thus the patients with OI type I had the fewest 
fractures with an average 11±12 fractures (84), patients with OI 
type III had 46±40 fractures, and patients with OI type IV had 21±17 
fractures (84). The standard deviations indicate that the data were 
not normally distributed, however, and presenting the median 
(range) would have reflected the data better. A 1975 British study 
included 42 adults with OI including 22 with mild OI, 3 with moder-
ate OI, and 17 with severe OI with average age of 24 years (range 
2-56) (95). The patients with the severe phenotype had 5 times as 
many fractures (43, range 6-100) at the end of the study than the 
mild phenotype  (8, range 1-25), but all patients had experienced 
fractures prior to study inclusion (95). The patients with moderate 
OI had 22 fractures (range 7-30) (95). The tendency for more frac-
tures in more severe phenotypes was also seen in a Danish study 
of 85 adults with OI types I, III or IV (20) with no significant age 
differences between phenotypes. Patients with OI type I reported 
a median of 10 (range 0-60) fractures, as did the patients with OI 
type IV (20). However, patients with OI type III reported signifi-
cantly more fractures than the OI types I and IV combined (median 
51, range 15-150) (20). 
The relatively large number of fractures experienced by patients 
with OI leads to some uncertainty when relying on patient memory 
of fractures, some of which may have occurred many years earlier. 
Different approaches for fracture data acquisition were used in the 
included studies. The most frequent methods were questionnaires 
or structured interviews (20, 48, 88, 95), which may mean the frac-
ture data is more anecdotal, retrospective, and prone to a recall 
bias that will increase the variance in the number of fractures re-
ported. Nevertheless, although the total number of fractures expe-
rienced by patients with OI may be biased, our data (Paper II) and 
the literature confirm the hypothesis that patients with OI have a 
much higher fracture risk throughout life compared to the general 
population. 
5.3 AGE AT FIRST FRACTURE IN DIFFERENT PHENOTYPES OF OI 
Age at first fracture may indicate the severity of OI, as we would 
expect that patients with more severe phenotypes would experi-
ence intrauterine fractures or fractures during birth.  
 
In the 42 British patients studied by Bauze et al. (95), 9 of 17 pa-
tients with a severe phenotype had fractures at birth, compared to 
1 of 22 patients with a mild phenotype. The average age at fracture 
onset ranged from 0-18 years for the mildest phenotype (average 
3.5 years) and 0-11 years for a severe phenotype (average 1 year 
and 3 months) (95).  Sillence et al. (7) evaluated 156 patients 
treated for OI in Victoria, Australia. In 21 patients described as hav-
ing a progressively deforming OI with normal sclera or the pheno-
type Sillence later described as OI type IV, 66.7% had fractures at 
birth and 28.6% had a fracture in their first year of life (7). In pa-
tients with OI type I, Sillence found that 7.7% had fractures at birth, 
23.1% had a fracture in their first year of life, and most fractures 
occurred in preschool or school years; five patients aged 21 months 
to 29 years with the mildest phenotype had no previous fracture 
at study inclusion (7). The studies by Bauze et al. (95) and the Sil-
lence et al. (7) aimed to describe and classify patients according to 
common clinical traits. The studies included larger populations of 
patients with known OI recruited through hospital units. Selection 
bias cannot be ruled out. In another study of 78 patients classified 
as OI type IV without signs of DI, the median age at first fracture 
was under 1 year (range 0-11), and 25 patients had experienced a 
fracture at birth (92). This study was part of a larger survey and the 
limitations to the design have been described previously. In an rel-
ative small Egyptian cohort of 43 children with OI evaluated at 
mean age of 5.7 years (range 0-20), all those with OI type III had 
had a fracture in infancy (40% at birth), 77% of those with OI type 
IV had fractures at birth or in infancy, while over 50% of those with 
type I OI had their first fracture in early childhood (87). Fracture 
assessment was based on a structured interview, and even if the 
mean age was 5.7 years (range 0-20), this method is prone to recall 
bias. This is a typical limitation to studies on fracture history in OI. 
In a Brazilian study of 62 patients with OI type I, type III or IV with 
median age of 8 years (IQR: 2-14), fractures at birth had occurred 
in 6 of 31 (19%) patients with OI type I, 8 of 9 (89%) patients with 
OI type III, and 9 of 22 (41%) patients with OI type IV (86). Three of 
the patients with OI type I and one patient with OI type IV had no 
fractures prior to 60 years old, while 50% of patients with OI type 
I, 59% of patients with OI type IV, and 100% of patients with OI type 
III had experienced fractures prior to 6 years old (86). The study 
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was primarily aimed to evaluate clinical and functional features of 
children and adolescents with OI, and recruited patients from a 
secondary treatment centre for OI. Even though the distribution of 
patients with different phenotypes are close to what would be ex-
pected, it is likely that the participants were recruited from a more 
severely affected group of patients than what would be expected 
in the general OI population. This selection bias is hard to over-
come in studies of OI.   
5.4 FRACTURE RATES IN OI 
Obviously, the total (cumulative) number of fractures increases 
with age if a patient continues to experience fractures. This can 
make it difficult to compare fracture risk between patient groups, 
and between patients and the general population, if the groups are 
not matched for age. Annual fracture rates are comparable be-
tween age groups and are likely to vary at different stages of life. 
The fracture rates, found in our study, over time are shown in Fig-
ure 10. In our study, the fracture rate was highest in patients aged 
0-19 years (233.9 [95% CI: 219.9-247-8] per 1000 patient years) 
and lowest in patients aged 20-54 years (84.8 [95% CI: 75.5-93.8] 
per 1000 patient years). For patients aged over 55 years, the frac-
ture rate (97.4 [95% CI: 81.8-113.0] per 1000 patient years) was 
higher than for patients aged 20-54 (2). Although the relative risk 
in patients with OI decreased with age, the absolute lifetime risk of 
fracture was far higher in the OI cohort than in the reference pop-
ulation.  
 
A questionnaire study involving 111 adults with mild forms of OI 
and mean of 40.8 years showed that most fractures occurred prior 
to the patient’s 18th birthday, but 47.3% of spine fractures, 39.0% 
of hip fractures, and 34.7% of ankle fractures occurred after 18 
years (88). Most patients had previous wrist fracture (58.6%) 
and/or forearm fracture (68.5%), and only 10.4% of wrist fractures 
and 20.4% of forearm fractures occurred during adult life (88). Da-
vie et al. (90) evaluated 9 children with OI and found a median an-
nual fracture rate of 0.69 (range: 0.28-0.91), close to that reported 
by Moore et al. (89) in 12 participants (median annual fracture rate 
0.6; range: 0.4-3.4). The limitations to these studies have been de-
scribed earlier (section 5.2). In a Canadian study of 86 children and 
adolescents with OI type I, the annual fracture rate of long bones 
in 48 patients not treated with bisphosphonates was 0.62 (in a cu-
mulative follow-up time of 83.9 years). Long bone fracture was de-
termined by radiography, and the authors only counted fractures 
occurring within 24 months of the primary visit and only included 
patients with at least 6 months follow-up. This approach to frac-
ture data collection strengthens the study, but the relatively short 
cumulative follow-up time limits the results. In 43 Egyptian chil-
dren, the annual fracture rate was much higher as patients with OI 
type III had 8.5 fractures per year, patients with OI type IV had 5.8 
fractures per year, and patients with OI type I had 3.9 fractures per 
year (87). The between-group differences in fracture rates were 
not statistically significant (87). Falvo et al. (96) calculated the frac-
ture rates by dividing the total of fractures reported by each pati-
ent to the observation time for the patient, this approach where 
also used by others and does not illustrate the actual annual frac-
ture rates but a median/mean fracture rate in patients with OI. 
Falvo et al. (96) included 90 patients followed at their hospital cen-
tre and used patient reported fractures to calculate the fracture 
rates in patients aged 1-16 and found that patients diagnosed at 
birth had mean 10.6 (range: 2.3-29.5) fractures per year, patients 
with a more moderate phenotype (OI tarda I) had mean 2.0 (range: 
0.06-10) fractures per year and patients with the mildest pheno-
type had mean 0.4 (range: 0.06-1.27) fractures per year. This is 
much as would be expected as the diagnosis of OI is made partly 
based on the prevalence of fractures, and that fracture during birth 
or in utero will lead to a diagnosis of a more severe phenotype and 
thus more fractures is given. A direct comparison between pheno-
types, based on clinical traits, will be biased by the fact that the 
outcome (fracture rates) is used to group the patients and any be-
tween group comparisons will thus be bias by indication. This is 
discussed in detail in section 8.1.3.     
 
In an American study of 544 patients with a median age of 12.6 
(range 0-67), the annual fracture rate for patients with OI type III 
(1.6±2.2) was significantly higher than for patients with OI type I 
(0.5±0.7) or type IV (0.8±1.4) (83). Based on the standard devia-
tions in the study, these data are unlikely to be normally distrib-
uted and median values would have displayed the between-group 
differences better. The fractures rates were calculated by asking 
the patients to recall any fractures in the 12 months prior to study 
entry. This possibly limits the recall bias compared to a longer recall 
period. In a Swedish study of 222 patients, those with OI type III 
had a significantly higher annual fracture rate (3.8±9.3) than pa-
tients with OI type IV (1.3±1.4) or OI type I (0.6±0.7) (84). Again, 
the standard deviations suggest that median (range) values would 
have been more appropriate.  Fracture data were based on the to-
tal number of fractures recorded in patient medical charts at data-
base lock, without information about when the fracture occurred 
(84). Digit and rib fractures were not counted, and the annual frac-
ture rate was calculated by dividing the total number of fractures 
by the participant age (84). Medical charts are primarily a tool for 
physicians to document and communicate key findings of the pa-
tient’s medical history rather than a research tool, and their use 
may result in information bias. 
 
The annual fracture rates reported in patients with OI type I in the 
American, Swedish, and Egyptian studies were higher than those 
for patients with type I in a Norwegian study of adults with OI that 
reported an annual fracture rate of 0.12 (48). Fracture history was 
based on a structured interview, and recall bias cannot be ruled 
out although participants were only asked to recall fractures or or-
thopaedic surgery in the previous 12 months. The authors could 
not demonstrate any correlation between age and total number of 
self-reported fractures in women aged under 50 years, women 
over 50 years, or in men (48). This contrasts with the findings of 
Paterson et al. in their study of 45 women and 20 men over 50 
years old, where fracture rates increased from just above 0.1 frac-
tures per year in premenopausal women to nearly 0.5 fractures per 
year in women 20-25 years after menopause (93). Both studies col-
lected fracture data using structured interviews or questionnaires 
about experienced fractures and are prone to recall bias. The lack 
of an association between age and fractures in the Norwegian 
study could be because the youngest participants reported more 
fractures (range 1-170) than the oldest participants (range 4-100). 
Whether this was due to recall bias or lower fracture risk in pa-
tients with milder phenotypes is unclear. The authors of the Swe-
dish study compared fracture rates in children and adults with OI 
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types I, III and IV and found a non-significant higher annual fracture 
rate for children with all OI types (84). The standard deviations did 
indicate that the fracture rate data was not normally distributed. 
The authors used student’s t-test to evaluate the differences in 
fracture rates between adults and children with OI. This test as-
sumes a normal distribution of the data. No information was given 
about a transformation of the data to try to achieve a normal dis-
tribution and using a non-parametric statistical analysis would 
have been a more correct analysis of the between group differ-
ences.  Paterson et al.(93) reported a peak fracture rate of 1.6 frac-
tures per year in males with OI at the age of 5-10 years and a rapid 
decline to around 0.2 fractures per year in males older than 25 (93). 
Decreasing fracture rates were also found by Vetter et al. (91) who 
followed 127 patients with OI type I (n=40), OI type III (n=39) or OI 
type IV (n=48) for 10 years. Patients with OI type I had 0-1 fractures 
per year with a peak at 5 years of age, patients with OI type IV had 
a median fracture rate of 1 per year and decreasing fractures rates 
from the age of 2, while patients with OI type III had a median frac-
ture rate of 3 per year from birth, which slowly decreased over the 
observation period (91). Vetter et al. (91) evaluated all their pa-
tients every year for the first 10 years of life, and all fractures were 
confirmed by the authors using radiographs (91). This study design 
is the least prone to bias when evaluating fracture rate, site and 
number in patients with OI.  
 
In the American study by Patel et al. (83), 16 patients were catego-
rised as OI type V (OI with calcification in intraosseous membranes) 
and had an annual fracture rate of 1.6±2.7, 11 patients were cate-
gorised as OI type VI (a progressively deforming phenotype) and 
had an annual fracture rate of 1.8±1.6, five patients were catego-
rised as OI type VII (a common variable OI with normal sclera) and 
had an annual fracture rate of 0.4±0.8, and 21 patients were cate-
gorised as ‘unclassified and other’ and had an annual fracture rate 
of 11.8±14.5 (83). Due to the relatively large standard deviations, 
it is unlikely that the fracture rate data were normally distributed, 
and medians (range) would have been more appropriate. No data 
is available about changes in fracture rates over time in these more 
rare forms of OI.  
 
As would expected fracture rates are associated with OI type, as 
patients with OI type I appear to have under 1 fracture per year, 
whereas more severe phenotypes have more than 1 fracture per 
year. It must be remembered that the clinical grouping of patients 
according to severity will bias the results of any between OI type 
differences in typical fracture rates, as the most severe patients 
will have more frequent fractures than the mildly affected pa-
tients by definition. Only one study has evaluated the correlation 
between fracture rates and the genetic variants. The Swedish 
study did not, however, find any differences in the fracture rates 
between patients with helical mutations in the α1- vs. α2- chains 
or between patients with any qualitative mutations in the α1- vs. 
α2- chains (84). Fractures are more common in childhood than 
adulthood, and adult fracture rates appear to be highest in post-
menopausal women and older males. Our data (Paper II) and the 
literature confirm the hypotheses that fracture rates in OI follow 
the same pattern as in the general population, but with higher ab-
solute risk (and thus higher-rates). 
 
 
Figure 10. Fracture rates in OI in Denmark Fracture rates (shown 
in 5-year bands as rates per 1000 patient years) are highest in the 
youngest patients with OI and then decrease during adult life. The 
fracture rate increases in women of postmenopausal age, espe-
cially in the reference population. The OI and reference groups were 
fully matched for age, but shown here with a small offset on the x-
axis to make space for confidence interval bars. 
5.5 FRACTURE SITES IN OI 
In our study (Paper II), the sites with highest fracture incidence 
were the forearm and lower leg and ankle. The incidence rate ra-
tios for all sites (except for spine fractures in women over 55 and 
hip fractures in men over 55) were significantly higher in the OI co-
hort than in the reference population (2). Again it must be kept in 
mind that the clinical grouping of patients according to severity will 
bias the results of any between OI type differences in frequent 
fracture sites, as the most severe patients will have more frequent 
fractures than the mildly affected patients by definition. A study of 
genotype and fracture site correlation is not available.   
5.5.1 Long bone fractures in OI 
Fractures associated with falls, such as forearm and lower limb 
fractures, are frequent in young children. Among 62 patients aged 
0-18 years, 21 (78%) patients with OI type I had experienced an 
upper limb fracture, and 21 (78%) a lower limb fracture, while all 9 
(100%) patients with OI type III had experienced both upper and 
lower limb fractures. Among patients with OI type IV, 13 (59%) had 
experienced suffered an upper limb fracture and 22 (100%) a lower 
limb fracture (86). The study aimed at evaluating muscle strength, 
joint range of motion, and gait in children with OI, and they cor-
rected their analysis of the primary endpoints for differences in 
fracture history (which was gathered via clinical evaluation and 
structured interviews) (86). Lower limb fractures have been re-
ported as being more frequent than upper limb fractures in smaller 
study populations (87, 90).  
5.5.2 Vertebral fractures in OI 
Vertebral fractures are frequent in both children and adults with 
OI. In a Canadian study of 58 children with type I OI evaluated with 
lateral spine radiographs, fractures were found in 41 patients (49). 
In the total patient cohort, 179 vertebrae from Th3 to L4 were eval-
uated, and the most frequent fractures were in the Th7 or Th8 ver-
tebrae (49). The median number of fractures was higher in girls 
than to boys (median 4; range 0-14 vs. median 1; range 0-8, p=0.03) 
(49). In an Italian study including 44 children with OI type I, 4 chil-
dren with OI type III and 10 children with OI type IV, Diacinti et 
al.(85) visualised 738 vertebrae from Th4 to L4 on lateral x-rays. 
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Twenty-two of the 58 patients (38%) had no signs of vertebral frac-
tures, ten patients had one fracture, and 26 (45%) patients had 
more than one vertebral fracture (85). There seems to be a corre-
lation, as would be expected, between OI type and prevalence of 
vertebral fractures in children – vertebral fractures were seen in 47 
of 72 (65%) Swedish children with OI type I, 13 of 16 (82%) children 
with OI type IV, and all 15 children with OI type III (84). 
 
Vertebral fractures were more prevalent in adults. In the Swedish 
cohort, 62 of 79 (78%) adults with OI type I, 25 of 26 (95%) adults 
with OI type IV, and all 14 (100%) adults with OI type III had one or 
more vertebral fractures (84). In a Norwegian study of 92 adults 
with OI types I, III or IV, the most frequently deformed vertebra 
was Th7 with 50% of all patients showing deformity of this vertebra 
(25). The authors evaluated a spinal deformity index by semi-quan-
titatively evaluating each visible vertebra and grading the deform-
ity from normal to severe; they found the index to be higher in pa-
tients with OI type IV than in patients with OI type I (25). 
5.5.3 Other fractures frequently reported in OI 
In a group of 166 patients with OI type I, 49 (29.5%) patients re-
ported at least one previous rib fracture, and 14 (8.4%) patients 
reported a previous skull fracture (94). In a group of 78 patients 
with OI type IV without DI, 31 (39.7%) patients had experienced a 
rib fracture, and 22 (28.2%) had had a skull fracture (92). Among 
111 participants in a questionnaire study evaluating the musculo-
skeletal manifestations of mild OI in adults, 67% reported finger 
fractures, 49% foot fractures, and 63% toe fractures (88). Among  
the Norwegian study participants, 54% reported fractures to the 
ribs, clavicle, mandible or maxilla, nose, pelvis, or scapula (48).  
 
In most of the reviewed literature, more patients had experienced 
a lower limb fracture than an upper limb fracture. In British chil-
dren, however, the most frequent fracture in both sexes was lower 
arm or wrist fractures (97). The reason for this difference is un-
clear. The Swedish lifetime risk of a fracture was 13.3% for shoul-
der, 21.5% for forearm, 23.3% for hip, and 15.4% for spine in oth-
erwise healthy women aged 45 (98). The lifetime risk of fracture in 
otherwise healthy men aged 45 was 4.4% for shoulder, 5.2% for 
forearm, 11.2% for hip, and 8.6% for spine (98). The lifetime risk 
for these fractures in OI patients is close to 100% for all OI types.  
5.6 CONCLUSION 
Our study (Paper II) and the literature confirm our hypothesis that 
patients with OI have higher fractures rates than the general pop-
ulation, and that the relative fracture risk decreases with increas-
ing age. Furthermore, our study (Paper II) and the literature con-
firm our hypothesis that the fracture pattern in OI (i.e. which bones 
fracture at which stages of life) mimics that in the general popula-
tion. To better understand the mechanisms and causes of fractures 
in OI longitudinal studies of OI patient cohorts are needed, prefer-
ably powered to be able to evaluate the genotype to fracture rate 
correlation. These studies should also include a sizeable group of 
treatment naïve patients, patients who start fracture prophylactic 
treatment and the possibility to evaluate the effect of treatment 
over time. These studies should also include routine evaluation of 
the spine to capture clinically silent vertebral compression frac-
tures as well as close follow-up to minimise the risk of recall bias 
and non-registration bias of ‘home-treated’ fractures.  
6. BONE -MINERAL DENSITY, -GEOMETRY AND -MICROARCHITEC-
TURE IN OI 
This chapter evaluates the current literature on bone mineral den-
sity (BMD), bone geometry, and bone microarchitecture in OI. 
Whole-bone strength depends on the amount of bone (or bone 
mass, often measured as BMC), the spatial distribution of the bone 
mass (geometry), microarchitecture of the bone (often evaluated 
by e.g. pQCT, HRpQCT or histomorphometric evaluations of bone 
biopsies), and the intrinsic properties of the materials that form 
the bone (65). In otherwise healthy individuals, BMD decreases 
with age more rapidly in women in the peri-menopausal years than 
in men, meaning that more women than men have areal BMD 
(aBMD) in the osteoporotic range (100). Human bone is about 60% 
mineralised to provide optimal flexibility without becoming brittle 
(101). Bone stiffness is increased in OI; the bones are more “brittle” 
and absorb less energy before fracturing (68). A change in collagen 
properties may alter the amount and disposition of the mineral, 
which would by itself affect the bone properties and strength 
(102). We know that collagen type I is quantitatively or qualita-
tively altered in most forms of OI (9). Defects in ossification and 
mineralisation have been described in more rare forms of OI, such 
as OI type V and VI where the primary defects are in endochondral 
bone ossification or mineralisation (9). In recessive OI types XV, XVI 
and XII, the osteoblast differentiation is impaired (9), further un-
derlining the multifactorial causes of bone fragility in OI.  
 
Bone adapts to sustain the loads it is exposed to. With the age-
related bone loss that is seen in otherwise healthy individuals, tra-
becular thinning leads to trabecular loss and decreased bone 
strength, and the continued bone remodelling results in trabecu-
larisation of the endosteal surface of cortical bone (101). The cor-
tical thinning and increased porosity is compensated by increased 
bone area through the deposition of new bone on the periosteal 
surface of the bone (101). The increase in outer diameter helps to 
maintain the resistance to bending and torsional loads (65). 
Whether these mechanisms hold true for human OI bone is un-
known. In OI mouse models, compensatory periosteal apposition 
has been found (103). More knowledge about the skeletal pathol-
ogy in OI may improve our understanding of the mechanisms be-
hind the increased fracture rates in OI. 
 
We performed a cross-sectional study including 39 patients with OI 
type I and evaluated the three main components of whole-bone 
strength (BMD, bone geometry, and bone microarchitecture) using 
HRpQCT and DXA. We compared patients with OI to an age- and 
gender-matched reference population selected from a random 
sample of the general population, as described in Paper III (3). 
HRpQCT is designed for in vivo assessment of volumetric bone min-
eral density, bone geometry, and bone microarchitecture at the 
distal radius and tibia. The analysis is quick, taking approximately 3 
minutes, and gives less than 5 µSv of radioactive exposure per scan, 
covering a 0.9 cm volume of interest at the ultradistal radius and 
tibia. The voxel resolution is 82 μm, as the scan is made up of 110 
parallel scan slices. This allows for segmentation of cortical and tra-
becular bone volumes. Trabecular bone volume per tissue volume 
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(BV/TV) is derived from the mean trabecular volume density, as-
suming a mineral density of fully mineralised bone of 1.2g HA/cm3 
(104). Three-dimensional assessments of trabecular thickness and 
spacing are derived from BV/TV by the formula: Tb.Th= BV/TV / 
Tb.N and Tb.Sp= (1-BV/TV)/Tb.N, as used for standard histomor-
phometric evaluation of bone biopsies (105). The trabecular num-
ber (Tb.N) is extracted directly. The standard structure extraction 
and morphometric evaluation is performed as described by Laib et 
al. (106). Burghardt et al. (107) have developed a fully automatic 
segmentation method that identifies the periosteal and endosteal 
boundaries of the bone, thus isolating the cortical bone compart-
ment and allowing evaluation of the cortical volumetric density, 
cortical thickness, and cortical porosity. A fixed offset of 9.5 mm in 
radius and 22.5 mm in tibia from the reference line, typically 1/3 
to 1/2 of the endplate midline in the horizontal direction, forms the 
start of the scan region, which is 9.02 mm in the axial length of the 
radius and tibia. This may result in some bias to cross-sectional 
studies, as scanning patients with shorter limbs and comparing 
them to persons with longer limbs may result in a comparison of 
relatively more distal parts of the radius and tibia to more proximal 
parts of the bones (108). This may have introduced some bias to 
our study, as we did not take extremity length into account.   
6.1 LITERATURE SEARCH 
The literature search was conducted as described in section 3.3 
(inclusion and exclusion-criteria) and Appendix 1.3 (search dates, 
search strings and search results) and aimed to identify all studies 
evaluating BMD, bone geometry, and bone microarchitecture in 
OI. A flow diagram of the study selection can be seen in Figure 11. 
A total of 2155 publications were found via Embase, 1470 via 
PubMed, and 102 via Cochrane Library. After excluding 920 dupli-
cates, 2807 titles and/or abstracts were screened for eligibility 
and resulted in 77 publications for full-text screening. After ex-
cluding 44 articles not covering the subject matter, including less 
than 10 patients with OI or no reference group of non-OI individu-
als (though accepting fewer participants for histomorphometric 
studies on bone biopsies), describing mineralisation rates, re-
views or without patient data, a total of 33 (including Paper III (3)) 
publications were included in the review. Details about the differ-
ent study methods and participant characteristic can be seen in 
Table 5 and 6. 
 
 
Figure 11. Flow diagram of study selection for studies on bone 
mass, geometry, and microarchitecture OI 
 
Table 5. Studies on bone mass, geometry, and microarchitecture in OI 
Author (year) Met All patients Reference population Type I Type III Type IV Other types  
N (W) Age N (W) Age N (W) Age N (W) Age N (W) Age N (W) Age D G S 
Hald  
(2016) (20) 
A, B 85 
(47) 
- - - 58 
(34) 
46.5 
±16.6 
12 
(5) 
38.8 
±13.5 
15 
(8) 
43.5 
±12.4 
- - Y Y Y 
Kocijan 
(2015) (109) 
A, B 30 
(13) 
42.8 
[34.1-57.5] 
30 
(13) 
43.5 
[38.2-51.9] 
18 
(9) 
41.8 
[34.7-55.7] 
- - - - 12 
(4)1 
47.6 
[35.3-58.4] 
Y Y Y 
Lindahl 
(2015) (84) 
A 222 
(121) 
- - - 151 
(86) 
17.51 
±13.94 
29 
(8) 
17.72 
±14.08 
42 
(27) 
17.32 
±10.61 
- - Y   
Diacinti 
(2015) (85) 
A 58 
(25) 
9.7 
±8.5 
- - 44 - 4 - 10 - - - Y   
Patel 
(2015) (83) 
A 544 
(304) 
12.6 
(0-67) 
- - 244 
(131) 
13.6 
(0-67) 
100 
(58) 
11.4 
(0-54) 
147 
(82) 
12.0 
 (0-63) 
53 
(33)2 
1-33 Y   
Imbert 
(2014) (110) 
C 6 
(3) 
13 
(7-21) 
3 
(2) 
14 
(8-16) 
- - - - - - - -   Y 
Veilleux 
(2015) (111) 
D 30 
(20) 
11.20 
±3.89 
30 
(20) 
11.02±4.15 30 
(20) 
11.20 
±3.89 
- - - - - - Y Y  
Ben Amor 
(2013) (49) 
A 86 
(50) 
13.3 
(0.6-54) 
- - 86 
(50) 
13.3 
(0.6-54) 
- - - - - - Y   
Folkestad (2012) (3) A,B 39 
(26) 
53 
(21-77) 
39 
(26) 
53 
(21-77) 
39 
(26) 
53 
(21-77) 
- - - - - - Y Y Y 
Swinnen 
(2012) (112) 
A,D 56 
(34) 
43 
±13.7 
- - 49 
(-) 
- - - 7 
(-) 
- - - Y  Y 
Aglan 
(2012) (87) 
A 43 
(26) 
5.7 
(0.05-20.0) 
- - 11 
(9) 
6.6 
(3.3-12.6) 
22 
(11) 
5.5 
(1.4-17.8) 
9 
(5) 
10.0 
(3.9-20.0) 
1 
(1)3 
0.5 Y   
Wekre 
(2011) (48) 
A 90 
(-) 
adult - - 68 
(-) 
Adult 9 
(-) 
adult 11 
(-) 
adult - - Y   
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Kutilek 
(2010) (113) 
E 18 
(6) 
9.8 
±3.5 
- - - - - - - - - - Y   
Garnero 
(2009) (114) 
A 64 
(25) 
37 
±12 
- - - - - - - - - - Y   
Roschger 
(2008) (115) 
A, C 19 
(6) 
2-15 19 
(6) 
- 19 
(6) 
2-15 - - - - - - Y Y Y 
Rauch 
(2005) (116) 
A, D 42 
(17) 
6.0-19.9 - - 42 
(17) 
6.0-19.9 - - - - - - Y Y Y 
Kok 
(2003) (117) 
A 54 
(29) 
1-18 - - 30 
(17) 
1-18 - - - - 24 
(12)1 
6-16 Y   
Gatti 
(2003) (118) 
A,D 27 
(15) 
34.0 
±6.8 
41 
(23) 
32.1±7.7 19 
(9) 
- 2 
(2) 
- 6 
(4) 
- - - Y Y Y 
Rauch 
(2000) (119) 
C 70 
(40) 
7.6 
±3.6 
27 
(10) 
7.6±3.9 32 
(12) 
7.6 
±3.8 
11 
(5) 
7.9 
±2.9 
27 
(13) 
7.5 
±3.6 
- -   Y 
Cepollaro 
(1999) (120) 
A,E 21 
(10) 
35.1 
±15.9 
21 
(10) 
34.9±10.9 - - - - - - 21 
(10)4 
35.1 
±15.9 
Y   
Lund 
(1999) (121) 
A 63 
(30) 
5.0-63.5 - - 36 
(17) 
5.0-63.5 13 
(5) 
4.0-37.2 14 
(8) 
5.0-52.9 - - Y   
Miller 
(1999) (122) 
F 14 
(-) 
0.8-45 <1000 Adults + 7 infants 14 
(-) 
0.8-45 - - - - - - Y   
Moore 
(1998) (89) 
A 12 
(7) 
7.35 
(4.5-16.9) 
14 
(9) 
9.45 
(5.1-16.6) 
- - - - - - - -    
McCarthy 
(1997) (123) 
C 8 
(5) 
34-50 - - 8 
(5) 
34-50 - - - - - -   Y 
Jones 
(1997) 
(124) 
C 54 
(?) 
1.9-17.3 58 
(?) 
1.9-22.9 23 
(?) 
1.9-13.6 8 
(?) 
5.3-13.8 18 
(?) 
4.6-17.3 5 
(?)5 
5.1-13.8   Y 
Paterson 
(1994) (125) 
A 61 
(-) 
Adult 380 Adults 47 
(32) 
Adult 3 
(0) 
Adult 11 
(8) 
Adult   Y   
Nuti 
(1988) (126) 
A 12 
(7) 
8-53 162 
(88) 
- 12 
(7) 
8-53 - - - - - - Y   
Kurtz 
(1985) (127) 
F 27 
(14) 
6-73 22 - 14 
(7) 
6-73 8 
(5) 
10-48 5 
(2) 
12-60 - - Y   
Ste-Marie 
(1984) (128) 
C 12 
(4) 
5-69 - - - - - - - - 12 
(4)1 
5-69   Y 
Baron 
(1983) (129) 
C 9 
(7) 
6.3-14.1 5 
(-) 
6-15 - - - - - - 9 
(7)7 
6.3-14.1   Y 
Pedersen 
(1979) (130) 
A 22 
(14) 
14-78 63 
(28) 
21-68 - - - - - - 22 
(14)8 
14-78 Y  Y 
Nielsen 
(1979) 
(131) 
A 21 
(13) 
14-78 - - - - - - - - 21 
(14)8 
14-78 Y   
Riley 
(1973) (132) 
C 20 
(8) 
0.1-33 - - 4 
(1) 
6-13 4 
(2) 
1.7-33 12 
(5) 
0.1-30 - -   Y 
The table shows the number of participants and distribution of phenotypes in each publication. The different modalities used to evaluate 
BMD, bone geometry or bone microstructure were A) DXA, B) HRqQCT, C) Bone biopsy, D) pQCT, E) Quantitative ultrasonometry of the 
calcaneus, and F) CT scan. 1) Including patients with types III and IV. 2) Group comprising 16 (11 women) OI type V, 11 (5) type VI, 5 (5) 
type VII, and 21 (12) unclassified/other. 3) Type II OI. 4) Group comprising OI types I and IV. 5) Patients with OI Type V. 6) Same popula-
tion as described in Jones et al. (1999). 7) OI tarda. 8) Phenotype not state 
 
6.2 BONE MINERAL DENSITY IN OI 
Measurements of areal BMD (aBMD, in gHA/cm2) in the spine and 
hip are used as in vivo surrogate measures for bone fragility. aBMD 
is, at least in the general population and patients with osteoporo-
sis, correlated to the risk of fractures (133). The risk of vertebral 
fractures is doubled for every standard deviation decrease in lum-
bar aBMD (134). The correlation between aBMD and fracture risk 
in OI is not well described, and the effect of a decrease in aBMD on 
the OI fracture risk is unknown. Eventhough studies regarding the 
fracture predictability using aBMD is lacking, aBMD is often used  
clinically to evaluate the need for fracture prevention treatment in 
patients with OI and for research as an endpoint in most treatment  
trials. aBMD, as measured by DXA, is a measurement of the com-
bined cortical and trabecular BMD and is confounded by bone size 
Due to the mode of measuring the BMC by DXA will overestimate 
the true BMD in larger bones. It is possible to measure the volu-
metric BMD (vBMD) of the cortex and cancellous compartment 
alone using pQCT or HRpQCT (135). This measurement of vBMD, in  
gHA/cm3, is independent of bone size (135). The differences in 
aBMD and vBMD is shown in figure 12.  
 
 
Figure 12. Bone size and aBMD The bone size will influence the 
aBMD due to the lack of the third dimension during measurement. 
The figure shows how the aBMD is overestimated in large bones 
due to bone area alone. The DXA scanner sends two beams (with 
different energy) of small dose ionizing radiation from the x-ray 
source above the patient aimed at the patient’s hip or lumbar spine. 
The detector underneath the patient can then be used to calculate 
the BMD. Adapted from Binkley et al. (135) and Boudreaux  et al. 
(136) 
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6.2.1 aBMD in OI 
In the cross-sectional study (Paper III) of patients with OI type I, 
we found significantly lower aBMD in the lumbar spine and the 
total hip than in age- and gender-matched otherwise healthy indi-
viduals, randomly selected from the general population (3). Table 
6 summarises the findings for aBMD from the studies that re-
ported a T- or Z-score included in this review. 
Table 6. Areal bone mineral density in patients with OI 
Author (year) Site Age group or  
(range) 
OI type I OI type III OI type IV Other OI Ty-
pes 
Kocijan 
(2015) 
(109) 
Spine Adult -2.5 
[-3.3 to -
1.0]1 
  -3.1 
[-4.6 to -
1.9]1,2 
Kocijan 
(2015) 
(109) 
Hip Adult* -1.3 
[-1.9 to -
0.6]1 
  -2.7 
[-3.4 to -
2.7]1,2 
Lindahl (2015) 
(84) 
Spine Children* -2.4±1.5 -5.0±1.4 -4.2±1.4  
Lindahl (2015) 
(84) 
Spine Adult* -3.0±1.4 -5.0±2.6 -4.3±1.8  
Diacinti 
(2015) 
(85) 
Spine Children    -2.5±1.33 
Patel 
(2015) 
(83) 
Spine Children* 
(9-11) 
-1.5±1.0 -2.8±1.7 -1.8±1.1  
Patel 
(2015) 
(83) 
Spine Children* 
(12-18) 
-1.4±1.4 -4.3±3.4 -2.3±14  
Patel  
(2015) 
(83) 
Spine Adults -2.0 
[-3.5 to -
0.5] 
-3.8 
[-4.5 to -
3.5] 
-2.3 
[-3.5 to -
1.0] 
 
Patel 
(2015) 
(83) 
Spine (1-33) - - - -1.84 
-1.35 
-3.36 
Swinnen 
(2012) 
(112) 
Spine Adult - - - -2.1±1.47 
Ben Amor 
(2012) 
(49) 
Spine (0.5-54) -3.0±1.2 - - - 
Algan  
(2012) 
(87) 
Spine (0-20) -1.6 -3.4 -2.7 - 
Wekre (2011) 
(48) 
Spine Adult* -1.9±1.1 - -3.2±0.7 - 
Author (year) Site Age group or  
(range) 
OI type I OI type III OI type IV Other OI Ty-
pes 
Wekre (2011) 
(48) 
Hip Adult -1.6±1.3 - -1.1±1.8 - 
Wekre (2011) 
(48) 
WB Adult* -0.3±1.0 -1.3±0.9 -0.5±0.9 - 
Garneo 
(2009) 
(114) 
Spine Adult - - - -3.6±1.01,7 
Garneo 
(2009) 
(114) 
Hip Adult - - - -2.2±1.01,7 
Roschger 
(2008) 
(115) 
Spine Children -3.7 
[-4.9 to -
2.5]8 
- - - 
Roschger 
(2008) 
(115) 
Spine Children -3.9 
[-5.0 to – 
2.9]9 
- - - 
Rauch (2005) 
(116) 
Spine Children -2.8±1.0 - - - 
Gatti  
(2003) 
(118) 
Spine Adult - - - -36%10 
Gatti  
(2003) 
(118) 
Hip Adult - - - -32%10 
Cepollaro 
(1999) 
(120) 
Spine Adult - - - -3.91,7 
Lund  
(1999) 
(121) 
Spine Children* -4.2 -11.4 -5.6 - 
Lund  
(1999) 
(121) 
WB Children* -1.6 -4.2 -2.6 - 
Lund  
(1999) 
(121) 
WB Adult* -2.21 -5.21 -3.11 - 
Moore (1998) 
(89) 
Spine Children - - - -3.1±0.911 
Moore (1998) 
(89) 
WB Children - - - -2.4±1.711 
McCarthy 
(1997) 
(123) 
Fem 
Neck 
Adult -1.6 
[-2.1 to 0] 
- - - 
McCarthy 
(1997) 
Spine Adult -2.8 - - - 
(123) [-0.3 to -
4.1] 
Nuti 
(1988) 
(126) 
WB 8-53 ~30%12 - - - 
Nielsen 
(1979) 
(131) 
Fore-
arm 
Adult - - - 77.1%13 
The table shows the Z- or T-scores in patients with OI. 1) T-scores 
reported. 2) Including patients with OI type III AND IV. 3) Including 
patients with OI type I, III and IV. 4) Patients with OI type V. 5) pa-
tients with OI type VI. 6) Patients with OI type VII. 7) Including pa-
tients with OI type I AND IV. 8) Patients with OI type I and quanti-
tative collagen defects. 9) Patients with OI type I and qualitative 
collagen defects. 10) Includes patients with OI type I, III AND IV and 
indicates the ∆% difference between patients and healthy age- and 
gender-matched controls. 11) OI type not clearly stated. 12) Per 
cent of BMD in a young healthy individual. 13) Phenotype not 
stated, shows the % of forearm BMC compared to age and gender 
normal values  * The between-group difference is significant. WB: 
whole body. 
 
All the included studies were cross-sectional in nature, and only a 
few included a non-OI reference group. Most studies reported the 
participants’ mean or median Z-score for aBMD. Z-scores indicate 
the number of standard deviations a measured aBMD differs from 
a normative database matched for age, gender, ethnicity, and 
sometimes weight (137). The median number of participants in the 
studies was 56 (range: 8-544). Study participants were usually re-
cruited through hospital wards, and selection bias favouring more 
severely affected patients cannot be ruled out. 
 
In patients with OI the aBMD was lower than the reference mate-
rial or reference group at both the total hip, lumbar spine , whole 
body and as was aBMC at the forearm compared to demograph-
ically similar populations from normative database data (3, 48, 49, 
83-85, 87, 89, 109, 112, 114-118, 120, 121, 124-126, 130). When 
different OI types were compared, patients with the most severe 
types had the lowest aBMD at the hip, spine and whole-body (20, 
48, 83, 84, 109, 121). Among children aged 0-8 years, Patel et al. 
(83) found no difference between OI types in lumbar spine aBMD, 
but from age 9, the patients with OI type I had a significantly higher 
aBMD than patients with OI type IV and OI type III (83). The ratio 
of aBMD to body weight was higher in healthy children than in chil-
dren with OI, meaning that the OI bone was more heavily loaded 
than healthy bone (117). In patients, the aBMD to weight ratio was 
lower in the more severe types III and IV than in OI type I. The study 
included 30 children with OI type I and 24 children with OI type III 
or IV, and compared their measured values to aBMD of the general 
population and weight reference material (117). 
Four studies reported aBMD T-score in adults and found that pa-
tients with OI type I had T-scores of -2.5 at the spine, -1.3 at the 
hip, and -2.2 for whole-body BMD. T-scores were lower in more 
severe types (-3.6 to -3.9 for spine, -2.2 for hip, and -2.2 to -5.2 for 
whole-body aBMD) (109, 114, 120, 121). It should be noted that 
these studies had few patients with severe OI types, and the inter-
individual variation was large.  
An increase in aBMD would be expected in puberty, as children 
grow and achieve peak bone mass in early adulthood (138). In an 
American cross-sectional multicentre study, Patel et al. (83) com-
pared the aBMD of young OI children to that of young OI adults to 
investigate for a pattern of increasing aBMD with age. For OI type 
I and IV, they found a higher aBMD in children aged 12-18 than in 
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children aged 9-11, but this was not seen in OI type III (83). While 
the Z-score in children with OI type I and IV came closer to 0.0 with 
increasing age, this was not seen in patients with OI type III 
(83).This study was not longitudinal and therefore a direct compar-
ison between the age groups cannot be made. For reasons not 
known, the patients aged 12-18 in the Patel et al. study (83) may 
have been more severely affected by their disease than the 
younger patients. While 100 children with OI type III were enrolled 
in the study, the number of participants in each age group is un-
known, and a low statistical power cannot be ruled out when com-
paring the two age groups.   
 
The aBMD seen in patients with OI overlaps the range seen in oth-
erwise healthy individuals (125). In patients with OI type I, 62% had 
a distal radius aBMD above -2 standard deviations, and 30% had a 
distal radius aBMD above -1 standard deviation (125). The propor-
tion of patients with distal or proximal radius aBMD above -2 
standard deviations was similar in OI type IV (125). There are cur-
rently no longitudinal studies powered to evaluate whether aBMD 
can predict fractures in OI (as it does in osteoporosis). Patel et al. 
(83) performed a logistic-regression analysis to evaluate if aBMD 
could predict fractures, and found no significant correlation be-
tween the lumbar spine aBMD (by DXA) and fractures in the previ-
ous 12 months. The clinical heterogeneity observed in their partic-
ipants limited the analysis, as patients with near-normal aBMD had 
had fractures in the previous year while patients with very low 
aBMD had not (83). In patients with OI type I, whole-body BMD and 
male gender were predictors of more prevalent fractures in the 
Norwegian OI population (48). While neither of these studies was 
designed to evaluate the predictive value of aBMD for fractures in 
OI, there seems to be a poor correlation between aBMD and frac-
ture risk in OI. Typical skeletal findings are shown in figure 13. 
 
 
Figure 13. Typical bone findings in OI The figure summarises the 
densitometric, geometric, and microarchitectural findings in OI. 
Cort. = Cortical, aBMD= areal BMD, vBMD= volumentric BMD, 
Trab.= trabecular, Tb.N= trabecular number, Tb.Th = trabecular 
thickness, Tb.1/N.SD = the inhomogeneity of the trabecular net-
work, BV/TV= bone volume per tissue volume. 
6.2.2 vBMD in OI 
6.2.2.1 Total vBMD in OI 
Using HRpQCT we compared 39 patients with OI type I to 39 
healthy age- and gender-matched reference participants (Paper 
III), and found the total vBMD of the ultradistal radius was non-
significantly lower in the OI group (285±75 vs. 316±83 mgHA/cm3, 
p=0.13) (3). Similar results were reported in an Austrian population 
of 30 patients with OI types I, III or IV using HRpQCT to evaluate the 
total vBMD of the ultradistal radius (109). In contrast the total 
vBMD in the ultradistal radius was significantly lower (-19%), how-
ever, in patients with OI types I, III and IV compared to a matched 
non-OI reference group when evaluated by pQCT (118). We did 
find that the total vBMD of the ultradistal tibia was significantly 
lower in patients with OI than in the reference group (3), and this 
has been confirmed in later studies in adults with OI type I or type 
III and IV using HRpQCT (109) and in children with OI type I using 
pQCT (111).  
 
Total vBMD in the radius was lower in children with type I OI than 
in healthy individuals in the metaphysis but not the diaphysis (116). 
Children with OI type I have higher total vBMD in diaphyseal bone 
than expected for their age, gender, and height, explained by the 
relatively large cortical area and an elevated cortical vBMD (116). 
In contrast to aBMD, total vBMD in radius and tibia was highest in 
more severe phenotypes (OI type IV or III) than in OI type I (20, 
109). Patients are seated for the HRpQCT evaluation, and the arm 
or leg is placed in a carbon-fibre cast that slides into the HRpQCT 
gantry. In some patients with severe OI, it may be difficult to eval-
uate the bone using HRpQCT due to bone deformities and short 
limbs. This may introduce some selection bias by excluding the 
most severely affected patients.  
6.2.2.2 Cortical vBMD in OI 
We found no difference in cortical vBMD in the ultradistal radius 
or tibia between patients with OI type I and a healthy reference 
group (Paper III) (3). In severe phenotypes, cortical vBMD in the 
radius was equal in adult patients to than in a healthy reference 
group, but trended towards higher values of vBMD (109, 118). In 
the diaphyseal radius in children with OI type I, the cortical vBMD 
was 6% higher than expected according to age, gender, and height 
(116). In tibia, no difference in vBMD was found compared to non-
OI participants, regardless of age or phenotype (109, 111). Millar 
et al. (122) found that cortical vBMD was higher in 4 adults, 3 young 
adults, and 7 children with OI compared to healthy age-matched 
reference individuals using plain CT of the distal radius and tibia, 
but this study was small and type I error (findings being by chance) 
cannot be ruled out. Furthermore, the study included participant 
from two families that may share genetic background, and thus se-
lection bias cannot be ruled out. In other long bones, the cortical 
vBMD was significantly lower in patients with OI compared to a ref-
erence population (110), although these data were based on 6 
bone samples extracted during orthopaedic surgery in patients 
with OI, and 3 samples from age-matched children without OI. The 
reliability of the reference material can be questioned, and patient 
selection may be biased by indication for surgery. There were no 
significant differences in cortical vBMD in the radius or tibia be-
tween patients with OI type I and more severe phenotypes (20, 
109). This is summarized in figure 13.  
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6.2.2.3 Trabecular vBMD in OI 
In patients with OI type I, we found trabecular vBMD to be signifi-
cantly lower than in a healthy reference group (3). This has been 
consistently reported in both radius and tibia regardless of pheno-
type and age (109, 111, 116, 118, 122, 127). Danish patients with 
OI type III had lower trabecular vBMD in the radius when compared 
to patients with OI type I or OI type IV (20). Austrian patients with 
OI type I had higher trabecular vBMD in both radius and the tibia 
when compared to patients with more severe phenotypes (109). 
 
Our data (Paper III) and the literature confirm the hypothesis that 
bone mass is lower in patients with OI than in non-OI individuals. 
This is summarized in figure 13.  
6.3 BONE GEOMETRY IN OI 
Bone size is an important predictor of bone strength, as larger bone 
is stronger than smaller bone. Laboratory testing of bone strength 
using human cadaveric vertebrae, distal radii and proximal femora 
have shown that larger bones have higher compression and bend-
ing strength, independent of aBMD (65). The geometrical proper-
ties of the hip, as evaluated with hip structure analysis based on 
DXA, are more strongly correlated with hip strength than aBMD 
(139). Whether this is true for patients with OI is unknown, but us-
ing the commercially available software for hip structure analysis 
we were able to illustrate that patients with OI had lower aBMD of 
the hip and shorter hip axis length, as well as narrower cross-sec-
tional area and lower cross-sectional moment of inertia and sec-
tional modulus (both indicators of bone strength) in the femoral 
neck, intertrochanteric region, and the femoral shaft (140). Age-
related changes in bone geometry occur and to some extent atten-
uate the impact of the age-related decrease in BMD and bone 
strength. In the appendicular skeleton, endosteal resorption and 
periosteal apposition lead to an age-related increase in total bone 
area but decreased cortical thickness (65). Men have larger bone 
than women, but also load the skeleton with more weight (65). 
Correlations have been shown between fracture risk and bone size, 
reduced cross-sectional area of the radius is a risk factor for wrist 
fractures in young girls and postmenopausal women, and cortical 
thickness is consistently lower in those with hip fractures (65). To-
tal bone cross-sectional area, cortical area, and trabecular area can 
be evaluated non-invasively using HR-pQCT or pQCT for distal tibia 
and radius or QCT for the hip or vertebrae. Findings regarding bone 
size is summarized in figure 13.  
6.3.1 Total bone area in OI 
We found that patients with OI type I had significantly smaller total 
bone area in the radius than in age- and gender-matched healthy 
controls (3). Adults with OI type I, III or IV had significantly smaller 
total bone area at both proximal (diaphyseal) and distal (metaph-
yseal) radius (118), as did children with OI type I (116). We saw no 
difference in total bone area in the distal tibia between patients 
with OI type I and healthy adults (3). Total bone area was similar 
between patients with OI type I, type III, and type IV in both tibia 
and radius (20). 
6.3.2 Cortical bone area in OI 
We and others have found that the cortical area at the distal radius 
was significantly smaller in patients with OI than in healthy refer-
ence individuals (3, 116, 118). In children, the cortical area was sig-
nificantly larger at the diaphyseal site of the radius when evaluated 
by pQCT (116). We found a smaller cortical area in the distal tibia 
in patients with OI type I compared to healthy controls when eval-
uated by HRpQCT (3). This has also been found using pQCT to eval-
uate the tibia in patients with OI type I (111). Cortical bone area in 
both radius and tibia was larger in patients with OI type IV than in 
patients with OI type I, and smallest in patients with OI type III (20). 
6.3.3 Trabecular bone area in OI 
We found that trabecular bone area in the radius tended to be 
smaller (p=0.07) in OI than in age- and gender-matched healthy in-
dividuals, but there was no significant difference in trabecular 
bone area in the tibia (3). No other publications are available eval-
uating the trabecular area in patients with OI compared to the gen-
eral population. There was no difference between patients with OI 
type I, type III or type IV regarding trabecular area in either the ra-
dius or the tibia (20). 
 
Our study (Paper III) and the literature confirm our hypothesis that 
patients with OI have smaller total bone area, smaller cortical area 
at the distal sites, and smaller trabecular bone area compared to a 
reference population.  
                                                                                                                                
6.4 Bone microarchitecture in OI                                                    The 
bone microarchitecture, or structure, plays an important role in 
maximising the bending strength and flexibility for energy absorp-
tion when the bone is compressed (101). While the surface area of 
trabecular bone is far greater than that of cortical bone, 80% of the 
skeleton is cortical bone (141). Cortical thickness, cortical porosity, 
trabecular number, trabecular thickness, trabecular spacing, and 
the trabecular distribution are all important for bone strength 
(101). The trabecular microarchitecture was correlated to the fail-
ure load in an ex vivo study of human vertebrae (142). The degree 
to which the different parameters contribute to total bone 
strength differs between bone types (141). Findings regarding 
bone microarchitecture summarised in Figure 12.  
6.4.1 Cortical microarchitecture in OI 
We found the bone cortex to be thinner in patients with OI type I 
in the tibia. This has been confirmed in patients with OI type I, IV 
and III in tibia evaluated by pQCT or HRpQCT (3, 109, 111). Com-
parison of bone biopsies with predicted normal values or a refer-
ence population had also shown a thinner cortex in 193 patients 
with OI type I, III and IV (115, 119, 123, 124, 128, 132). In radius, 
we could not show any differences in cortical thickness between 
patients with OI type I and the reference group (3). When evaluat-
ing patients different types of OI including more severe pheno-
types (OI type I, type III, and IV), no differences were found in cor-
tical thickness in the radius compared to a non-OI reference group 
(109). This is in contrast to Gatti et al. (118) who found that cortical 
thickness in adults with OI type I, III or IV was 15% thinner than in 
a non-OI reference group. Whether this was due to a more distal 
volume of interest, and thus a cross-section of radius with theoret-
ically less cortical bone than a more proximal site, is unknown. 
Gatti et al. (118) included patients who had previously participated 
in a treatment trial and were thus known to the authors. This 
method of recruitment is prone to selection bias, as the trial’s in-
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clusion and exclusion criteria may not have selected typical pa-
tients with OI. When evaluating the clinical characteristics of real-
life alendronate users for the treatment of osteoporosis to the in-
clusion and exclusion criteria for a large RCT for an anti-osteopo-
rotic drug, one in two alendronate users would have been excluded 
from participating in the trial (143), further underlining the selec-
tion bias when including patients for RCTs.  
 
Rauch et al. (116) showed that the cortex in bone biopsies was 25% 
± 16% thinner in 70 children with OI type I compared to age- and 
gender-matched reference children who were recruited from pa-
tients admitted for various orthopaedic procedures. It is unlikely 
that the reference population was representative of the general 
population, however the authors did note that participants were 
excluded if they had a metabolic bone disease.    
 
Hald et al. (20) found that patients with OI type IV had wider corti-
ces in the radius and tibia than patients with type I and type III. This 
was in contrast to Rauch et al. (119) in iliac bone biopsies and Koci-
jan et al. (109) in HRpQCT of the ultradistal tibia and radius, where 
patients with OI type I had wider cortices than more severe pheno-
types. Some of this difference may be because Rauch et al. (119) 
only included children in their study, while the Austrian study of 
Kocijan et al. (109) compared cortical thickness between patients 
with OI type I and patients with either OI type III or type IV.  
 
While the study by Kocijan et al. (109) recruited patients from a 
single hospital centre, the authors noted that they see most of the 
adult patients with OI in the eastern part of Austria, and thus their 
patient population is likely to be representative of the general OI 
population. The study included 30 patients, but the size of their OI 
population was not given, and selection bias cannot be ruled out. 
Patients were matched for age and gender with controls from a 
population-based HRpQCT register recruiting individuals from the 
general Austrian population, who were excluded if they had meta-
bolic bone disease (109). The authors tried to avoid confounders 
by excluding patients with known diseases that could influence 
bone microarchitecture, geometry or mass. The small study size 
was a major limitation, and patients with OI type III and IV, who 
had shorter arm and legs than the reference population, were also 
included. Using a fixed offset for the volume, it is likely that a rela-
tively more proximal region of the tibia and radius were scanned 
than in the reference group, and the scanned bone may have in-
cluded more cortical bone than in a more distal cross-section.  
    
We could not demonstrate any differences in cortical porosity be-
tween patients with OI type I and a non-OI reference group when 
evaluated by HRpQCT (3). In an Austrian study of patients with OI 
type I, III or IV, there were no detectable differences in cortical po-
rosity when compared to a healthy reference population even for 
the most severe phenotypes (109). In bone biopsies, cortical po-
rosity was higher in patients with OI type I, but both these studies 
included only 6 patients (110, 123). While Imbert et al. (110) in-
cluded three controls, McCarthy et al. compared patients to previ-
ously published reference material from age-matched healthy con-
trols (123). Selection bias of patients cannot be ruled out in the 
Imbert et al. (110) study, where patient biopsies were acquired 
during surgery. The most likely reason that we could not illustrate 
increased cortical porosity in patients with OI was that the voxel 
resolution of the HRpQCT technique is 82 micrometres and thus 
will only detect pores larger than that.  
6.4.2 Trabecular microarchitecture 
In patients with OI type I, we found that the trabecular microarchi-
tecture evaluated by HRpQCT was compromised when compared 
to a healthy reference population (3). In the radius, patients with 
OI type I have lower bone volume to tissue volume (BV/TV), a lower 
number of trabeculae (Tb.N) that are also more widely spaced 
(Tb.Sp), and the trabecular network is more inhomogeneous 
(Tb.1/N.SD) compared to a non-OI reference group (3). This was 
also found in Austrian patients with more severe phenotypes (109). 
The radius trabeculae seem to be thicker in patients with OI type I, 
although the differences between patients with OI type I and the 
reference groups were non-significant (3, 109). In tibia, there were 
no differences in trabecular thickness between patients with OI 
type I and the reference populations (3, 109). 
 
When evaluating the trabecular microarchitecture using transiliac 
bone biopsies, the findings were similar to those found using non-
invasive techniques. BV/TV was lower in patients with OI type I, IV 
or III than in healthy reference individuals (115, 119, 129), with 
lower trabecular number and thinner trabeculae (119). Jones et al. 
(124) found that in children with OI Type III and IV the trabecular 
bone was markedly sparse compared to a reference group of age 
matched otherwise healthy children.   
 
In children, the trabecular number was highest in patients with OI 
type I and lowest in patients with OI type III, but no difference was 
found between phenotypes regarding trabecular thickness (119). 
In adults evaluated by HRpQCT, Hald et al. (20) showed that pa-
tients with OI type IV had larger BV/TV, higher trabecular number, 
and a less inhomogeneous trabecular network in the radius when 
compared to patients with OI type I. Patients with OI type III had 
the lowest values for BV/TV and trabecular number, and the most 
inhomogeneous trabecular network (20). Similar patterns were 
seen in the tibia, but the differences between phenotypes were 
non-significant (20). Kocijan et al. found that patients with OI type 
I had higher BV/TV, trabecular number and thickness than patients 
with OI type III or IV (109). These diverging results from the Danish 
patients could be due to different analysis strategies. Hald et al. 
(20) analysed between-group differences among patients with OI 
type I, type III or type IV, while Kocijan et al. (109) compared pa-
tients with OI type I to patients with OI types III AND IV. Hald et al. 
(20) showed that bone microarchitecture parameters where clos-
est to that of non-OI individuals in patients with OI type IV and fur-
thest from what would be expected in patients with OI type III, so 
combining these two groups may have evened out any between-
group differences when comparing to patients with OI type I, as in 
Kocijan et al. (109).      
 
6.5 CONCLUSION 
Our study and the current literature shows that patients with OI 
have lower areal BMD and trabecular volume BMD, but not lower 
cortical volume BMD. In children with OI type I, however, the di-
aphyseal site of the radius had higher than expected total volume 
BMD due to a relatively large cortical area with elevated cortical 
volume BMD. The bones are smaller in patients with OI, as the to-
tal, cortical, and trabecular bone areas are lower in patients with 
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OI than in non-OI individuals. Bone microarchitecture is also al-
tered in patients with OI, who have lower cortical thickness, higher 
cortical porosity, and fewer trabeculae of similar thickness to that 
in non-OI individuals but further apart in a more inhomogeneous 
network. This result in lower BV/TV of OI cancellous bone com-
pared to non OI-bone. In other words, OI bone has lower bone 
mass, is smaller (altered geometry), and has altered bone microar-
chitecture compared to the non-OI population. This could explain 
why patients with OI have increased fracture rates compared to 
non-OI individuals, as the findings would in otherwise healthy indi-
viduals be associated with higher fracture risk.  
Our study (Paper III) and the literature confirm our hypothesis 
that patients with OI have altered bone microarchitecture, lower 
bone mass and different bone geometry compared to healthy 
non-OI individuals. 
 
7 CARDIOVASCULAR DISEASES IN OSTEOGENESIS IMPERFECTA 
Collagen type 1 is an important constituent of various parts of the 
cardiovascular system, including the heart valves, chordae 
tendineae, fibrous rings of the heart, interventricular septum, 
aorta, and most other arteries (37, 38). Collagen fibres in the ven-
tricular myocardium contribute to tensile stiffness and maintain 
the architecture of the myocytes (40). The aorta and most arteries 
are rich in type III and type I collagen (38). In the Aga2 OI mouse 
model, Thiele et al. (39) showed that both severe (postnatally fatal) 
phenotypes and mild phenotypes (animals surviving to adulthood) 
had cardiovascular disease. Severely affected mice had enlarged 
septum, right ventricular hypertrophy, and significantly lowered 
ejection fraction (EF) compared to wild type mice (39). The type 1 
collagen was disoriented, and there were fewer and thinner colla-
gen fibrils in the cardiac tissue (39). The OIM mouse model has 
both a bone and a cardiovascular phenotype (38, 40, 144). Weis et 
al. (40) found that homozygote OIM mice had decreased collagen 
area fraction with lower fibre number density compared to wild-
type mice. The homozygote OIM mice had thicker septal and pos-
terior walls, but normal systolic function as evaluated by echocar-
diography (40). It is feasible that patients with OI will have cardio-
vascular disease.  
 
We performed a register-based cohort study including all patients 
with OI registered in the NPR to compare the risk of cardiovascular 
disease in patients with OI to that in reference individuals ran-
domly selected from the CPR matched 5:1 on age and gender to 
each identified patient with OI, as described in Paper IV and section 
8.3 of this thesis. While case series and cross-sectional studies may 
provide more detailed clinical information about each participant, 
a nationwide cohort study using register data is (in Denmark) rep-
resentative of the entire OI population with little or no loss to fol-
low-up. Nationwide coverage also ensures a large sample for con-
ditions with low base rates. The register-based approach enabled 
us to correct for confounders or risk factors for cardiovascular dis-
ease in OI and the general population. This made it possible to eval-
uate the effect of the general collagenopathy suspected in patients 
with OI on the risk of developing a cardiovascular disease. The dif-
ferent pathways that could theoretically influence the risk of cardi-
ovascular disease in patients with OI are summarised in Figure 1 of 
Paper IV.  
 
7.1 Literature search 
The literature search was conducted as described in section 3.3 
(inclusion and exclusion-criteria) and Appendix 1.4 (search dates, 
search strings and search results) and aimed to identify all studies 
that included evaluation of cardiovascular function in patients 
with OI and the prevalence or risk of cardiovascular disease in OI. 
A flow diagram of the study selection can be seen in Figure 14. 
We identified 588 publications via Embase, 306 via PubMed, and 
102 via Cochrane Library. After excluding 163 duplicates, 833 ti-
tles and/or abstracts were screened for eligibility and resulted in 
26 publications for full-text screening. After excluding 13 articles 
that were conference papers, did not cover the subject matter, or 
included only few patients with OI, 13 publications were included 
in the review. Information on participants and study design is 
summarised in Table 7. The extracted data are presented in Ta-
bles 8-11. 
 
Figure 14. Flow diagram of study selection for cardiovascular 
disease in OI 
Table 7. Studies on cardiovascular disease in OI 
Author (year) Study design Methods Total patients N(W) Age (years) Ref. pop 
N(W) 
Age (years) Mild N(W) Age (years) Moderate N(W) Age (years) Severe N(W) Age (years) 
Folkestad (2016) 
(Paper IV) 
Cohort study A 687  
(379)1 
0 
[IQR:  
0-65.4]2 
3435 
(1895)3 
0 
[IQR:  
0-65.4]2 
- - - - - - 
Radunovic (2015, 2012, 2011) 
(145-147) 
Cross-sectional B, C, D 99 
(57) 
43.9±12.3 52 
(30) 
43.7 
±13.9 
77  
(48) 
44.7 
±13.0 
11 
(2) 
47.4 
±7.3 
10 
(7) 
34.7 
±7.1 
Al-Senaidi (2015) 
(148) 
Cross-sectional B, C 8 
(5) 
7.3±4.3 24 
(13) 
6.9 
±2.5 
- - 1 
(?) 
- 7 - 
Karamifar (2013) 
(149) 
Cross-sectional B 24 
(?) 
4.9±3.7 24 
(?) 
4.8 
±3.6 
- - - - - - 
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Thiele (2012) 
(39) 
Case series B, C 46 
(27) 
12±4.2 (range:3-23) - - - - 23 
(15) 
12.1 (range:  
4-23) 
23 
(12) 
11.9 (range:  
3-23) 
Migliaccio (2007) 
(150) 
Cross-sectional B 40 
(21) 
40 40 
(20) 
41 35 
(?) 
- 2 
(?) 
- 3 
(?) 
- 
Van Brussel (2008) 
(64) 
RCT4 E 34 
(22) 
7.9-18.6 17 
(?) 
13.2 
±3.6 
27 - 7 - - - 
Takken (2004) 
(78) 
Case series B, C, E 17 
(15) 
13.3±3.9 R1 - 17 
 (15) 
13.3 
±3.9 
- - - - 
Vetter (1989) 
(151) 
Case series B 58 
(?)5 
1-16 - - 18 
(?) 
2-16 - - 24 
(?) 
1-15 
Kalath (1987) 
(152) 
Cross-sectional B, C, D 31 
(?) 
? 50 
(11) 
? 22 
(?) 
? 7 
(?) 
?   
Hortop (1985) 
(153) 
Case-series B, C, D 109 
(53) 
1-75 R2 - 83 
(?) 
? 10 
(?) 
? 16 
(?) 
? 
White (1982) 
(154) 
Case-Series B, C, D 20 
(15) 
41 
(13-68) 
- - 17  
(12) 
40.5  
(13-68) 
3 
(1) 
55 
(29-64) 
1 
(1) 
45 
A) Nationwide register-based, B) Echocardiography, C) 12-lead ECG, D) Blood pressure measurements, E) Cardiopulmonary exercise test. 
1) The patient time at risk for the primary outcomes was 23,588 [range: 23,497-23,645]. 2) Median age at start of observation. 3) Me-
dian person time at risk for the primary outcomes was 120,005 [range: 119,931-120,104]. 4) RCT comparing supervised training 30-45 
min sessions over 12 weeks with no supervised training. 4) 15 patients could not be classified on Sillence’s classification, age range 1-10 
years. ?) Information not given in original work. IQR: interquartile range. W: women R1) Predicted age- and sex-specific VO2 peak values 
R2) Predicted mean values from age- and weight-matched control
7.2 CARDIOVASCULAR RISK FACTORS IN OI 
In our study (Paper IV), more patients with OI were diagnosed with 
hypertension and were more frequently treated with antihyper-
tensive drugs than the reference population (28.1% vs. 21.6%, 
p<0.001) (Paper IV). Danish patients with OI did not have increased 
prevalence of diabetes (5.5% vs. 4.3%, p=0.15) or dyslipidaemia 
(10.6% vs. 10.4%, p=0.84) (Paper IV). More patients with OI used  
non-steroidal anti-inflammatory drugs (NSAIDs) compared to the 
reference population (56.6% vs. 47.2%, p <0.001). Several observa-
tional studies using Danish health registers have shown increased 
risk of adverse cardiovascular effects associated with NSAID use in 
the Danish general population (155). 
 
In a small case series (n=20) of patients with mild OI, White et al. 
(154) found that 11 of 20 patients had systolic blood pressure 
above 140 mmHg (median 151 mmHg, range 140-190), and one 
patient had a diastolic blood pressure above 100 mmHg, meaning  
that 60% of the patients were hypertensive (154). This was a very 
small study thus both the power and the generalisability of the 
study must be questioned. In a Norwegian cross-sectional study by 
Radunovic et al. (145-147) including 99 adults with OI type I, III or  
 
 
IV aged 43.9±12.3 and a reference group of 52 non-OI individuals 
aged 43.7±13.9, 37.4% of the patients with OI had hypertension,  
but the prevalence in the reference population was not reported, 
and a comparison was not made (146). In a cross-sectional study of 
30,577 Norwegians aged 20-75 years not treated with antihyper-
tensive drugs, the prevalence of hypertension was 30.9% (156). Di-
abetes was found in 5.0% of the Norwegian OI patients, similar to 
that expected in the general population in Norway (146). There 
were significantly more smokers or previous smokers among the  
 
 
 
patients with OI than in the control group (41% vs 21%, p<0.01). In 
our cross-sectional study (Paper III) of patients with OI type I and a 
healthy age- and gender-matched reference group, there were no 
significant difference in smoking habits (3). However, as the study 
included only 39 patients and only with OI Type I, it is questionable 
if the results can be generalised to the Danish OI cohort.  
 
Patients with OI experience more fractures, and may be burdened 
by bone deformation and dystrophy and frequently depend on 
walking aids or wheelchairs, than non-OI individuals (2). This could 
lead to a less physically active lifestyle, although few data are avail-
able to support this claim. In a study of 14 Canadian children and 
adolescents with OI, none of the patients reached the daily recom-
mendation for physical activity (157). The forearm cross-sectional 
area (CSA) of subcutaneous fat is closely correlated to the total 
body percentage fat mass when comparing pQCT and whole-body 
DXA (158). In a study of 266 patients with OI (126 patients with OI 
type I, 37 patients with OI type III, and 103 patients with OI type IV) 
aged 5-20 who were compared to a reference group of 255 age- 
and gender-matched healthy controls, patients with OI had lower 
muscle mass but the cross-sectional area fat was similar in differ-
ent types of OI and the controls, even after correcting for differ-
ences in arm length (158). It has been shown that mice with more 
severe OI phenotypes have low fat mass (159). Furthermore, chil-
dren with OI may have a higher basal metabolism than expected,  
 
which would lead to low body fat stores (160). Two studies in-
cluded 51 children with OI type I or type IV and evaluated cardio-
pulmonary fitness and the effect of training (64, 78) by comparing 
patient VO2max and VO2peak values with predicted age- and gender-
specific VO2max and VO2peak values (78). Tekken et al. (78) found a 
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VO2peak (mL/kg/min) Z-score of -1.41±1.52 but no evidence of circu-
latory abnormalities as a cause of this reduced cardiopulmonary 
fitness. Van Brussel et al. (64) randomised children with OI to 12 
weeks of supervised 45-minute training sessions to evaluate the 
effect of training on cardiopulmonary fitness and found an 18% in-
crease in the VO2peak measurements from baseline to the end of the 
intervention (64). This increase in fitness was more than that ex-
pected in healthy children after a comparable training period, but 
no direct comparison was made between patients with OI and non-
OI individuals (64). The authors suggested that the relative hypo-
activity and lower initial levels of VO2peak/kg in the patients with OI 
could explain the relatively large improvement in fitness during the 
intervention.  
 
The increased prevalence of scoliosis, kyphosis, and vertebral de-
formities in patients with OI affects pulmonary function and in-
creases the risk of restrictive pulmonary disease (24, 25, 77). This 
can reduce cardiopulmonary fitness and increase the risk of cardi-
opulmonary failure (76, 78). In a Swedish study on the causes of 
death in otherwise healthy patients with untreated scoliosis, 17 of 
115 patients had died due to cardiovascular causes (161). The pre-
dicted number of cardiovascular deaths in the same cohort was 10 
(161), indicating that scoliosis, which is frequent in patients with 
OI, may on its own increase the risk of cardiovascular disease due 
to a higher prevalence of restrictive pulmonary impairment, which 
has been associated with hypertension and other cardiovascular 
diseases (81). In 1039 patients with a restrictive pulmonary impair-
ment and no cardiovascular disease at baseline, the HR compared 
to 7865 persons with normal pulmonary function and no cardio-
vascular disease at baseline was 1.6 (95% CI: 1.2-2.2) for a major 
cardiovascular event (AMI or stroke) over 15 years of observation 
(162).  
 
In a non-OI population, the risk of heart failure is closely associated 
with ischaemic heart disease and with increasing age (163). Even if 
patients with OI may have a higher risk of cardiovascular disease, 
it did not lead to increased risk of myocardial ischaemic infarction 
in our study (11.0% vs. 10.7%, p=0.79) (Paper IV 
 
7.3 Valvulopathies in OI 
Prevalence data on valvulopathies in OI are summarised in Table 
10 for mitral valve regurgitation and Table 11 for aortic valve re-
gurgitation. In our population-based cohort study (Paper IV), sig-
nificantly more patients with OI were registered in the NPR with a 
mitral regurgitation diagnosis or surgery code compared to the ref-
erence population (1.6% vs 0.2%, SHR 6.3 [95% CI: 2.5-15.5]). After 
adjusting for ischaemic heart disease (a risk factor for mitral valve 
regurgitation (164)), the SHR was still significantly higher in the OI 
cohort (6.7 [95% CI: 2.8-16.2]) (Paper IV). In the same population, 
significantly more patients than reference individuals were regis-
tered in the NPR with an aortic regurgitation diagnosis or surgery 
code (0.9% vs. 0.2%, SHR 4.5 [95% CI: 1.4-13.9]). The cumulative 
sub-hazard increased from the age of 40 in the OI group, meaning 
that patients were more likely to experience the event (mitral re-
gurgitation diagnosis in the NPR) before the given time compared 
to the reference population. Table 8 and 9 summarises the preva-
lence and risk of valvulopathies in patients with OI.  
Table 8. Mitral regurgitation in OI 
Author 
(year) 
Type I 
OI 
N(%) 
Type IV 
OI 
N(%) 
Type III 
OI 
N(%) 
Unknown 
pheno-
type 
N(%) 
Ref. 
pop. 
N(%) 
Bet-
ween-
group   
p value 
HR / 
SHR 
[95% 
CI] 
Unad-
justed 
HR / 
SHR 
[95% 
CI] Ad-
justed 
Folke-
stad 
(2016) 
(Paper 
IV) 
- - - 11  
(1.6%) 
8  
(0.2%) 
- 6.3  
[2.5-
15.5] 
6.7  
[2.8-
16.2] 
Al-
Senaidi 
(2015) 
(148) 
- 0  
(0%) 
0 (0%) - 0  
(0%) 
NA - - 
Karami-
far 
(2013) 
(149) 
- - - 0 (0%) 0  
(0%) 
NA - - 
Thiele  
(2012) 
(39) 
- 8 
(34.8%) 
4 
(17.4%) 
- - - - - 
Raduno-
vic 
(2011) 
(146) 
- - - 64 
(64.7%) 
32 
(61.5%) 
<0.001 - - 
Migliac-
cio 
(2007) 
(150) 
- - - 38 (95%) 1  
(4%) 
<0.001 - - 
White 
(1983) 
(154) 
1 
(7.1%) 
0  
(0%) 
0  
(0%) 
- - - - - 
Ref.pop. = reference population or reference group, HR = Hazard 
ratio, SHR = Sub-hazard ratio, - no available data 
Table 9. Aortic valve regurgitation in OI 
Author 
(year) 
Type 
I OI 
N(%) 
Type IV 
OI 
N(%) 
Type 
III OI 
N(%) 
Unknown 
pheno-
type 
N(%) 
Ref. 
pop 
N(%) 
Bet-
ween-
group p 
value 
HR / 
SHR 
[95% 
CI] 
Unad-
justed 
HR / 
SHR 
[95% 
CI] 
Adju-
sted 
Folke-
stad 
(2016) 
(Paper 
IV) 
- - - 6  
(0.9%) 
6 
(0.2%) 
- 4.5  
[1.4-
13.9] 
- 
Al-
Senaidi 
(2015) 
(148) 
- 0 
(0%) 
0  
(0%) 
- 0  
(0%) 
NA - - 
Karami-
far 
(2013) 
(149) 
- - - 2  
(8.3%) 
0  
(0%) 
0.15 - - 
Thiele 
(2012) 
(39) 
- 3 
(13.0%) 
1 
(4.3%) 
- - - - - 
Radu-
novic 
(2011) 
(146) 
- - - 20  
(20.2%) 
0  
(0%) 
0.001   
Migliac-
cio 
(2011) 
(150) 
- - - 16  
(40%) 
0  
(0%) 
<0.001 - - 
White  
(1983) 
 (154) 
0 
(0%) 
0  
(0%) 
0  
(0%) 
- - - - - 
Ref.pop. = reference population or reference group, HR = Hazard 
ratio, SHR = Sub-hazard ratio, - no available data 
 
Al-Senaidi et al. (148) found no evidence of aortic or mitral valve 
regurgitation in children with OI type III or IV and an age-matched 
reference population. However, the statistical power of this study 
must be questioned, however, as the patient sample was a small 
cohort of 8 children. Furthermore the study will be prone to selec-
tion bias as the patient sample was a cohort from a single hospital 
clinic. The healthy controls were children referred for echocardiog-
raphy for a heart murmur that was later found to be physiological 
or absent. In contrast, Thiele et al. (39) included 46 children with 
OI type III or IV who were participating in a longitudinal natural his-
tory study and evaluated at a NIH clinical centre every 1-2 years. 
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They found that 4 of 23 patients with OI type III had mild to mod-
erate mitral regurgitation, 7 of 23 patients with OI type IV had mild 
mitral regurgitation, and one patient with OI type IV had mitral 
valve prolapse. Only 3 patients with OI type IV and none of the pa-
tients with OI type III had aortic regurgitation (39). Of the 58 Ger-
man children included in a study by Vetter et al. (151), two patients 
with type III OI had congenital mitral valve prolapse, and two other 
patients with OI type III developed mitral valve prolapse at 8 and 
11 years of age, respectively. None of the 18 patients with OI type 
I or the 15 patients who did not fit a Sillence classification devel-
oped valvulopathy during the study (151). No information about 
participant recruitment was provided in this study. In a group of 
Iranian children with OI, 2 of 24 patients had aortic regurgitation 
and no mitral regurgitations were reported, while no valvulopa-
thies were reported among the 24 non-OI children (149). No infor-
mation was given about the clinical OI phenotype of the patients 
with valvulopathies in this study (149). It should be noted that the 
study included children referred for intravenous bisphosphonate 
treatment, and possible selection bias must be kept in mind.   
 
No significant difference was found in the proportion of mild mitral 
regurgitation between adult Norwegian patients with OI and a 
non-OI reference group (57.5% vs. 61.5%, p=0.64, Pearson’s Chi2-
squared test) (146). However, significantly more patients had mod-
erate mitral regurgitation (7.1% vs 0.0%, p=0.05) (146). Further-
more, significantly more patients had mild or moderate aortic 
valve regurgitation (20.2% vs 0%, p<0.001) (146). Radunovic et al. 
(145-147) included patients from a population-based study (23), 
but only 99 of 154 patients had echocardiography, so volunteer 
bias favouring patients with symptoms of cardiovascular disease 
cannot be ruled out. Migliaccio et al. (150) included 40 patients 
with OI type I, III or IV and a mean age of 40 years, and excluded all 
patients with symptoms of cardiovascular disease. They found that 
38 of 40 patients and 1 of 40 age- and gender-matched cardiovas-
cular-healthy controls had mitral regurgitation (95% vs 1%, 
p<0.001) controls (150). Furthermore, 40% of patients with OI had 
aortic regurgitation, but none of the reference group had aortic 
valve pathologies (150). As this study design would only identify 
patients with subclinical disease (seeing that all patients with car-
diovascular symptoms were excluded), the clinical importance of 
the findings can be questioned.  
 
In the 20 patients with OI included by White et al. (154), the aortic 
valve movement appeared normal but the cusps in 13 patients 
showed systolic fluttering, and were described as thin in 17 pa-
tients. Mitral valve prolapse was found in a 20-year-old woman 
with OI type I, while in 10 other patients the mitral valve leaflets 
were considered thin (154). The median age of the participants in 
this study was 41 years (range: 13-68), and it is unknown whether 
the thin and fluttering cusps later caused valvulopathies.  
 
Blinding of echocardiographic procedures is difficult and was only 
done by Radunovic et al. (145-147), who performed a post hoc 
analysis of the images recorded through three heart cycles for each 
participant for every standard projection, thus blinding the evalu-
ator to diagnosis of OI. In the other studies, echocardiographs were 
interpreted by the investigator during the procedure and may in 
theory have been influenced by expectations about patients with 
severe OI. In the study by Migliaccio et al. (150), in which two in-
dependent investigators performed the echocardiography, inter- 
and intra-observer coefficients of variance were 2%. 
 
Mitral and aortic valvulopathies are more common in patients with 
OI than in the general population, and echocardiographic signs of 
valvulopathy seem more prevalent in adults with OI than children 
with OI. While up to 95% of adult patients had mitral valve regur-
gitation and up to 40% had aortic valve regurgitation, up to 35% of 
paediatric patients had mitral regurgitation and 13% had mitral re-
gurgitation. It has to be kept in mind that the included cross-sec-
tional studies in this review were often very small and generally 
prone to selection bias. In the Danish health registers, we could 
only identify 1.6% of the OI population with a mitral regurgitation 
diagnosis and 0.9% with an aortic valve diagnosis in the NPR.  
7.4 CARDIAC VENTRICULAR FUNCTION IN OI 
In our study (Paper IV), more patients than reference individuals 
were registered in the NPR with a heart failure diagnosis (1.0% vs 
0.2% for males, SHR 2.4 [95% CI: 1.2-5.0] and 4.0% vs 1.7% for fe-
males, SHR 2.5 [95% CI: 1.4-4.6]) (Paper IV), even after adjusting 
for risk factors for heart failure, such as atrial arrhythmias and is-
chaemic heart disease (165, 166). The median age at diagnosis was 
58 years (IQR: 44-69) in the OI cohort and 76 years (IQR: 62-83) in 
the reference population. The cumulative incidence from age 40 
increased more in the OI cohort than in the reference population.  
 
Children with OI did not show decreased ejection fraction (EF) 
compared to reference groups of healthy non-OI controls (148, 
149). The limitations to these studies have been described earlier 
(section 7.3). In adults, however, the EF was significantly lower in 
the Norwegian OI group compared to the reference group, but 
ventricular function was within normal ranges (147). There were 
no between-group differences in left ventricular systolic or dias-
tolic function after exclusion of patients with established coronary 
disease, hypertension, cardiomyopathy (n=1) or treated with β-
blockers (n=8) (147). Migliaccio et al. (150) only included patients 
without subjective symptoms of cardiovascular disease and in 
NYHA class I (i.e. no limitation of physical activity, and ordinary 
physical activity does not cause undue fatigue, palpitations or 
dyspnoea). The authors found no difference in EF between adults 
with OI and non-OI healthy individuals, although 95% of the pa-
tients with OI and 4% of the reference population had diastolic dys-
function (150). Diastole involves the isovolumetric relaxation and 
filling phase of the cardiac cycle and has both active and passive 
components; the filling of the left ventricle is biphasic, with rapid 
filling in early diastole and late filling by atrial contraction (167). In 
diastolic dysfunction, the ventricle cannot accept blood at low 
pressures, and ventricular filling is slow or incomplete unless atrial 
pressure rises (167). 
  
The heart chamber dimensions may be affected in OI as the lack of 
collagen can cause the chambers to dilate, and furthermore the 
chamber dimensions will change according to the demands of the 
heart (168). Myocardial function is affected in heart failure due to 
changes in contractility, preload (left ventricular end-diastolic pres-
sure) and afterload (systemic vascular resistance). A reduction in 
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contractility is initially compensated by activation of the sympa-
thetic nervous system (compensatory increase in heart rate and 
contractility) as well as dilatation of the left ventricle (168). Meas-
urements of heart chamber dimensions may indicate compensa-
tory mechanisms to maintain normal ventricular function in OI. 
Studies investigating chamber dimensions in patients with OI are 
summarised in Table 10.  
Table 10. Heart chamber dimensions in OI 
Atria  
Author  
(year) 
OI vs Reference 
population /pre-
dicted values 
OI type I vs Refer-
ence population 
/predicted values 
OI type IV vs Ref-
erence population 
/predicted values 
OI type III vs Ref-
erence population 
/predicted values 
 Ac-
tual 
va-
lues 
Cor-
rected 
for BSA 
Ac-
tual 
va-
lues 
Cor-
rected 
for BSA 
Ac-
tual 
va-
lues 
Cor-
rected 
for BSA 
Ac-
tual 
va-
lues 
Cor-
rected 
for BSA 
Al-Senaidi 
(2015)(148) 
      =1  
Thiele  
(2012) (39) 
    -  -  
Migliaccio 
 (2009) (150) 
=        
Vetter 
 (1989) (151) 
  =      
Hortop 
(1983) (153) 
<        
Right ventri-
cle end-dias-
tolic area 
 
Radunovic 
(2012) (145) 
 >  =  =  > 
Migliaccio 
(2009) (150) 
=        
Left ventricle 
end-diastolic 
diameter 
 
Al-Senaidi 
(2015) (148) 
      = > 
Karamifar 
(2013) (149) 
= >       
Thiele 
(2012) (39) 
    -  -  
Radunovic 
(2011) (146) 
> > > > > > = > 
Migliaccio 
(2009) (150) 
=        
Vetter 
(1989) (151) 
  =      
Hortop 
(1983) (153) 
>        
= no significant between-group difference,  > OI chamber dimen-
sions larger than in reference population (or predicted values), < 
OI chamber dimensions smaller than in reference population (or 
predicted values), - measured in study but no comparisons made, 
// indicates that two analysis were done. 1) 7 patients with OI 
type III and 1 patient with OI type IV 
Radunovic et al. (145) and Migliaccio et al. (150) evaluated the right 
ventricle end-diastolic area. Radunovic et al. (145) found that pa-
tients with OI had larger right ventricle end-diastolic area than con-
trols, after correcting for the patient’s smaller body surface area. 
They also found that the right ventricular end-diastolic area was 
larger in patients with OI type III than in patients with OI type I or 
type IV (145).  
 
While Migliaccio et al. (150) found no differences between patients 
with OI and their reference group, adult Norwegian patients with 
OI and Iranian and Omanian children with OI had larger left ven-
tricular end-diastolic diameter than their reference groups after 
correction for body surface area (146, 148, 149). Radunovic et al. 
(146, 147) also found that left ventricular end-diastolic diameter 
(corrected for body surface area) was greater in patients with OI 
type III than in patients with OI type I or IV, but no differences were 
found in EF. However, neither Migliaccio et al. (150) nor Vetter et 
al. (151) found any differences in left ventricular end-diastolic di-
ameter comparing patients with OI to healthy non-OI individuals or 
to predicted age- and gender-matched mean values. Migliaccio et 
al. (150) did not take differences in body surface area between the 
two groups into account.  Thiele et al. (39) found normal left ven-
tricle dimensions in all 46 participants. Both Vetter et al. (151) and 
Thiele et al. (39) only included children, and it is unknown whether 
the differences in chamber dimensions are congenital or develop 
over time. Ventricular chamber dimensions are larger in patients 
with OI compared to non-OI individuals, after correction for the 
smaller body size seen in patients with OI.  
 
Enlarged atria are associated with increased risk of atrial fibrilla-
tion. The Framingham Heart Study reported a 39% increased risk 
of new onset atrial fibrillation for each 5 mm increase in the left 
atrium diameter in patients evaluated by echocardiography (169). 
In a case series of 109 individuals from 66 families referred for ge-
netic counselling, the atrial size found by Hortop et al. (153) was 
smaller than expected in patients with OI compared to the ex-
pected gender- and age-matched predicted values. This could not 
be reproduced in Omanian, Egyptian or German children, where 
atrial size was the same as that in the reference population (148, 
150, 151, 153). Thiele et al. (39) found that 3 of 23 patients with OI 
type IV and 2 of 23 patients with OI type III had dilated left atrium, 
while 3 patients with OI type III had a left to right shunt. The study 
did not include a reference population, so it is unknown whether 
the proportion of dilated atria in children was greater than ex-
pected. In adult patients, Migliaccio et al. (150) could not find any 
difference in chamber dimensions but did not correct for differ-
ences in body size between the reference population and the pa-
tients with OI. There is little evidence to support that patients with 
OI have enlarged atria compared to the general population.  
7.5 AORTIC ROOT DIMENSIONS, ANEURISMS AND VASCULAR DIS-
SECTIONS IN OI  
There have been case reports of vascular aneurisms and vascular 
dissections in OI (42). In our register-based study (Paper IV), we 
identified 9 (1.3%) patients with OI and 29 (0.8%) participants in 
the reference population that were registered in the NPR with a 
vascular dissection or aneurism diagnosis. The relative risk was not 
significantly different between patients with OI and the reference 
population (SHR 1.4 [95% CI: 0.6-3.0], p=0.38). Similarly, there 
were no significant differences between the two groups regarding 
the prevalence of surgery on peripheral arteries, aorta and its main 
branches, or cerebral aneurisms.  
 
The aortic annulus was consistently shown to be greater in both 
children and adults with OI, regardless of clinical phenotype (146, 
148, 149, 151). The aortic root and the ascending aorta were 
found enlarged in children with OI, and in adults with OI after cor-
rection for differences in body surface area (146, 150, 151, 153). 
Furthermore, Kalath et al. (152) found increased aortic stiffness in 
the circumferential direction associated with decreased aortic 
pumping efficiency. These authors included 7 patients with OI 
type IV and 24 patients with OI type I and compared the aortic 
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root diameter to that of 50 healthy controls (152). This is sum-
merised in Table 11. 
Table 11. Aortic root dimensions in OI 
Atria  
Author  
(year) 
OI vs Reference 
population /pre-
dicted values 
OI type I vs Refer-
ence population 
/predicted values 
OI type IV vs Refer-
ence population 
/predicted values 
OI type III vs Refer-
ence population /pre-
dicted values 
         
Karami-
far 
(2015) 
(149) 
= >       
Al-
Senaidi 
(2012) 
(148) 
      =1,2 >1,2 
Raduno-
vic 
(2011) 
(146) 
>1 >1 > > = > = > 
Raduno-
vic 
(2011) 
(146) 
=3 >3 =3 >3 = >3 =3 >3 
Migliac-
cio 
(2007) 
(150) 
=4        
Vetter 
(1989) 
(151) 
      >4  
Hortop 
(1986) 
(153) 
>4        
= no significant difference between the groups, > OI aorta meas-
urements larger than in the reference group. 1) Measuring the 
aorta annulus. 2) Including 7 patients with OI type III and one pa-
tient with OI type IV. 3) Measuring the ascending aorta at 3 cm 
from valve. 4) Measuring the aortic root. 
There is little evidence to support any increased risk of vascular 
dissection or aneurism in OI, but we acknowledge that absence of 
evidence is not evidence of absence, and further studies are 
needed.  
7.6 ECG CHANGES IN OI  
In our study (Paper IV), patients with OI had increased risk of atrial 
fibrillation or atrial flutter compared to the reference population 
(SHR 1.7 [95% CI: 1.1-2.8]). The median age at diagnosis was 64 
years (IQR: 50-72) in the OI cohort and 76 years (IQR: 62-83) in the 
reference population. Correcting for ischaemic heart disease did 
not influence the between-group relative risk of atrial fibrillation 
or atrial flutter (Paper IV). There was no difference in the risk of 
developing an atrial arrhythmia between women with OI and 
women in the reference population. The sensitivity of the NPR for 
cardiovascular diseases (the likelihood of being in the NPR when 
having a given cardiovascular disease) has been questioned, but 
the positive predictive value (registered with a given cardiovascu-
lar disease diagnosis and actually having his disease) remains high 
(170). This could result in underestimating the prevalence of some 
cardiovascular diseases in our study – in both the OI population 
and the reference population – but the relative risk difference be-
tween the two groups should not be affected. Furthermore, the 
patients we identify as having a given cardiovascular disease are 
likely to have that disease, due to the high positive predictive value 
of the NPR regarding cardiovascular diseases. In a British study on 
the epidemiology of arterial fibrillation, 2.0% [95% CI: 1.6-2.4] of 
participants randomly selected from the general population were 
diagnosed with atrial fibrillation (171). This is comparable to the 
prevalence of atrial fibrillation or flutter of 1.8% in our reference 
population that was randomly selected from the Danish general 
population. As patients with OI are followed at two paediatric cen-
tres and four adult highly specialised adult centres (according to 
Danish national guidelines), our study is subject to surveillances 
bias. Only hospital contact diagnoses are registered in the NPR, and 
patients with OI are more likely to come into contact with the hos-
pital system than participants in the reference population. Further-
more, as patients could potentially undergo more frequent surgery 
than the general population due to differences in fracture rates, 
patients might more often be evaluated with ECG and auscultation 
(as part of the pre-surgical routines). This will increase the likeli-
hood of other investigations such as echocardiography being done 
in patients with OI. 
 
In children with OI type IV or III, Thiele et al. (39) found ECG 
changes in 7 of 46 patients. Sinus tachycardia, sinus arrhythmia and 
premature atrial contractions were the most frequently reported 
ECG findings (39). The mean heart rate per minute trended to-
wards being higher in children with severe OI than in the non-OI 
healthy reference group (105.5±22.0 vs. 85.9±17.0, p=0.054) (148). 
In adults, 39 of 99 patients with OI and 10 of 52 of the reference 
population had one or more ECG abnormalities (39.5% vs 19%, 
p=0.01) (147). The most frequent ECG abnormalities were ST-T seg-
ment changes and negative T-waves, while the prevalence of tach-
ycardia was not reported (147). Three patients with OI were sus-
pected to have paroxysmal supraventricular arrhythmias, but no 
information about the prevalence of atrial fibrillation or flutter was 
given (147). However, palpitations were reported more frequently 
by the patients with OI than by the non-OI reference group (47.5% 
vs. 0%, p<0.001).  
7.7 CONCLUSION 
Our study (Paper IV) and the current literature confirm the hypoth-
esis that patients with OI will have increased risk of aorta and mi-
tral valve insufficiency, increased risk of heart failure and increased 
risk of atrial fibrillation, but we cannot confirm the hypothesis that 
patients with OI have increased risk of vascular dissections and an-
eurisms.  
 
8. DISCUSSION AND CONCLUSIONS  
We aimed to describe key elements of the natural history of OI 
such as mortality rate, life expectancy, causes of death in patients 
with OI and furthermore explore the risk of fractures, the cause of 
reduced bone strength in patients with OI and the risk of cardio-
vascular disease as we hypothesized that these factors would to 
some extent influence the risk of premature death and morbidity 
in patients with OI.  
8.1 LIMITATIONS AND DISCUSSION – STUDY DESIGN 
This PhD study includes two different study designs. Papers I, II, 
and IV are nationwide population- and register-based epidemio-
logical studies that include all patients registered with an OI diag-
nosis and a reference population of matched individuals randomly 
selected from the general population. In contrast, Paper III is a 
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cross-sectional study of adults with OI type I and a matched refer-
ence group. The studies were powered to allow us to control for 
confounders (factors that might be associated with the outcome, 
but also with the exposure) and we also tried to limit bias by match-
ing and/or using a population-based design whenever possible. 
The different approaches used are described in detail in the at-
tached publications. However, we cannot conclusively rule out any 
residual confounding or systematic error that may influence our 
results. As an example, we found that patients with OI had lower 
BMD measured by DXA. A large portion of the patients and none 
of the reference individuals were treated with bisphosphonates, 
which are antiresorptive drugs known to alter bone loss in patients 
with OI, and in some cases even result in increased BMD (8). This 
will conservatively bias a study of reduced BMD as it narrows the 
true biological gap between cases and controls. In spite of this 
treatment difference between the two groups, BMD was signifi-
cantly lower in the patients with OI. Any differences found be-
tween patients with OI and the general population can be regarded 
as real despite the bias introduced by therapy.   
 
LF alone did the literature searches, screening of eligible publica-
tions, and data extraction for this thesis. It would have strength-
ened the review design if a second reviewer had participated in the 
study selection, but this was found to be outside the constraints of 
a PhD thesis. 
8.1.1 Advantages and disadvantages of cohort studies 
Cohort studies in general 
The identifying features of a cohort study design is that individuals 
who are either exposed or not exposed to a specific factor are fol-
lowed over time, and the subsequent development of the out-
comes of interest is evaluated (172). This is exemplified by Study 1 
in this thesis, i.e. comparing individuals with OI (exposed) to a ref-
erence population (unexposed) regarding the risk of premature 
death (outcome). This differs from a case-control study in which 
the past history of exposure is compared for individuals who have 
the outcome and individuals without the outcome (172). The ad-
vantages of the cohort design are that we can identify new cases 
of the outcome and can look at disease progression and the natural 
history following exposure (e.g. OI and the risk of fractures). More-
over, case-control studies are often prone to recall bias and allow 
for calculation of odds-ratios but cannot be used to evaluate the 
absolute or relative risk. In contrast, cohort studies can also yield 
incidence rates and relative risks, and may even be able - to some 
extent - to assess causality due to the temporal nature of the study 
design (172).  
 
Cohort studies in this PhD study 
There are limitations to our epidemiological cohort study design. 
First, we had no information about how the OI diagnosis was made 
in the individual cases, i.e. whether it was based on DNA analysis, 
collagen analysis, and/or clinical presentation. We assume that the 
diagnosis was correct and was based on classic symptoms of OI 
since that is the contemporary common medical routine in Den-
mark. Second, clinical information about the individuals with OI 
were limited. Thus, we could not stratify patients according to clin-
ical severity, e.g. Sillence’s classification, as we only had access to 
ICD-8 or ICD-10 diagnoses for a given disorder. Third, we cannot 
rule out underreporting of the different outcomes that were inves-
tigated in the studies. Epidemiological studies reflect the burden to 
the health care provider rather than to the individual patient. The 
studies capture the morbidity and mortality in patients with OI in 
Denmark given the current standard of care, and the results may 
or may not be different had the OI disease been allowed to take its 
natural course in all patients. Finally, we have no information on 
risk factors for e.g. cardiovascular disease such as smoking, exer-
cise or diet.  
 
The Danish health registers are valued sources of epidemiological 
research, as they have high quality data with near-complete fol-
low-up. The nationwide population-based design ensured that 
even with exposures and outcomes at low basal rates, the number 
of events would be sufficient to calculate rates and ensure statisti-
cal power to evaluate between-group differences for even rare dis-
eases. In a cross-sectional design, we would risk selection bias (in-
cluding individuals with, relative to the general patient population, 
too high or too low prevalence of the outcome) and may over- or 
underestimate the prevalence of certain outcomes. The cohort de-
sign that includes all patients with a known disease is less prone to 
this bias.  
The NPR was established in 1977 and at first included information 
on somatic hospital contacts in relation to surgery and hospital 
stays in surgical wards, and data on psychiatric  hospital stays were 
added shortly after (173). Since 1995, diagnoses relating to outpa-
tient clinic and emergency room visits have also been included in 
the NPR (173). The NPR data can be divided into two groups. The 
administrative data include the patient identification number, pa-
tient’s municipality, identification of hospital ward, date and time 
of activity, and information on accidents leading to the hospital 
contact (173). The NPR clinical data are based on patient records 
where the treating physicians have registered diagnostic and sur-
gical procedure codes. It is mandatory by Danish law to register this 
information in the NPR, as the register is used for management and 
financial control of the tax-financed Danish health care system 
(173). The Danish health registers are valued research tools, as rec-
ord linkage is easy due to the unique personal identification num-
ber (174). The registers have high coverage (above 99%) of all hos-
pital contacts and less than 5% missing data on surgical procedures 
(173). The overall positive predictive value of the NPR is above 
95%, meaning that if you are registered with a given diagnosis, the 
likelihood of you actually having this disease is 95% (174). Statistics 
Denmark offers remote access to all individual-level data in the 
health registers – from education level, housing and family condi-
tions to health-related data on diagnosis and dispensed medical 
prescriptions (174). However, only aggregated results and statisti-
cal analyses can be published to ensure the anonymity of study 
participants. The access to information on important exposures, 
confounders such as education, income and ethnicity, and to vari-
ous health-related outcomes offers great possibilities for doing ep-
idemiological research on the association and causal network be-
tween disease incidence, mortality, social issues, occupational 
exposures, clinical indicators, and rehabilitation (175). 
 
No information was available on the positive or negative predictive 
value of having an OI diagnosis registered in the NPR. The positive 
predictive value indicates the likelihood of actually having OI if you 
are registered with an OI diagnosis in the NPR, while the negative 
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predictive value indicates the likelihood of not having an OI diag-
nosis if you are not registered in the NPR. In a Danish study of 91 
adults with suspected OI aged 19-78 years, who were recruited 
through the patient society and clinical hospital databases, six pa-
tients were excluded after clinical evaluation as the authors con-
sidered it unlikely they had OI –even though they were registered 
with OI in a hospital treatment database (20). Three patients had 
idiopathic osteoporosis, and three were first-degree relatives to 
patients with OI but did not display enough typical clinical features 
of OI for the diagnosis to be accepted (20). The hospital databases 
used should represent what is normally entered into the NPR. We 
identified 687 patients with OI. The population prevalence of OI in 
Denmark has previously been reported to be 10.6 per 100,000 (5), 
which would in a population of approximately 5.5 million inhabit-
ants lead to 583 patients with OI. This is very close to the number 
of patients we found through the NPR who were still alive at the 
end of the observation period. According to current national guide-
lines, children with OI are now treated at two highly specialised 
paediatric centres, and adults with OI are treated at four highly 
specialised university hospital centres. These patients thus see 
physicians with clinical experience in evaluating patients with OI, 
and it is highly likely that a patient with (suspected) OI will be seen 
by an OI specialist. We cannot rule out that patients with the mild-
est forms of OI will not seek medical attention and thus never be 
recorded in the NPR. These cases will not be included in epidemio-
logical studies using register based data and this limits our data. 
The patients included in our studies are the patients diagnosed 
with OI and represents the patients seen in everyday OI clinics in 
Denmark.  
 
Misclassification of patients featured in the NPR cannot be ruled 
out, but it is expected that most patients with an OI diagnosis are 
registered, and that the number of misclassified patients is low. 
Thus we firmly believe that we have identified all patients with OI 
in Denmark through the algorithm explained in Paper I, II, and IV 
and in section 4 of this thesis.    
8.1.2 Cross-sectional study using HRpQCT and DXA 
A cross-sectional study is an observational study in which exposure 
and outcome are determined simultaneously for each subject, of-
ten described as taking a “snapshot” of a group of individuals (172). 
The cross-sectional design is limited by the simultaneous assess-
ment of both exposure and outcome, and a temporal relationship 
between exposure and outcome is thus difficult to establish (172). 
Seeing that OI (or exposure) is a congenital disease, any association 
between patients and an outcome is more plausible than if the ex-
posure was temporal. A cross-sectional study will measure preva-
lent rather than incident outcomes, leaving the study more vulner-
able to selection bias.  
 
HRpQCT offers assessment of bone geometry, density, and micro-
architecture in the distal tibia and radius in vivo. The technique is 
limited by the image resolution, segmentation, and structure ex-
traction that may affect some of the parameters such as cortical 
porosity and trabecular thickness. The results from HRpQCT scans 
have shown high reproducibility and low coefficients of variance 
between measurements. Our study in patients with OI type I may 
be biased by the fact that we used a fixed offset for the volume of 
interest in both radius and tibia and compared patients with possi-
bly shorter limbs to healthy non-OI reference individuals. The vol-
ume of interest may thus have been relatively more proximal in 
patients with OI than in the reference population. This would result 
in relatively thicker cortical bone and relatively less trabecular 
bone compared to more distal cross-sections. In otherwise healthy 
individuals, changing from the fixed offset for the volume of inter-
est to a 4% tibial length and 7% radial length offset (a proximal shift 
of 1 mm at the radius and up to 2 mm at the tibia, and a distal shift 
of up to 3 mm at the radius and 8 mm at the tibia – from the stand-
ard offset of 9.5 and 22.5 mm) resulted in large morphological 
changes at both the radius (up to 34%) and the tibia (36%) (108). 
Whether this is also true in patients with OI is not known, and cur-
rently no studies have evaluated the effects of differences in ex-
tremity length on bone geometry and microarchitecture in individ-
uals with and without OI.  
 
Altered bone properties due to defective or decreased amounts of 
collagen are present in all patients with OI. Our study is further lim-
ited by the fact that we did not measure bone quality and did not 
undertake collagen analysis. However, we did participate in a study 
(outside the scope of this PhD), where we could confirm that the 
mutations leading to haplotype insufficiency seen in patients with 
OI type I lead to lower vBMD measures compared to patients with 
OI type IV (20). More patients with OI type III had missense muta-
tions in COL1A1 or COL1A2, leading to a qualitatively defective col-
lagen type 1, and had severely reduced aBMD and vBMD compared 
to patients with less severe OI (20). The quantitative defects in col-
lagen type 1 lowered the trabecular number compared to patients 
with OI type IV, in whom the structural bone parameters were 
more similar to previous observations in healthy bone (20).  
 
The study was the first to evaluate the bone phenotype in OI using 
HRpQCT and was strengthened by the age- and gender-matched 
reference group, which had participated in a large population-
based study of bone geometry and bone microarchitecture. The 
selection of participants in that study is described in detail in Han-
sen et al. (176). The study was powered to correct for confounders 
of bone mineral density, bone geometry, and bone microarchitec-
ture such as weight and smoking habits. 
8.1.3 Bias of clinical severity when comparing prevalence/risk of 
outcomes between different phenotypical groups 
The grouping of patients with OI according to Sillence’s classifica-
tion is based on clinical features, and mode of inheritance in the 
individual patient. The assessment of the clinical severity may be 
based on objective findings, when evaluating the patient for diag-
nosis, but the clinical severity is contingent on subjective interpre-
tation of these findings. In a newly proposed severity grading scale 
of OI the clinical features is further specified (6). This approach will 
aide clinicians and researchers to gather data that can be com-
pared across different clinics and clinical routines. The grouping of 
patients according to clinical severity does however introduce a 
bias to studies aimed at evaluating clinical outcomes between 
groups of patients with different clinical severity. Exemplified in OI 
when comparing the fracture risk in patients with severe OI to pa-
tients with mild OI. The grouping of the patients into severe, mod-
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erate and mild OI groups using fracture rates as one of the param-
eters which the patients are grouped according to, introduce a sys-
tematic error into the analysis as the patients are grouped accord-
ing to their risk of fractures. In other words the outcome is used to 
group the patients – any differences in outcome is therefore given. 
Any conclusions drawn from such a study will be subject to circular 
reasoning.      
 
Confounding by indication is a commonly used term that refers to 
an extraneous determinant of the outcome parameter that is pre-
sent if a perceived high risk or poor prognosis is an indication for 
intervention (177). It can be argued that the risks of certain clinical 
outcomes are confounded by indication (i.e. clinical severity / Sil-
lence’s type) in OI. A confounder is associated with the exposure 
and the outcome, but cannot be an intermediate in the causal 
pathway between the exposure and the outcome. It can be dis-
cussed if the clinical severity is not a part in the causal pathway 
between the exposure (the mutation) and the risk of outcomes 
(e.g. fractures). Studies correlating genotype, or collagen defect, to 
clinical outcomes would not be biased by the classification accord-
ing to clinical features. Many of the included studies in this review, 
however, base their classification of the different types of OI on the 
clinical features of the disease.  
 
This classification-bias is hard to overcome. When describing the 
natural history of OI and thus describing the differences between 
the phenotypes of the disease we must acknowledge that by defi-
nition the most severe individuals are defined as the most severely 
affected individuals when they were grouped. Any between group 
differences will be given. The clinical grouping of the patients does 
however make it possible to compare patients within the same 
clinical syndromes e.g. treatment effect. 
8.2 DISCUSSION OF THEMES INCLUDED IN THIS THESIS 
8.2.1 Causes of death in OI 
We found that patients with OI had increased risk of all-cause mor-
tality compared to a reference population (HR: 2.90 [95% CI: 2.3-
3.6], women HR 2.4 [95% CI: 1.8-3.3], men HR 3.7 [95% CI: 2.6-5.2]) 
(1). This resulted in a lower median survival time of 9.5 years in 
men with OI and 7.1 years in women with OI compared to a refer-
ence population. There was also an increased relative risk of death 
due to respiratory disease (SHR 3.1 [95% CI: 1.4-6.9]), gastrointes-
tinal disease (SHR 4.2 [95% CI: 1.6-10.8]), and external causes of 
mortality and morbidity (including trauma and fractures) (SHR 4.7 
[95% CI: 1.4-16.3]) when comparing patients with OI to the refer-
ence population. Death due to cardiovascular disease was fre-
quently reported in OI, but there was no increased relative risk 
compared to the reference population of randomly selected indi-
viduals from the general population. 
 
The studies included in this review included patients born over the 
last century, and this may bias the results. Firstly, much has 
changed in neonatal treatment options and survival of severely af-
fected patients has increased during the last decades. Second, 
mortality rates following and treatment options for common ill-
nesses such pneumonia may have changed over the time course of 
the different studies. In studies including a matched reference 
group this would not alter the relative risk between the groups for 
all cause mortality as the gains would positively affect the outcome 
in both groups, but when comparing the results across studies this 
may influence the results and generalisability to the current OI 
population. 
 
Any evaluation of causes of death will be subject to competing risk 
bias. This can be illustrated by an example of a fictive disease that 
only occurs in persons over 75 years of age. If the exposed group 
has markedly reduced survival compared to the unexposed group, 
their risk of developing the disease is lower simply because many 
will die before reaching the age where they will be at risk of the 
disease. We took this into account in our analysis of the causes of 
death in OI by using a competing risk regression model to evaluate 
the relative risk for the different causes of death in patients with 
OI compared to the reference population. McAllion and Peterson 
(43) did not take this into account when they evaluated the causes 
of death in OI. They made no direct comparisons to the general 
population but relied on the proportion of people dying from a 
given disease in the general population (from official mortality sta-
tistics) and compared this to the mortality observed in patients 
with OI.  
8.2.2 Fractures in OI 
We found that patients with OI have increased risk of fractures 
throughout their life compared to the reference population of ran-
domly selected individuals from the general population (IRR 8.1 
[95% CI: 7.5-8.8]). The relative risk of fractures declined with age. 
We showed that fractures occurred with the same pattern as seen 
in the general population, with a peak during the toddler and ado-
lescent years (IR 233.9 [95% CI: 219.9-247.8] per 1000 person 
years), fewer fractures during adulthood (IR 84.5 [95% CI: 75.5-
93.8] per 1000 person years), and increased fracture rates in the 
elderly (IR 111.9 [95% CI: 81.8-113.0] per 1000 person years in 
women over 55). 
 
Children with OI are likely to be more susceptible to long bone frac-
tures when they start to walk and become more active, in part due 
to falls. In a British study of childhood fractures, the peak fracture 
rates were at age 11-15 years (97), which was remarkably close to 
the age at which the disconcordance between height gain and ac-
crual of vBMD is most pronounced (97, 178). Rauch et al. (116) 
found that vBMD in the shaft of the radius was increased in chil-
dren with OI type I due to increased cortical area and vBMD. This 
should result in a protective mechanism for long bone fractures in 
OI in this age group, so we must therefore consider other theories 
to explain the higher fracture rate. The growing skeleton adapts to 
the needs of increased bone strength and body weight, but there 
seems to be a lag in bone strength during periods of accelerated 
growth as seen during the pubertal growth spurt, meaning that 
weight-bearing bone can only sustain smaller traumas before 
breaking (179). We speculate that the inapt gains in bone strength 
during growth could explain some of the increased fracture rates 
seen in patients with OI during the first two decades of life. 
 
It is likely that adults with OI have learned to live with their disease 
and make choices in daily activity that will lower their fracture risk. 
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This can explain some of the decrease in fracture rates in the adult 
life, however there are few data to support this claim.  
 
With increasing age comes increasing risk and incidence of falls 
(180). Falls and bone loss could increase the fracture rates in el-
derly patients with OI. Furthermore, we should keep in mind that 
most patients with OI will reach a peak bone mass that is lower 
than non-OI individuals, leaving them even more exposed to frac-
tures. Only two studies evaluated fracture rates with increasing 
age and found increasing risk of fractures in women after meno-
pause compared to pre-menopausal women with OI (2, 93). While 
several fracture types showed increased IRR among women with 
OI aged 55 years and over, IRR was lower in men with OI in this age 
group compared to the reference population in our study. How-
ever, this may be due to the low number of older men in our cohort 
as a result of higher mortality (1). Patients with the most severe 
phenotypes of OI will have increased risk of premature death (43) 
and this could lead to positive selection of patients with milder 
phenotypes, and thus fewer fractures, in older age groups.  
 
Fracture rates and the risk of fractures varied between OI pheno-
types but also within each phenotype. Patients with OI were more 
likely to fracture lower limbs than upper limbs, and the absolute 
risk of an upper or lower limb fracture was close to 100% in pa-
tients with OI.  
8.2.3 BMD, bone geometry and bone microarchitecture in OI 
Patients with OI type I had altered bone geometry (lower total 
bone area in the radius), altered bone microarchitecture (de-
creased trabecular number, increased trabecular spacing, and 
greater trabecular inhomogeneity), and lower bone mass (de-
creased areal and volumetric BMD) compared to healthy reference 
individuals when assessed by HRpQCT and DXA. Our results suggest 
that the increased risk of fractures in patients with OI is a combined 
result of low bone mass, and altered bone microstructure and ge-
ometry. 
 
Patients with OI had lower total vBMD compared to the non-OI in-
dividuals. This could be explained by the low trabecular vBMD 
found in patients with OI. The total vBMD did not follow the same 
pattern as for aBMD, which decreased with increasing clinical se-
verity, as patients with the moderate phenotypes had the highest 
total vBMD. It is difficult to conclude how the cortical vBMD in pa-
tients with OI would typically differ from non-OI individuals based 
on the current literature. Cortical vBMD seems to be dependent on 
skeletal site, as cortical vBMD was higher in more proximal parts of 
the radius. One cause of the lower bone mass seen in patients with 
OI could be the altered osteoblast function, with osteoblasts se-
creting reduced amounts of biologically normal collagen type I, 
thus preventing accumulation of bone mass early in life and leading 
to a lower peak bone mass that will be associated with lower bone 
mass later in life (116). Rauch et al. (116) found differences in bone 
size (and thus bone mass) at various skeletal sites compared to 
non-OI children, as osteoblasts throughout the skeleton would be 
equally affected in children with OI type I. Another explanation 
could be related to the mechanostat theory that bone adapts to 
the bone strength needed to prevent fractures. The dendritic net-
work of osteocytes in the skeleton enables systematic signalling of 
needs for bone strength gain and may be activated at a set time. 
This activation may occur later in patients with OI, and the adapta-
tions in bone mass, geometry and microstructure result in bone 
strength below the actual mechanical needs (116). It could be ar-
gued that the governing of bone strength and the adaptation to 
changes in bone strength requirements works as they would in 
non-OI individuals, but are overruled by other factors such as in-
creased bone turnover, remodelling or an unknown factor (119).   
 
The literature consistently reported altered bone microarchitec-
ture in patients with OI. Patients with OI type IV (i.e. with abnormal 
collagen type I in normal quantities) had larger bone, higher bone 
mass, and ‘better’ microarchitecture than patients with type I OI  
(i.e. with normal collagen type 1 in low quantities) (20). In contrast, 
patients with OI type IV experienced more fractures than patients 
with OI type I, suggesting that the collagen defect plays an im-
portant role in the bone strength of patients with OI. It can be ar-
gued that the increased bone turnover in OI results in trabecular 
perforations, loss of thin trabeculae, and increased mean thickness 
of remaining trabeculae (possibly explaining the normal trabecular 
thickness found in OI). In contrast, a non-OI individual would have 
a higher number of trabeculae but with a lower mean thickness, 
and a wider range of trabecular thickness.  
 
All of the included studies were case series or cross-sectional in na-
ture, and only a few included a non-OI reference group. Most stud-
ies used age, gender, and height-specific normal values to calculate 
mean Z-scores for the parameters measured. This is a limitation to 
the quality of evidence. None of the studies were longitudinal or 
powered to evaluate whether the densitometric, geometric or mi-
crostructural parameters could predict fractures in patients with 
OI.  
8.2.4 Cardiovascular disease in OI 
We found that patients with OI had increased risk for heart failure 
(SHR 2.3 [95% CI: 1.4-3.7]), mitral valve regurgitation (SHR 6.3 [95% 
CI: 2.5-15.5]), aortic valve regurgitation (SHR 4.5 [95% CI: 1.4-
13.9]), and atrial fibrillation or flutter (SHR 1.7 [95% CI: 1.1-2.8]) 
compared to the reference population. However, we did not find 
any increased relative risk for vascular dissections or aneurisms.  
The sub-hazard ratio remained higher in the OI cohort after adjust-
ing for diseases that may cause valvulopathy, atrial arrhythmia, 
and heart failure. We found no increased risk of arterial dissection 
or aneurisms in patients with OI. The development of cardiovascu-
lar diseases in OI is multifactorial, as described in Figure 1 of Paper 
4.  
 
It could be argued that the increased prevalence of fractures and 
bone deformities seen in the more severe OI phenotypes lead to 
immobilisation and a less cardiovascular-healthy lifestyle. This 
could result in increased cardiovascular morbidity. In the Norwe-
gian study, 18% of the patients and none of the non-OI reference 
participants described dyspnoea during exertion (147). This could 
indicate more ischaemic heart disease in patients with OI, but also 
a lower fitness level in the OI cohort that results in more dyspnoea 
upon physical activity. We could not find an increased risk of is-
chaemic heart disease in our cohort. There were more ECG 
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changes in the Norwegian patients with OI compared to the refer-
ence individuals, but the authors found no increase in ischaemic 
heart disease in patients with OI (147). Hypertension was more 
prevalent in patients with OI, possibly due to changes in the vascu-
lar construction, as the collagen deficiency could alter the elasticity 
of the vascular system. Elasticity of the arterial tree is associated 
with hypertension (181). The increased prevalence of hypertension 
in OI could also be due to Berkson’s bias i.e. when a person is fol-
lowed for one disorder, the odds of finding another disorder is in-
creased, as evaluations will find subclinical disease. Patients with 
OI are closely followed at hospital centres, and systematic screen-
ing for other diseases is part of the normal work-up. This surveil-
lance bias is not present in the reference population, who will have 
to contact their own physician with symptoms of a disease. Treat-
ment for other disorders may this be started earlier in patients with 
OI than in the reference population, resulting in a lower cardiovas-
cular risk profile for patients with OI.    
 
Differences between patients with OI and a reference group in the 
prevalence of valvulopathies, heart failure and atrial arrhythmias, 
even after adjusting for known risk factors for mitral regurgitation, 
atrial fibrillation or flutter, and heart failure were found. This sug-
gests that the decreased collagen type 1 seen in OI could have a 
role in the development of cardiovascular disease in OI. 
8.3 CONTRIBUTION TO THE OI FIELD 
Our studies have provided new knowledge on the natural history 
of OI and the risks of skeletal and non-skeletal morbidity in OI. The 
epidemiological studies have long-term follow-up of a large num-
ber of patients and a representative reference population, allowing 
detailed analysis of risks and disease rates in patients with OI com-
pared to the general population, even for outcomes with low basal 
rates. Large, population-based longitudinal studies are generally 
lacking in the OI field due to the low incidence of the disease. Find-
ings from studies on bone structure and geometry using traditional 
histomorphometric analysis of bone biopsies in adults with OI need 
to be corroborated by studies using more advanced stereological 
techniques such as HR-pQCT. We were the first to evaluate bone 
mineral density, bone geometry, and bone microarchitecture in OI 
using HRpQCT. The new insight into bone phenotypes in OI in-
creases the knowledge of the natural history of OI and may in time 
shed light on the development of bone fragility in patients with OI. 
8.4 CONCLUSIONS 
We confirm that patients with OI have increased all-cause mortal-
ity, with a higher risk of death due to respiratory diseases, gastro-
intestinal diseases, and trauma (bone fractures). The shorter sur-
vival of patients with OI may be due to increased risk of neonatal 
death associated with more severe OI phenotypes, and to in-
creased risk of death throughout life (Paper I) (1).  
 
We confirm that patients with OI have increased risk of fractures 
throughout their life compared to the general population. Though 
the relative risk declines with age, fractures as a whole appear to 
have the same pattern of absolute rates as in the general popula-
tion, with a peak fracture rate during the toddler and adolescent 
years (IR 233.9 per 1000 person years), fewer fractures during 
adulthood (IR 84.5 per 1000 person years), and increased fracture 
rates in older women (IR 111.9 per 1000 person years) (Paper II) 
(2). 
 
We confirm that patients with OI type I had altered bone geometry 
(lower total bone area in the radius), altered bone microstructure 
(decreased trabecular number, increased trabecular spacing, and 
greater trabecular inhomogeneity), and lower bone mass (de-
creased areal and volumetric BMD) compared to healthy controls. 
Our results suggest that the increased risk of fractures in patients 
with OI type I is a combined result of the known altered bone ma-
trix quality, low bone mass, and altered bone microarchitecture 
and geometry (Paper III) (3). 
 
We confirm that patients with OI have increased risk of cardiovas-
cular disease. From the age of 50 years there was a significant in-
crease in cumulative incidence of heart failure, mitral valve regur-
gitation, aortic valve regurgitation, and atrial fibrillation or flutter 
in the OI cohort. The sub-hazard ratio remained higher in the OI 
cohort after adjusting for diseases that can cause valvulopathy, 
atrial arrhythmia, and heart failure, which is in line with the idea 
that the decreased collagen type 1 found in OI can cause these dis-
eases. We found no increased risk of vascular dissection, but larger 
systematic cross-sectional studies including a reference population 
are needed to further evaluate the risk of vascular abnormalities in 
patients with OI (Paper IV).  
9 FUTURE PERSPECTIVES AND RESEARCH 
The studies included in this thesis have generated new questions 
that will need to be answered to better understand the systemic 
implications of a genetic variants causing altered biosynthesis of 
collagen type 1, as seen in OI. It appears that OI is a generalised 
connective tissue disorder that influences most organ systems, but 
also affects the patient’s life choices due to fracture risk, pain, and 
hypermobility. Both clinical and epidemiological studies are 
planned for the future. 
9.1 FRACTURE PREDICTION IN OI 
Longitudinal data on the changes in bone mass, bone geometry, 
and bone microarchitecture are needed. We are currently re-eval-
uating the participants in Paper 3 to evaluate changes over time. 
This study is not powered to fracture prediction, but collaboration 
with other authors using baseline HRpQCT data to evaluate frac-
ture risk is being sought. There are no studies on the predictive 
value of DXA on fractures in OI, and there is no knowledge about 
the additive effect of HRpQCT derived parameters on fracture pre-
diction. These studies would help in identifying patients with OI 
who would benefit most from fracture prevention. Further studies 
on who to treat and when to initiate treatment and furthermore 
studies on how to monitor patients during fracture prophylactic 
treatment are needed.  
9.2 NON-SKELETAL MORBIDITY IN OI 
Cardiovascular, respiratory, and gastrointestinal morbidity may re-
duce longevity in patients with OI. The Danish health registers will 
enable us to evaluate the prevalence and relative risk of respiratory 
diseases in OI, such as asthma and COPD, as well as acute admis-
sions due to respiratory tract infections.  
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Patients with Ehlers-Danlos Syndrome, another connective tissue 
disorder, have significantly more frequent respiratory symptoms 
and reduced exercise tolerance compared to healthy non-Ehlers-
Danlos Syndrome individuals (OR: 3.1 [95% CI: 1.8-5.2] p<0.001) 
(182). During forced expiration in pulmonary function tests, ap-
proximately 60% of patients had lower airway collapse demon-
strated by flow volume loops (182). We would hypothesise that the 
same would be true in patients with OI, and a clinical trial including 
patients with different OI types and a matched reference popula-
tion, powered to allow correction for confounders of pulmonary 
function (such as smoking habits, differences in height and physical 
activity, scoliosis, and vertebral fractures) would enable us to test 
this hypothesis. Most of the current literature is cross-sectional, 
and a longitudinal design would strengthen the study. It would also 
allow us to evaluate the rate of change in pulmonary function over 
time. 
 
Using the Danish health registers to evaluate the risk of gastroin-
testinal ulcerative diseases would enable us to confirm the hypoth-
esis that the increased risk of death due to gastrointestinal dis-
eases is based on increased incidence of gastrointestinal ulcers. 
The increased bleeding time and easy bruising seen in OI may 
worsen the outcome of any gastrointestinal bleeding. It may be 
that the reduced collagen in the arterial walls of an OI patient does 
not promote platelet activation to form a platelet plug in the dam-
aged artery to the same degree as in non-OI individuals. Evaluation 
of platelet function and activation in patients with OI are also 
needed.  
 
There are no studies on the arterial tree and pulse wave velocity in 
patients with OI. We found increased prevalence of hypertension 
in the OI cohort, but have not explored what would normally be 
regarded as end-organ-damage in hypertensive patients. This 
would require a more detailed evaluation of the patients than is 
available through the Danish health registers. Evaluation of pulse 
wave velocity, 24-hour blood pressure, nephropathy, and reti-
nopathy would enable us to describe the degree of stiffness in to 
the arterial tree in patients with OI, and thus the effect of the col-
lagen defect on the vascular system.  
 
In our population-based cohort study, we did not find any differ-
ences between the OI group and the reference population in prev-
alence of vascular dissection or aneurisms. The extent of underre-
porting or under-diagnosis of these conditions in OI is unknown. A 
systematic screening for aorta aneurisms in the general population 
of Southern Denmark is currently underway, and evaluating a 
group of patients with OI using the same protocol would identify 
any differences between patients with OI and the general popula-
tion. 
9.3 THE SOCIOECONOMIC CONSEQUENCES OF HAVING OI 
Hald et al. (183) compared the health-related quality of life 
(HRQoL) of 85 adults with mild to severe OI to that of the general 
population using the SF-36  questionnaire and normal reference 
material for Danish inhabitants. The study showed that patients 
with OI, regardless of severity, had significantly lower mean scores 
in domains describing physical HRQoL and lower mean physical 
component scores. In contrast, mental health scores did not gen-
erally differ between OI sub-types or compared to the general pop-
ulation. A mixed-methods systematic review, aimed at describing 
HRQoL in patients with OI, found that physical HRQoL in children 
and adults was poorer than that of the general population, 
whereas mental and psychosocial HRQoL were similar or better in 
patients with OI compared to the general population (184).  
 
In a Norwegian population-based study on activities of daily living 
(ADL), patients with OI scored well on the Sunnaas ADL Index (23). 
Most patients in the study were married, had children, were highly 
educated, and lived independently without organised assistance 
for the activities tested for in the study (23).  
 
In an interview study of 55 adults with OI type III and IV, the author 
concluded that patients with OI have high emotional endurance 
and cope well with adversity (185). In a mixed-methods systematic 
review, aimed at describing the psychosocial experiences of living 
with OI, the authors found that the patients demonstrated a strong 
drive for achievement in their academic, extracurricular, profes-
sional, and community involvements (186). 
 
The psychological resilience often seen in patients with OI sug-
gests that the group as a whole is able to cope with the disorder 
in a way that may compensate for some of the limitations they 
are faced with. Further research on adherence to the labour mar-
ket, education choices, and family life is needed to understand 
the socioeconomic consequences of OI. The Danish health regis-
ters would be a valuable tool for projects evaluating socioeco-
nomic differences between patients with OI and the general pop-
ulation. 
10. LITERATURE SEARCH STRATEGIES 
1.1 Causes of Death and life expectancy in OI 
We searched PubMed from 1962 until 1st May 2016, Embase 
classic and Embase from 1947 to 1st May 2016, and all avail-
able literature in the Cochrane Library until the 1st May 2016. 
Appendix 1.1.1 – PubMed Search Strategy and results 
 Search string Num-
ber of 
pub-
licati-
ons 
1 (("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "oste-
ogenesis imperfecta"[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "oste-
ogenesis imperfecta"[All Fields] OR 
("brittle"[All Fields] AND "bone"[All 
Fields] AND "disease"[All Fields]) OR 
"brittle bone disease"[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
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AND "imperfecta"[All Fields]) OR "oste-
ogenesis imperfecta"[All Fields] OR 
("fragilitas"[All Fields] AND "ossium"[All 
Fields]) OR "fragilitas ossium"[All 
Fields]) OR ("osteogenesis imper-
fecta"[MeSH Terms] OR ("osteogene-
sis"[All Fields] AND "imperfecta"[All 
Fields]) OR "osteogenesis imper-
fecta"[All Fields] OR ("lobstein's"[All 
Fields] AND "disease"[All Fields]) OR 
"lobstein's disease"[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "oste-
ogenesis imperfecta"[All Fields] OR 
("lobstein"[All Fields] AND "disease"[All 
Fields]) OR "lobstein disease"[All 
Fields]) OR (Lobstein[All Fields] AND 
("syndrome"[MeSH Terms] OR "syn-
drome"[All Fields])) OR (Lobstein's[All 
Fields] AND ("syndrome"[MeSH Terms] 
OR "syndrome"[All Fields])) OR 
(Bruck[All Fields] AND ("syn-
drome"[MeSH Terms] OR "syn-
drome"[All Fields])) OR (Fibrogene-
sis[All Fields] AND imperfecta[All 
Fields] AND ossium[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfect 
a"[All Fields]) OR "osteogenesis imper-
fecta"[All Fields] OR "osteopsathyro-
sis"[All Fields]) OR (Periostal[All Fields] 
AND ("abnormalities"[Subheading] OR 
"abnormalities"[All Fields] OR "apla-
sia"[All Fields]))) 
2 Causes of Death [MeSH Term] 39043 
3 Vital Statistics [MeSH Term] 736805 
4 Mortality [MeSH Term] 307135 
5 Death [MeSH Term] 128533 
6 Survival [MeSH Term] 4272 
7 Life Expectancy [MeSH Term] 14864 
8 #2 OR #3 OR #4 OR #5 OR #6 OR #7 852941 
9 #1 AND #8 154 
10 Limit to Danish, Norwegian or English 129 
 
Appendix 1.1.2 – Embase Search Strategy and results 
 Search string Number 
of pub-
lications 
1 exp osteogenesis imperfect / 6616 
2 (Osteogenesis imperfecta or Brittle 
Bone Disease or Fragilitas Ossium or 
Lobstein's Disease or Lobstein Dis-
ease or Lobstein syndrome or Lob-
stein's syndrome or Bruck syndrome 
or Fibrogenesis imperfecta ossium or 
Osteopsathyrosis or Periostal apla-
sia).mp. [mp=title, abstract, heading 
7394 
word, drug trade name, original title, 
device manufacturer, drug manufac-
turer, device trade name, keyword] 
3 exp “causes of death” 89880 
4 exp vital statistics 5779 
5 exp mortality 836775 
6 exp death 622487 
7 exp survival 800834 
8 exp life expectancy 38163 
9 #1 or #2 7394 
10 #3 or #4 or #5 or #6 or #7 or #8 1905273 
11 #9 and #10 280 
12 Limit #11 to publications in Danish, 
Norwegian or English 
242 
Appendix 1.1.3 – Cochrane Library Search Strategy and re-
sults 
 Search String Number 
of pub-
lications 
1 Osteogenesis Imperfecta (MeSH-Term) 39 
2 Osteogenesis imperfecta OR Brittle Bone 
Disease OR Fragilitas Ossium OR Lob-
stein's Disease OR Lobstein Disease OR 
Lobstein syndrome OR Lobstein's  syn-
drome OR Bruck syndrome OR Fibrogen-
esis imperfecta ossium OR Osteopsathy-
rosis OR Periostal aplasia 
64 
3 #1 OR #2 64 
 
1.2 Fracture rates in OI 
We searched PubMed from 1962 until 1st May 2016, Embase 
classic and Embase from 1947 to 17th June 2016, and all 
available literature in the Cochrane Library until 1st May 2016. 
Appendix 1.2.1 – PubMed Search Strategy and results 
 Search string Number of 
publicati-
ons 
1 (("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "os-
teogenesis imperfecta"[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "os-
teogenesis imperfecta"[All Fields] OR 
("brittle"[All Fields] AND "bone"[All 
Fields] AND "disease"[All Fields]) OR 
"brittle bone disease"[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "os-
teogenesis imperfecta"[All Fields] OR 
("fragilitas"[All Fields] AND "os-
sium"[All Fields]) OR "fragilitas os-
sium"[All Fields]) OR ("osteogenesis 
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imperfecta"[MeSH Terms] OR ("osteo-
genesis"[All Fields] AND "imper-
fecta"[All Fields]) OR "osteogenesis 
imperfecta"[All Fields] OR ("lob-
stein's"[All Fields] AND "disease"[All 
Fields]) OR "lobstein's disease"[All 
Fields]) OR ("osteogenesis imper-
fecta"[MeSH Terms] OR ("osteogene-
sis"[All Fields] AND "imperfecta"[All 
Fields]) OR "osteogenesis imper-
fecta"[All Fields] OR ("lobstein"[All 
Fields] AND "disease"[All Fields]) OR 
"lobstein disease"[All Fields]) OR (Lob-
stein[All Fields] AND ("syn-
drome"[MeSH Terms] OR "syn-
drome"[All Fields])) OR (Lobstein's[All 
Fields] AND ("syndrome"[MeSH 
Terms] OR "syndrome"[All Fields])) OR 
(Bruck[All Fields] AND ("syn-
drome"[MeSH Terms] OR "syn-
drome"[All Fields])) OR (Fibrogene-
sis[All Fields] AND imperfecta[All 
Fields] AND ossium[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "os-
teogenesis imperfecta"[All Fields] OR 
"osteopsathyrosis"[All Fields]) OR 
(Periostal[All Fields] AND ("abnormali-
ties"[Subheading] OR "abnormali-
ties"[All Fields] OR "aplasia"[All 
Fields]))) 
2 "fractures, bone"[MeSH Terms] OR 
("fractures"[All Fields] AND "bone"[All 
Fields]) OR "bone fractures"[All Fields] 
OR "fracture"[All Fields] 
231489 
3 ("epidemiology"[Subheading] OR "epi-
demiology"[All Fields] OR "inci-
dence"[All Fields] OR "inci-
dence"[MeSH Terms])  
2292132 
4 ("epidemiology"[Subheading] OR "epi-
demiology"[All Fields] OR "preva-
lence"[All Fields] OR "preva-
lence"[MeSH Terms])  
2139102 
5 #2 OR #3 OR #4 2685748 
6 #1 AND #5 1493 
7 Limit to Danish, Norwegian or English 1232 
 
Appendix 1.2.2 – Embase Search Strategy and results 
 Search string Number of pub-
lications 
1 exp osteogene-
sis imperfect / 
6669 
2 (Osteogenesis 
imperfecta or 
Brittle Bone Dis-
ease or Fragilitas 
Ossium or Lob-
stein's Disease 
or Lobstein Dis-
ease or Lobstein 
syndrome or 
Lobstein's syn-
drome or Bruck 
syndrome or Fi-
brogenesis im-
perfecta ossium 
or Osteopsathy-
rosis or Periostal 
aplasia).mp. 
[mp=title, ab-
stract, heading 
word, drug trade 
name, original ti-
tle, device manu-
facturer, drug 
manufacturer, 
device trade 
name, keyword] 
7452 
3 exp Fractures, 
bone/ 
255460 
4 #1 or #2 7452 
5 #4 AND #3 1718 
6 Limit #5 to publi-
cations in Dan-
ish, Norwegian 
or English 
1423 
Appendix 1.2.3 – Cochrane Library Search Strategy and re-
sults 
 Search String Number of pub-
lications 
1 Osteogenesis Imperfecta 
(MeSH-Term) 
39 
2 Osteogenesis imperfecta OR 
Brittle Bone Disease OR Fragil-
itas Ossium OR Lobstein's Dis-
ease OR Lobstein Disease OR 
Lobstein syndrome OR Lob-
stein's  syndrome OR Bruck 
syndrome OR Fibrogenesis im-
perfecta ossium OR Osteop-
sathyrosis OR Periostal aplasia 
102 
3 #1 OR #2 102 
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1.3 Bone mineral density, bone geometry and bone mi-
croarchitecture in OI 
We searched PubMed from1962 until 20th June 2016, Em-
base classic and Embase from 1947 to 17th June 2016, and 
all available literature in the Cochrane Library until 1st May 
2016. 
Appendix 1.3.1 – PubMed Search Strategy and results 
 Search string Number of 
publications 
1 (("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "os-
teogenesis imperfecta"[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "os-
teogenesis imperfecta"[All Fields] OR 
("brittle"[All Fields] AND "bone"[All 
Fields] AND "disease"[All Fields]) OR 
"brittle bone disease"[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "os-
teogenesis imperfecta"[All Fields] OR 
("fragilitas"[All Fields] AND "os-
sium"[All Fields]) OR "fragilitas os-
sium"[All Fields]) OR ("osteogenesis 
imperfecta"[MeSH Terms] OR ("osteo-
genesis"[All Fields] AND "imper-
fecta"[All Fields]) OR "osteogenesis 
imperfecta"[All Fields] OR ("lob-
stein's"[All Fields] AND "disease"[All 
Fields]) OR "lobstein's disease"[All 
Fields]) OR ("osteogenesis imper-
fecta"[MeSH Terms] OR ("osteogene-
sis"[All Fields] AND "imperfecta"[All 
Fields]) OR "osteogenesis imper-
fecta"[All Fields] OR ("lobstein"[All 
Fields] AND "disease"[All Fields]) OR 
"lobstein disease"[All Fields]) OR 
(Lobstein[All Fields] AND ("syn-
drome"[MeSH Terms] OR "syn-
drome"[All Fields])) OR (Lobstein's[All 
Fields] AND ("syndrome"[MeSH 
Terms] OR "syndrome"[All Fields])) 
OR (Bruck[All Fields] AND ("syn-
drome"[MeSH Terms] OR "syn-
drome"[All Fields])) OR (Fibrogene-
sis[All Fields] AND imperfecta[All 
Fields] AND ossium[All Fields]) OR 
("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All Fields] 
AND "imperfecta"[All Fields]) OR "os-
teogenesis imperfecta"[All Fields] OR 
"osteopsathyrosis"[All Fields]) OR 
(Periostal[All Fields] AND ("abnormali-
ties"[Subheading] OR "abnormali-
ties"[All Fields] OR "aplasia"[All 
Fields]))) 
5165 
2 "bone and bones"[MeSH Terms] OR 
("bone"[All Fields] AND "bones"[All 
Fields]) OR "bone and bones"[All 
Fields] 
557886 
3 "bone density"[MeSH Terms] OR 
("bone"[All Fields] AND "density"[All 
Fields]) OR "bone density"[All Fields] 
77038 
4 "bone matrix"[MeSH Terms] OR 
("bone"[All Fields] AND "matrix"[All 
Fields]) OR "bone matrix"[All Fields] 
31593 
5 ("bone and bones"[MeSH Terms] OR 
("bone"[All Fields] AND "bones"[All 
Fields]) OR "bone and bones"[All 
Fields] OR "bone"[All Fields]) AND 
Histomorphometry[All Fields] 
4287 
6 high-resolution[All Fields] AND periph-
eral[All Fields] AND quantitative[All 
Fields] AND ("tomography, x-ray com-
puted"[MeSH Terms] OR ("tomogra-
phy"[All Fields] AND "x-ray"[All Fields] 
AND "computed"[All Fields]) OR "x-ray 
computed tomography"[All Fields] OR 
("computerized"[All Fields] AND "to-
mography"[All Fields]) OR "computer-
ized tomography"[All Fields]) 
360 
7 HRpQCT [All Fields] 53 
8 HR-pQCT [All Fields] 332 
9 peripheral[All Fields] AND quantita-
tive[All Fields] AND ("tomography, x-
ray computed"[MeSH Terms] OR ("to-
mography"[All Fields] AND "x-ray"[All 
Fields] AND "computed"[All Fields]) 
OR "x-ray computed tomography"[All 
Fields] OR ("computerized"[All Fields] 
AND "tomography"[All Fields]) OR 
"computerized tomography"[All 
Fields]) 
1524 
10 quantitative[All Fields] AND ("tomogra-
phy, x-ray computed"[MeSH Terms] 
OR ("tomography"[All Fields] AND "x-
ray"[All Fields] AND "computed"[All 
Fields]) OR "x-ray computed tomogra-
phy"[All Fields] OR ("computerized"[All 
Fields] AND "tomography"[All Fields]) 
OR "computerized tomography"[All 
Fields]) 
9694 
11 QCT [All Fields] 1428 
12 "absorptiometry, photon"[MeSH 
Terms] OR ("absorptiometry"[All 
Fields] AND "photon"[All Fields]) OR 
"photon absorptiometry"[All Fields] OR 
"dual energy x ray absorptiometry"[All 
Fields] 
26771 
13 Dxa [All Fields] 8080 
14 Dexa [All Fields] 3516 
15 ("bone and bones"[MeSH Terms] OR 
("bone"[All Fields] AND "bones"[All 
Fields]) OR "bone and bones"[All 
Fields] OR "bone"[All Fields]) AND ge-
ometry[All Fields] 
5070 
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16 ("bone and bones"[MeSH Terms] OR 
("bone"[All Fields] AND "bones"[All 
Fields]) OR "bone and bones"[All 
Fields] OR "bone"[All Fields]) AND mi-
croarchitecture[All Fields] 
1824 
17 ("bone and bones"[MeSH Terms] OR 
("bone"[All Fields] AND "bones"[All 
Fields]) OR "bone and bones"[All 
Fields] OR "bone"[All Fields]) AND mi-
crostructure[All Fields] 
2442 
18  #2 OR #3 OR #4 OR #5 OR #6 OR #7 
OR #8 OR #9 OR #10 OR #11 OR #12 
OR #13 OR #14 OR #15 OR #16 OR 
#17  
638691 
19 #18 AND #19 1734 
20 Limit #19 to publications in Danish, 
Norwegian or English 
1470 
 
Appendix 1.3.2 – Embase Search Strategy and results 
 Search string Number of 
publicati-
ons 
1 exp osteogenesis imperfect / 6669 
2 (Osteogenesis imperfecta or Brittle 
Bone Disease or Fragilitas Ossium 
or Lobstein's Disease or Lobstein 
Disease or Lobstein syndrome or 
Lobstein's syndrome or Bruck syn-
drome or Fibrogenesis imperfecta 
ossium or Osteopsathyrosis or Peri-
ostal aplasia).mp. [mp=title, abstract, 
heading word, drug trade name, orig-
inal title, device manufacturer, drug 
manufacturer, device trade name, 
keyword] 
7452 
3 BMD.mp. or exp bone density/ 74239 
4 Exp Bone/ 761756 
5 Exp dual energy X ray absorptiome-
try/ 
25888 
6 Exp high resolution computer tomog-
raphy/ 
6472 
7 Bone Histomorphometry.mp. 1950 
8 #1 OR #2 7452 
9 #3 OR #4 OR #5 OR #6 OR #7 815277 
10 #8 AND #9 2625 
11 Limit #10 to Danish, English and 
Norwegian 
2155 
 
Appendix 1.3.3 – Cochrane Library Search Strategy and re-
sults 
 Search String Number of 
publicati-
ons 
1 Osteogenesis Imperfecta (MeSH-
Term) 
39 
2 Osteogenesis imperfecta OR Brittle 
Bone Disease OR Fragilitas Ossium 
OR Lobstein's Disease OR Lobstein 
Disease OR Lobstein syndrome OR 
102 
Lobstein's  syndrome OR Bruck syn-
drome OR Fibrogenesis imperfecta 
ossium OR Osteopsathyrosis OR 
Periostal aplasia 
3 #1 OR #2 102 
 
1.4 Cardiovascular diseases in OI 
We searched PubMed from 1962 until 13th June 2016, Em-
base classic and Embase from 1947 until 10th June 2016, and 
the Cochrane Library until 13th June 2016. 
Appendix 1.4.1 – PubMed Search Strategy and results 
 Search string Number of 
publications 
1 (("osteogenesis imperfecta"[MeSH 
Terms] OR ("osteogenesis"[All 
Fields] AND "imperfecta"[All Fields]) 
OR "osteogenesis imperfecta"[All 
Fields]) OR ("osteogenesis imper-
fecta"[MeSH Terms] OR ("osteogen-
esis"[All Fields] AND "imperfecta"[All 
Fields]) OR "osteogenesis imper-
fecta"[All Fields] OR ("brittle"[All 
Fields] AND "bone"[All Fields] AND 
"disease"[All Fields]) OR "brittle 
bone disease"[All Fields]) OR ("oste-
ogenesis imperfecta"[MeSH Terms] 
OR ("osteogenesis"[All Fields] AND 
"imperfecta"[All Fields]) OR "osteo-
genesis imperfecta"[All Fields] OR 
("fragilitas"[All Fields] AND "os-
sium"[All Fields]) OR "fragilitas os-
sium"[All Fields]) OR ("osteogenesis 
imperfecta"[MeSH Terms] OR ("os-
teogenesis"[All Fields] AND "imper-
fecta"[All Fields]) OR "osteogenesis 
imperfecta"[All Fields] OR ("lob-
stein's"[All Fields] AND "disease"[All 
Fields]) OR "lobstein's disease"[All 
Fields]) OR ("osteogenesis imper-
fecta"[MeSH Terms] OR ("osteogen-
esis"[All Fields] AND "imperfecta"[All 
Fields]) OR "osteogenesis imper-
fecta"[All Fields] OR ("lobstein"[All 
Fields] AND "disease"[All Fields]) 
OR "lobstein disease"[All Fields]) OR 
(Lobstein[All Fields] AND ("syn-
drome"[MeSH Terms] OR "syn-
drome"[All Fields])) OR (Lob-
stein's[All Fields] AND 
("syndrome"[MeSH Terms] OR "syn-
drome"[All Fields])) OR (Bruck[All 
Fields] AND ("syndrome"[MeSH 
Terms] OR "syndrome"[All Fields])) 
OR (Fibrogenesis[All Fields] AND 
imperfecta[All Fields] AND os-
sium[All Fields]) OR ("osteogenesis 
imperfecta"[MeSH Terms] OR ("os-
teogenesis"[All Fields] AND "imper-
fecta"[All Fields]) OR "osteogenesis 
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imperfecta"[All Fields] OR "osteop-
sathyrosis"[All Fields]) OR (Peri-
ostal[All Fields] AND ("abnormali-
ties"[Subheading] OR 
"abnormalities"[All Fields] OR "apla-
sia"[All Fields]))) 
2 Cardiovascular Disease [MeSH 
Term] 
20400196 
8 #1 AND #2 436 
9 Limit to Danish, Norwegian or Eng-
lish 
306 
 
Appendix 1.4.2 – Embase Search Strategy and results 
 Search string Number of 
publications 
1 exp osteogenesis imperfect / 6659 
2 (Osteogenesis imperfecta or Brittle 
Bone Disease or Fragilitas Ossium 
or Lobstein's Disease or Lobstein 
Disease or Lobstein syndrome or 
Lobstein's syndrome or Bruck syn-
drome or Fibrogenesis imperfecta 
ossium or Osteopsathyrosis or Peri-
ostal aplasia).mp. [mp=title, abstract, 
heading word, drug trade name, orig-
inal title, device manufacturer, drug 
manufacturer, device trade name, 
keyword] 
7440 
3 exp “cardiovascular disease” 3628002 
4 #1 or #2 7440 
5 #3 and #4 685 
6 Limit #5 to publications in Danish, 
Norwegian or English 
588 
 
Appendix 1.4.3 – Cochrane Library Search Strategy and re-
sults 
 Search String Number of 
publicati-
ons 
1 Osteogenesis Imperfecta (MeSH-
Term) 
39 
2 Osteogenesis imperfecta OR Brittle 
Bone Disease OR Fragilitas Ossium 
OR Lobstein's Disease OR Lobstein 
Disease OR Lobstein syndrome OR 
Lobstein's  syndrome OR Bruck syn-
drome OR Fibrogenesis imperfecta 
ossium OR Osteopsathyrosis OR 
Periostal aplasia 
102 
3 #1 OR #2 102 
11. SUMMARY 
11.1 ENGLISH SUMMARY 
Ostegenesis Imperfecta (OI) is a hereditary disease of the connec-
tive tissue caused by mutations to, mainly, the genes that are in-
volved in the biosynthesis of collagen type 1. Patients are grouped 
according to clinical severity and mode of inheritance according to 
Sillence's classification (originally 1979, updated 2014). According 
to our data, the population prevalence of OI in Denmark was 10.3 
per 100,000, with 575 patients registered with an OI diagnosis in 
the NPR and alive at the end of 2012 out of a total population of 
5,602,628 persons. Hallmarks of the disease are multiple fractures, 
blue sclera and varying degrees of bone deformities. Collagen type 
1 is the most abundant collagen in the body and is an important 
part of the structure and function of the heart and lungs, the skel-
eton and many other organs. We hypothesize that patients with OI 
will have increased prevalence and risk of fractures throughout life, 
lower bone mineral density (BMD), impaired bone microstructure 
and bone geometry and increased risk of cardiovascular diseases  - 
thus increased risk of all cause mortality compared to the general 
population. 
 
This thesis is a systematic search and narrative review covering the 
four main areas of interest of the PhD scholarship (risk and causes 
of death, fracture rates, bone mineral density, -geometry and -mi-
crostructure and cardiovascular diseases in OI). In addition to the 
review the thesis include the following four studies: 
 
1) Study 1 aimed to investigate the main causes of death and the 
risk of premature death in patients with OI in Denmark. We used a 
nationwide, registry-based, cohort study design, and included all 
patients registered in the National Patient Register with an OI di-
agnosis and a matched reference population randomly selected 
from the Danish Civil Service Register (matched 5:1, on gender and 
month and year of birth for each OI patient). We identified 687 pa-
tients with OI (25,615 person years at risk) and a reference popu-
lation of 3435 (132,131 person years at risk). One hundred and 
twelve patients with OI and 257 persons in the reference popula-
tion died during the observation period from 1977 to 2013. The all-
cause mortality hazard ratio between the OI cohort and the refer-
ence population was 2.90. The median survival time for men with 
OI was 72.4 years, compared to 81.9 in the reference population. 
The median survival time for women with OI was 77.4 years, com-
pared to 84.5 years in the reference population. Patients with OI 
had a higher risk of death from respiratory diseases, gastrointesti-
nal diseases and trauma. 
Conclusion: The all-cause hazard ratio for premature death in OI 
was 2.9 compared to the reference population. There was an in-
creased risk of death due to respiratory diseases, gastrointestinal 
diseases and death following trauma. 
 
2) Study 2 aimed to compare the fracture rates across the lifespan 
of patients with OI with that of the general population. Using a na-
tionwide, registry-based, cohort study design, we counted all frac-
tures registered from 1995 in the National Patient Register. The 
study included the same population as in study 1, but patients who 
died before 1995 were excluded. We identified 644 patients 
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(55.6% females) in the OI cohort through the Danish National Pa-
tient Register and 3,361 persons (55.2% females), randomly se-
lected from the Civil Registry System. A total of 416 patients with 
OI experienced a total of 1,566 fractures during the observation 
period of median 17.9 years [IQ-range: 12.4-18.0], adding up to 
10,137 person years. In comparison, 709 persons in the reference 
population experienced a total of 1,018 fractures during follow-up. 
Both male and female patients with OI had an increased fracture 
rate throughout their life. The fracture rate ratio for participants 
aged 0-19 years was 10.7, for participants aged 20-54 years 17.2, 
and for participants aged 55 years and over 4.1 when compared to 
the reference population. The highest fracture rate was seen in 
males with OI aged 0-19 years (257 fractures per 1000 person 
years). The fractures appear to follow the same pattern as in the 
general population, with a peak during the toddler and adolescent 
years (IR (incidence rates) 233.9 per 1000 person years), fewer 
fractures during adulthood (IR 84.5 per 1000 person years), and in-
creased fracture rate in older women (IR 111.9 per 1000 person 
years). 
Conclusion: Patients with OI have increased risk of fractures 
throughout life compared to the general population. The relative 
risk of fractures generally declines with age, however, increases in 
older women. 
 
3) Study 3 aimed to evaluate the bone mineral density (BMD) and 
bone geometry and -microarchitecture in patients with OI type I 
using a cross-sectional study design and evaluating the participants 
using HRpQCT. The study included 39 patients with OI type I, and 
39 healthy age and gender matched non-OI individuals. The pa-
tients were shorter than the reference group (159 ± 10 cm versus 
170 ± 9 cm, p < 0.001), but had similar body weight. In patients 
with OI, areal bone mineral density (aBMD) was 8% lower at the 
hip (p < 0.05) and 13% lower at the spine (p < 0.001) compared 
with the reference group. The trabecular volumetric bone mineral 
density (vBMD) was 28% lower in radius (p < 0.001) and 38% lower 
in tibia (p < 0.001) in patients with OI compared with the reference 
group. At radius, total bone area was 5% lower in OI patients than 
in controls (p < 0.05). In the tibia, cortical bone area was 18% lower 
in patients with OI (p < 0.001). In both radius and tibia the number 
of trabeculae was lower in patients compared to the reference 
group (35% and 38%, respectively, p < 0.001 at both sites). Further-
more, trabecular spacing was 55% higher in OI patients in both tibia 
and radius (p < 0.001 at both sites) when compared with reference 
group.  
Conclusion: Patients with type I OI have lower aBMD, vBMD, bone 
area, and trabecular number when compared with healthy age- 
and gender-matched individuals. 
 
4) Study 4 aimed to evaluate the risk of valvulopathies, atrial ar-
rhythmias, heart failure and vascular dissections in patients with OI 
using a nationwide, registry-based, cohort study design. The study 
included the same population as in study 1. As patients with OI 
have increased risk of premature death, the risk of cardiovascular 
diseases is biased by the competing risk of death. We corrected for 
this increased risk by using a competing risk regression model. We 
found that the OI population had increased relative risk of mitral 
valve regurgitation (Sub Hazard Ratio (SHR) 6.3), aortic valve regur-
gitation (SHR 4.5), atrial fibrillation/flutters (SHR 1.7) and heart fail-
ure (SHR 2.3) compared to the reference population. There was no 
difference in the risk of arterial aneurisms or arterial dissections. 
Conclusion: Patients with OI have increased risk of valvulopathies, 
atrial arrhythmias and heart failure when compared to the refer-
ence population, even after adjusting for risk factors for these car-
diovascular diseases - indicating that the quantitative or qualitative 
defects of collagen type 1 synthesis seen in OI influence the risk of 
these cardiovascular diseases in patients with OI.  
12.  BIBLIOGRAPHY 
 
1. Folkestad L, Hald JD, Canudas-Romo V, Gram J, Hermann AP, 
Langdahl B, et al. Mortality and Causes of Death in Patients with 
Osteogenesis Imperfecta. A Register-Based Nationwide Cohort 
Study. J Bone Miner Res. 2016 Jun 27. PubMed PMID: 27345018. 
2. Folkestad L, Hald JD, Ersboll AK, Gram J, Hermann AP, Langdahl 
B, et al. Fracture Rates and Fracture Sites in Patients with 
Osteogenesis Imperfecta - A Nationwide Register-Based Cohort 
Study. J Bone Miner Res. 2016 Jul 22. PubMed PMID: 27448250. 
3. Folkestad L, Hald JD, Hansen S, Gram J, Langdahl B, 
Abrahamsen B, et al. Bone geometry, density, and 
microarchitecture in the distal radius and tibia in adults with 
osteogenesis imperfecta type I assessed by high-resolution pQCT. 
J Bone Miner Res. 2012;27(6):1405-12. PubMed PMID: 22407910. 
4. Communities CotE. Communication from the Commission to 
the European Parliament, the Council, the European Economic 
and Social Committee and the Committee of the Regions - on 
Rare Diseases: Europe's challenges 2009 2009 [07. August 2016]. 
Available from: 
http://ec.europa.eu/health/ph_threats/non_com/docs/rare_com
_en.pdf. 
5. Andersen PE, Jr., Hauge M. Osteogenesis imperfecta: a genetic, 
radiological, and epidemiological study. Clin Genet. 1989 
Oct;36(4):250-5. PubMed PMID: 2805382. 
6. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: clinical 
diagnosis, nomenclature and severity assessment. Am J Med 
Genet A. 2014 Jun;164A(6):1470-81. PubMed PMID: 24715559. 
Pubmed Central PMCID: 4314691. 
7. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in 
osteogenesis imperfecta. J Med Genet. 1979 Apr;16(2):101-16. 
PubMed PMID: 458828. Pubmed Central PMCID: 1012733. 
8. Lindahl K, Langdahl B, Ljunggren O, Kindmark A. Treatment of 
osteogenesis imperfecta in adults. Eur J Endocrinol. 2014 
Aug;171(2):R79-90. PubMed PMID: 24760541. 
9. Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2016 Apr 
16;387(10028):1657-71. PubMed PMID: 26542481. 
10. Reeder J, Orwoll E. Images in clinical medicine. Adults with 
osteogenesis imperfecta. N Engl J Med. 2006 Dec 28;355(26):e28. 
PubMed PMID: 17192533. 
  DANISH MEDICAL JOURNAL   44 
 
 
 
11. Orioli IM, Castilla EE, Scarano G, Mastroiacovo P. Effect of 
paternal age in achondroplasia, thanatophoric dysplasia, and 
osteogenesis imperfecta. Am J Med Genet. 1995 Nov 6;59(2):209-
17. PubMed PMID: 8588588. 
12. Forlino A, Marini JC. Osteogenesis imperfecta. Lancet. 2015 
Nov 2. PubMed PMID: 26542481. 
13. Kuurila K, Kaitila I, Johansson R, Grenman R. Hearing loss in 
Finnish adults with osteogenesis imperfecta: a nationwide survey. 
Ann Otol Rhinol Laryngol. 2002 Oct;111(10):939-46. PubMed 
PMID: 12389865. 
14. Andersen PE, Jr., Hauge M, Justesen P, Host A. [Osteogenesis 
imperfecta in Funen County. A clinical epidemiologic study]. 
Ugeskrift for laeger. 1986 Oct 13;148(42):2685-7. PubMed PMID: 
3787774. Osteogenesis imperfecta i Fyns amt. En klinisk 
epidemiologisk undersogelse. 
15. Statistikbanken. FOLK1: Folketal den 1. i kvartalet efter 
kommune, køn, alder, civilstand, herkomst, oprindelsesland og 
statsborgerskab 2016 [cited 2016 04.04.2016]. Available from: 
http://www.statistikbanken.dk/statbank5a/selectvarval/savesele
ctions.asp. 
16. Pepin MG, Byers PH. What every clinical geneticist should 
know about testing for osteogenesis imperfecta in suspected 
child abuse cases. Am J Med Genet C Semin Med Genet. 2015 
Dec;169(4):307-13. PubMed PMID: 26566591. 
17. van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, 
Rohrbach M, et al. EMQN best practice guidelines for the 
laboratory diagnosis of osteogenesis imperfecta. Eur J Hum 
Genet. 2012 Jan;20(1):11-9. PubMed PMID: 21829228. Pubmed 
Central PMCID: 3234509. 
18. Steiner RD, Adsit J, Basel D. COL1A1/2-Related Osteogenesis 
Imperfecta. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, 
Stephens K, editors. GeneReviews. Seattle (WA)1993. 
19. Bardai G, Lemyre E, Moffatt P, Palomo T, Glorieux FH, Tung J, 
et al. Osteogenesis Imperfecta Type I Caused by COL1A1 
Deletions. Calcif Tissue Int. 2016 Jan;98(1):76-84. PubMed PMID: 
26478226. 
20. Hald JD, Folkestad L, Harslof T, Lund AM, Duno M, Jensen JB, 
et al. Skeletal phenotypes in adult patients with osteogenesis 
imperfecta-correlations with COL1A1/COL1A2 genotype and 
collagen structure. Osteoporos Int. 2016. PubMed PMID: 
27256333. 
21. Lindert U, Cabral WA, Ausavarat S, Tongkobpetch S, Ludin K, 
Barnes AM, et al. MBTPS2 mutations cause defective regulated 
intramembrane proteolysis in X-linked osteogenesis imperfecta. 
Nature communications. 2016;7:11920. PubMed PMID: 
27380894. Pubmed Central PMCID: 4935805. 
22. Sillence DO. Craniocervical abnormalities in osteogenesis 
imperfecta: genetic and molecular correlation. Pediatr Radiol. 
1994;24(6):427-30. PubMed PMID: 7700720. 
23. Wekre LL, Froslie KF, Haugen L, Falch JA. A population-based 
study of demographical variables and ability to perform activities 
of daily living in adults with osteogenesis imperfecta. Disabil 
Rehabil. 2010;32(7):579-87. PubMed PMID: 20136476. 
24. Widmann RF, Bitan FD, Laplaza FJ, Burke SW, DiMaio MF, 
Schneider R. Spinal deformity, pulmonary compromise, and 
quality of life in osteogenesis imperfecta. Spine. 1999 Aug 
15;24(16):1673-8. PubMed PMID: 10472101. Epub 1999/09/03. 
eng. 
25. Wekre LL, Kjensli A, Aasand K, Falch JA, Eriksen EF. Spinal 
deformities and lung function in adults with osteogenesis 
imperfecta. Clin Respir J. 2014 Oct;8(4):437-43. PubMed PMID: 
24308436. 
26. Calder AD. Radiology of Osteogenesis Imperfecta, Rickets and 
Other Bony Fragility States. Endocr Dev. 2015;28:56-71. PubMed 
PMID: 26138835. 
27. Di Lullo GA, Sweeney SM, Korkko J, Ala-Kokko L, San Antonio 
JD. Mapping the ligand-binding sites and disease-associated 
mutations on the most abundant protein in the human, type I 
collagen. J Biol Chem. 2002 Feb 8;277(6):4223-31. PubMed PMID: 
11704682. 
28. Lund AM, Jensen BL, Nielsen LA, Skovby F. Dental 
manifestations of osteogenesis imperfecta and abnormalities of 
collagen I metabolism. J Craniofac Genet Dev Biol. 1998 Jan-
Mar;18(1):30-7. PubMed PMID: 9594376. 
29. Pedersen U. Hearing loss and stapedectomy in patients with 
osteogenesis imperfecta. Connect Tissue Res. 1995;31(4):S49-53. 
PubMed PMID: 15612382. 
30. Evereklioglu C, Madenci E, Bayazit YA, Yilmaz K, Balat A, Bekir 
NA. Central corneal thickness is lower in osteogenesis imperfecta 
and negatively correlates with the presence of blue sclera. 
Ophthalmic Physiol Opt. 2002 Nov;22(6):511-5. PubMed PMID: 
12477015. 
31. Dahl JH. Adult Osteogenesis Imperfecta - Genotype, 
Phenotype and Quality of Life. Aarhus University: Aarhus 
University Health; 2015. 
32. Wallace DJ, Chau FY, Santiago-Turla C, Hauser M, Challa P, Lee 
PP, et al. Osteogenesis imperfecta and primary open angle 
glaucoma: genotypic analysis of a new phenotypic association. 
Mol Vis. 2014;20:1174-81. PubMed PMID: 25324685. Pubmed 
Central PMCID: 4153423. 
33. Arponen H, Makitie O, Waltimo-Siren J. Association between 
joint hypermobility, scoliosis, and cranial base anomalies in 
paediatric Osteogenesis imperfecta patients: a retrospective 
  DANISH MEDICAL JOURNAL   45 
 
 
 
cross-sectional study. BMC Musculoskelet Disord. 2014;15:428. 
PubMed PMID: 25494634. Pubmed Central PMCID: 4300610. 
34. Evensen SA, Myhre L, Stormorken H. Haemostatic studies in 
osteogenesis imperfecta. Scand J Haematol. 1984 Aug;33(2):177-
9. PubMed PMID: 6474094. 
35. Hathaway WE, Solomons CC, Ott JE. Platelet function and 
pyrophosphates in osteogenesis imperfecta. Blood. 1972 
Apr;39(4):500-9. PubMed PMID: 4334923. 
36. Oakley I, Reece LP. Anesthetic implications for the patient 
with osteogenesis imperfecta. AANA J. 2010 Feb;78(1):47-53. 
PubMed PMID: 20977129. 
37. Millington-Sanders C, Meir A, Lawrence L, Stolinski C. 
Structure of chordae tendineae in the left ventricle of the human 
heart. J Anat. 1998 May;192 ( Pt 4):573-81. PubMed PMID: 
9723984. Pubmed Central PMCID: 1467811. 
38. Vouyouka AG, Pfeiffer BJ, Liem TK, Taylor TA, Mudaliar J, 
Phillips CL. The role of type I collagen in aortic wall strength with a 
homotrimeric. J Vasc Surg. 2001 Jun;33(6):1263-70. PubMed 
PMID: 11389427. Epub 2001/06/05. eng. 
39. Thiele F, Cohrs CM, Flor A, Lisse TS, Przemeck GK, Horsch M, 
et al. Cardiopulmonary dysfunction in the Osteogenesis 
imperfecta mouse model Aga2 and human patients are caused by 
bone-independent mechanisms. Hum Mol Genet. 2012 Aug 
15;21(16):3535-45. PubMed PMID: 22589248. Pubmed Central 
PMCID: 3406754. Epub 2012/05/17. eng. 
40. Weis SM, Emery JL, Becker KD, McBride DJ, Jr., Omens JH, 
McCulloch AD. Myocardial mechanics and collagen structure in 
the osteogenesis imperfecta murine (oim). Circ Res. 2000 Oct 
13;87(8):663-9. PubMed PMID: 11029401. Epub 2000/10/13. eng. 
41. Phillips CL, Pfeiffer BJ, Luger AM, Franklin CL. Novel collagen 
glomerulopathy in a homotrimeric type I collagen mouse (oim). 
Kidney Int. 2002 Aug;62(2):383-91. PubMed PMID: 12109999. 
42. Ashournia H, Johansen FT, Folkestad L, Diederichsen AC, 
Brixen K. Heart disease in patients with osteogenesis imperfecta - 
A systematic review. Int J Cardiol. 2015 Oct 1;196:149-57. 
PubMed PMID: 26100571. 
43. McAllion SJ, Paterson CR. Causes of death in osteogenesis 
imperfecta. J Clin Pathol. 1996 Aug;49(8):627-30. PubMed PMID: 
8881910. Pubmed Central PMCID: 500603. Epub 1996/08/01. 
eng. 
44. Pedersen U, Charles P, Hansen HH, Elbrond O. Lack of effects 
of human calcitonin in osteogenesis imperfecta. Acta Orthop 
Scand. 1985 Jun;56(3):260-4. PubMed PMID: 4036580. 
45. Kuzemko JA. Osteogenesis imperfecta tarda treated with 
sodium fluoride. Arch Dis Child. 1970 Aug;45(242):581-2. PubMed 
PMID: 5506948. Pubmed Central PMCID: 1647640. 
46. Hald JD, Evangelou E, Langdahl BL, Ralston SH. 
Bisphosphonates for the prevention of fractures in osteogenesis 
imperfecta: meta-analysis of placebo-controlled trials. J Bone 
Miner Res. 2015 May;30(5):929-33. PubMed PMID: 25407702. 
47. Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate 
therapy for osteogenesis imperfecta. The Cochrane database of 
systematic reviews. 2014;7:CD005088. PubMed PMID: 25054949. 
48. Wekre LL, Eriksen EF, Falch JA. Bone mass, bone markers and 
prevalence of fractures in adults with osteogenesis imperfecta. 
Arch Osteoporos. 2011;6:31-8. PubMed PMID: 22207876. 
49. Ben Amor IM, Roughley P, Glorieux FH, Rauch F. Skeletal 
clinical characteristics of osteogenesis imperfecta caused by 
haploinsufficiency mutations in COL1A1. J Bone Miner Res. 
2013;28(9):2001-7. PubMed PMID: 23529829. 
50. Orwoll ES, Shapiro J, Veith S, Wang Y, Lapidus J, Vanek C, et al. 
Evaluation of teriparatide treatment in adults with osteogenesis 
imperfecta. J Clin Invest. 2014 Feb;124(2):491-8. PubMed PMID: 
24463451. Pubmed Central PMCID: 3904621. 
51. ClinicalTrails.gov. TREATOI 2016 [cited 2016 17th of June]. 
Available from: 
https://clinicaltrials.gov/ct2/show/NCT01679080?term=TREATOI
&rank=1. 
52. Hoyer-Kuhn H, Franklin J, Allo G, Kron M, Netzer C, Eysel P, et 
al. Safety and efficacy of denosumab in children with 
osteogenesis imperfecta - a first prospective trial. J Musculoskelet 
Neuronal Interact. 2016 Mar;16(1):24-32. PubMed PMID: 
26944820. 
53. Sinder BP, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff 
KM. Rapidly growing Brtl/+ mouse model of osteogenesis 
imperfecta improves bone mass and strength with sclerostin 
antibody treatment. Bone. 2015 Feb;71:115-23. PubMed PMID: 
25445450. Pubmed Central PMCID: 4274252. 
54. Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, 
Recknor C, et al. Effects of Romosozumab Compared with 
Teriparatide on Bone Density and Mass at the Spine and Hip in 
Postmenopausal Women with Low Bone Mass. J Bone Miner Res. 
2016 Aug 3. PubMed PMID: 27487526. 
55. Roberts TT, Cepela DJ, Uhl RL, Lozman J. Orthopaedic 
Considerations for the Adult With Osteogenesis Imperfecta. J Am 
Acad Orthop Surg. 2016 May;24(5):298-308. PubMed PMID: 
27100300. 
56. Porsborg P, Astrup G, Bendixen D, Lund AM, Ording H. 
Osteogenesis imperfecta and malignant hyperthermia. Is there a 
relationship? Anaesthesia. 1996 Sep;51(9):863-5. PubMed PMID: 
8882252. 
57. Chiarello E, Donati D, Tedesco G, Cevolani L, Frisoni T, Cadossi 
M, et al. Conservative versus surgical treatment of osteogenesis 
  DANISH MEDICAL JOURNAL   46 
 
 
 
imperfecta: a retrospective analysis of 29 patients. Clinical cases 
in mineral and bone metabolism : the official journal of the Italian 
Society of Osteoporosis, Mineral Metabolism, and Skeletal 
Diseases. 2012 Sep;9(3):191-4. PubMed PMID: 23289037. 
Pubmed Central PMCID: 3535993. 
58. Ruck J, Dahan-Oliel N, Montpetit K, Rauch F, Fassier F. Fassier-
Duval femoral rodding in children with osteogenesis imperfecta 
receiving bisphosphonates: functional outcomes at one year. J 
Child Orthop. 2011 Jun;5(3):217-24. PubMed PMID: 22654983. 
Pubmed Central PMCID: 3100465. 
59. Ashby E, Montpetit K, Hamdy RC, Fassier F. Functional 
Outcome of Humeral Rodding in Children With Osteogenesis 
Imperfecta. J Pediatr Orthop. 2016 Feb 10. PubMed PMID: 
26866647. 
60. Ashby E, Montpetit K, Hamdy RC, Fassier F. Functional 
Outcome of Forearm Rodding in Children With Osteogenesis 
Imperfecta. J Pediatr Orthop. 2016 Feb 2. PubMed PMID: 
26840274. 
61. Basse PN, Burchardt AJ, Hede A, Wagner A, Moller-Madsen B, 
Christensen SB. [Osteogenesis imperfecta. The effect of 
intramedullary nails in long tubular bones]. Ugeskr Laeger. 2001 
Aug 6;163(32):4195-7. PubMed PMID: 11510237. Osteogenesis 
imperfecta. Effekt af marvsom i lange rorknogler. 
62. Palomo T, Fassier F, Ouellet J, Sato A, Montpetit K, Glorieux 
FH, et al. Intravenous Bisphosphonate Therapy of Young Children 
With Osteogenesis Imperfecta: Skeletal Findings During Follow Up 
Throughout the Growing Years. J Bone Miner Res. 2015 
Dec;30(12):2150-7. PubMed PMID: 26059976. 
63. Rijks EB, Bongers BC, Vlemmix MJ, Boot AM, van Dijk AT, 
Sakkers RJ, et al. Efficacy and Safety of Bisphosphonate Therapy in 
Children with Osteogenesis Imperfecta: A Systematic Review. 
Horm Res Paediatr. 2015;84(1):26-42. PubMed PMID: 26021524. 
64. Van Brussel M, Takken T, Uiterwaal CS, Pruijs HJ, Van der Net 
J, Helders PJ, et al. Physical training in children with osteogenesis 
imperfecta. J Pediatr. 2008 Jan;152(1):111-6, 6 e1. PubMed PMID: 
18154911. 
65. Bouxsein ML, Karasik D. Bone geometry and skeletal fragility. 
Current osteoporosis reports. 2006 Jun;4(2):49-56. PubMed 
PMID: 16822403. 
66. Sattui SE, Saag KG. Fracture mortality: associations with 
epidemiology and osteoporosis treatment. Nat Rev Endocrinol. 
2014 Oct;10(10):592-602. PubMed PMID: 25091729. 
67. Bouxsein ML. Determinants of skeletal fragility. Best Pract Res 
Clin Rheumatol. 2005 Dec;19(6):897-911. PubMed PMID: 
16301186. Epub 2005/11/23. eng. 
68. Bishop N. Characterising and treating osteogenesis 
imperfecta. Early Hum Dev. 2010 Nov;86(11):743-6. PubMed 
PMID: 20846798. Epub 2010/09/18. eng. 
69. Singer RB, Ogston SA, Paterson CR. Mortality in various types 
of osteogenesis imperfecta. J Insur Med. 2001;33(3):216-20. 
PubMed PMID: 11558400. 
70. Paterson CR, Ogston SA, Henry RM. Life expectancy in 
osteogenesis imperfecta. BMJ. 1996 Feb 10;312(7027):351. 
PubMed PMID: 8611834. Pubmed Central PMCID: 2350292. 
71. Shapiro F. Consequences of an osteogenesis imperfecta 
diagnosis for survival and ambulation. J Pediatr Orthop. 1985 Jul-
Aug;5(4):456-62. PubMed PMID: 4019761. 
72. Spranger J, Cremin B, Beighton P. Osteogenesis imperfecta 
congenita. Features and prognosis of a heterogenous condition. 
Pediatr Radiol. 1982;12(1):21-7. PubMed PMID: 7063264. 
73. Stephens AS, Purdie S, Yang B, Moore H. Life expectancy 
estimation in small administrative areas with non-uniform 
population sizes: application to Australian New South Wales local 
government areas. BMJ open. 2013;3(12):e003710. PubMed 
PMID: 24302503. Pubmed Central PMCID: 3856616. 
74. Scherbov S, Dalkhat E. Significance of life table estimates for 
small populaitons: Simulation-based study of standard errors. 
Demographic Research. 2011 31 March 2011;24:527-50. 
75. National Center for Health Statistics (U.S.). U.S. decennial life 
tables for 1989-91. Volume 1. Hyattsville, Md. 
Washington, DC: U.S. Dept. of Health and Human Services, 
Centers for Disease Control and Prevention 
For sale by the U.S. G.P.O., Supt. of Docs.; 1997. 
76. Hawes MC. The use of exercises in the treatment of scoliosis: 
an evidence-based critical review of the literature. Pediatr 
Rehabil. 2003 Jul-Dec;6(3-4):171-82. PubMed PMID: 14713583. 
77. LoMauro A, Pochintesta S, Romei M, D'Angelo MG, Pedotti A, 
Turconi AC, et al. Rib cage deformities alter respiratory muscle 
action and chest wall function in patients with severe 
osteogenesis imperfecta. PLoS One. 2012;7(4):e35965. PubMed 
PMID: 22558284. Pubmed Central PMCID: 3338769. Epub 
2012/05/05. eng. 
78. Takken T, Terlingen HC, Helders PJ, Pruijs H, Van der Ent CK, 
Engelbert RH. Cardiopulmonary fitness and muscle strength in 
patients with osteogenesis imperfecta type I. J Pediatr. 2004 
Dec;145(6):813-8. PubMed PMID: 15580207. 
79. Falvo KA, Klain DB, Krauss AN, Root L, Auld PA. Pulmonary 
function studies in osteogenesis imperfecta. Am Rev Respir Dis. 
1973 Nov;108(5):1258-60. PubMed PMID: 4746589. 
  DANISH MEDICAL JOURNAL   47 
 
 
 
80. Johnson JD, Theurer WM. A stepwise approach to the 
interpretation of pulmonary function tests. Am Fam Physician. 
2014 Mar 1;89(5):359-66. PubMed PMID: 24695507. 
81. Godfrey MS, Jankowich MD. The Vital Capacity Is Vital: 
Epidemiology and Clinical Significance of the Restrictive 
Spirometry Pattern. Chest. 2016 Jan;149(1):238-51. PubMed 
PMID: 26356330. 
82. Janus GJ, Engelbert RH, Beek E, Gooskens RH, Pruijs JE. 
Osteogenesis imperfecta in childhood: MR imaging of basilar 
impression. Eur J Radiol. 2003 Jul;47(1):19-24. PubMed PMID: 
12810217. 
83. Patel RM, Nagamani SC, Cuthbertson D, Campeau PM, 
Krischer JP, Shapiro JR, et al. A cross-sectional multicenter study 
of osteogenesis imperfecta in North America - results from the 
linked clinical research centers. Clin Genet. 2015;87(2):133-40. 
PubMed PMID: 24754836. 
84. Lindahl K, Astrom E, Rubin CJ, Grigelioniene G, Malmgren B, 
Ljunggren O, et al. Genetic epidemiology, prevalence, and 
genotype-phenotype correlations in the Swedish population with 
osteogenesis imperfecta. Eur J Hum Genet. 2015 Aug;23(8):1042-
50. PubMed PMID: 25944380. Pubmed Central PMCID: 4795106. 
85. Diacinti D, Pisani D, D'Avanzo M, Celli M, Zambrano A, Stoppo 
M, et al. Reliability of vertebral fractures assessment (VFA) in 
children with osteogenesis imperfecta. Calcif Tissue Int. 2015 
Apr;96(4):307-12. PubMed PMID: 25694358. 
86. Brizola E, Staub AL, Felix TM. Muscle strength, joint range of 
motion, and gait in children and adolescents with osteogenesis 
imperfecta. Pediatr Phys Ther. 2014 Summer;26(2):245-52. 
PubMed PMID: 24675130. 
87. Aglan MS, Hosny L, El-Houssini R, Abdelhadi S, Salem F, 
Elbanna RA, et al. A scoring system for the assessment of clinical 
severity in osteogenesis imperfecta. J Child Orthop. 2012 
Mar;6(1):29-35. PubMed PMID: 23449141. Pubmed Central 
PMCID: 3303020. 
88. McKiernan FE. Musculoskeletal manifestations of mild 
osteogenesis imperfecta in the adult. Osteoporos Int. 2005 
Dec;16(12):1698-702. PubMed PMID: 15902417. 
89. Moore MS, Minch CM, Kruse RW, Harcke HT, Jacobson L, 
Taylor A. The role of dual energy x-ray absorptiometry in aiding 
the diagnosis of pediatric osteogenesis imperfecta. Am J Orthop 
(Belle Mead NJ). 1998 Dec;27(12):797-801. PubMed PMID: 
9880097. 
90. Davie MW, Haddaway MJ. Bone mineral content and density 
in healthy subjects and in osteogenesis imperfecta. Arch Dis Child. 
1994;70(4):331-4. PubMed PMID: 8185368. 
91. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J. 
Osteogenesis imperfecta: a clinical study of the first ten years of 
life. Calcif Tissue Int. 1992 Jan;50(1):36-41. PubMed PMID: 
1739868. 
92. Paterson CR, McAllion SJ, Shaw JW. Clinical and radiological 
features of osteogenesis imperfecta type IVA. Acta Paediatr 
Scand. 1987 Jul;76(4):548-52. PubMed PMID: 3630672. Epub 
1987/07/01. eng. 
93. Paterson CR, McAllion S, Stellman JL. Osteogenesis imperfecta 
after the menopause. N Engl J Med. 1984 Jun 28;310(26):1694-6. 
PubMed PMID: 6727948. 
94. Paterson CR, McAllion S, Miller R. Heterogeneity of 
osteogenesis imperfecta type I. J Med Genet. 1983 Jun;20(3):203-
5. PubMed PMID: 6876111. Pubmed Central PMCID: 1049046. 
95. Bauze RJ, Smith R, Francis MJ. A new look at osteogenesis 
imperfecta. A clinical, radiological and biochemical study of forty-
two patients. J Bone Joint Surg Br. 1975 Feb;57(1):2-12. PubMed 
PMID: 1117018. 
96. Falvo KA, Root L, Bullough PG. Osteogenesis imperfecta: 
clinical evaluation and management. J Bone Joint Surg Am. 1974 
Jun;56(4):783-93. PubMed PMID: 4835822. 
97. Cooper C, Dennison EM, Leufkens HG, Bishop N, van Staa TP. 
Epidemiology of childhood fractures in Britain: a study using the 
general practice research database. J Bone Miner Res. 2004 
Dec;19(12):1976-81. PubMed PMID: 15537440. 
98. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, 
Dawson A, et al. Long-term risk of osteoporotic fracture in 
Malmo. Osteoporos Int. 2000;11(8):669-74. PubMed PMID: 
11095169. 
99. Driessen JH, Hansen L, Eriksen SA, van Onzenoort HA, Henry 
RM, van den Bergh J, et al. The epidemiology of fractures in 
Denmark in 2011. Osteoporos Int. 2016 Jun;27(6):2017-25. 
PubMed PMID: 26846775. Pubmed Central PMCID: 4863906. 
100. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, 
Seeman E, et al. Fracture incidence and association with bone 
mineral density in elderly men and women: the Rotterdam Study. 
Bone. 2004 Jan;34(1):195-202. PubMed PMID: 14751578. 
101. Seeman E, Delmas PD. Bone quality--the material and 
structural basis of bone strength and fragility. N Engl J Med. 2006 
May 25;354(21):2250-61. PubMed PMID: 16723616. 
102. Viguet-Carrin S, Garnero P, Delmas PD. The role of collagen 
in bone strength. Osteoporos Int. 2006;17(3):319-36. PubMed 
PMID: 16341622. 
103. Bonadio J, Jepsen KJ, Mansoura MK, Jaenisch R, Kuhn JL, 
Goldstein SA. A murine skeletal adaptation that significantly 
increases cortical bone mechanical properties. Implications for 
human skeletal fragility. J Clin Invest. 1993 Oct;92(4):1697-705. 
PubMed PMID: 8408623. Pubmed Central PMCID: 288329. 
  DANISH MEDICAL JOURNAL   48 
 
 
 
104. Laib A, Ruegsegger P. Calibration of trabecular bone 
structure measurements of in vivo three-dimensional peripheral 
quantitative computed tomography with 28-microm-resolution 
microcomputed tomography. Bone. 1999 Jan;24(1):35-9. PubMed 
PMID: 9916782. 
105. Parfitt AM, Mathews CH, Villanueva AR, Kleerekoper M, 
Frame B, Rao DS. Relationships between surface, volume, and 
thickness of iliac trabecular bone in aging and in osteoporosis. 
Implications for the microanatomic and cellular mechanisms of 
bone loss. J Clin Invest. 1983 Oct;72(4):1396-409. PubMed PMID: 
6630513. Pubmed Central PMCID: 370424. 
106. Laib A, Hauselmann HJ, Ruegsegger P. In vivo high resolution 
3D-QCT of the human forearm. Technol Health Care. 1998 
Dec;6(5-6):329-37. PubMed PMID: 10100936. 
107. Burghardt AJ, Buie HR, Laib A, Majumdar S, Boyd SK. 
Reproducibility of direct quantitative measures of cortical bone 
microarchitecture of the distal radius and tibia by HR-pQCT. Bone. 
2010 Sep;47(3):519-28. PubMed PMID: 20561906. Pubmed 
Central PMCID: 2926164. 
108. Shanbhogue VV, Hansen S, Halekoh U, Brixen K. Use of 
Relative vs Fixed Offset Distance to Define Region of Interest at 
the Distal Radius and Tibia in High-Resolution Peripheral 
Quantitative Computed Tomography. J Clin Densitom. 2015 Apr-
Jun;18(2):217-25. PubMed PMID: 25690769. 
109. Kocijan R, Muschitz C, Haschka J, Hans D, Nia A, Geroldinger 
A, et al. Bone structure assessed by HR-pQCT, TBS and DXL in 
adult patients with different types of osteogenesis imperfecta. 
Osteoporos Int. 2015;26(10):2431-40. PubMed PMID: 25956285. 
110. Imbert L, Auregan JC, Pernelle K, Hoc T. Mechanical and 
mineral properties of osteogenesis imperfecta human bones at 
the tissue level. Bone. 2014 Aug;65:18-24. PubMed PMID: 
24803077. 
111. Veilleux LN, Lemay M, Pouliot-Laforte A, Cheung MS, 
Glorieux FH, Rauch F. Muscle anatomy and dynamic muscle 
function in osteogenesis imperfecta type I. J Clin Endocrinol 
Metab. 2014 Feb;99(2):E356-62. PubMed PMID: 24248189. 
112. Swinnen FK, De Leenheer EM, Goemaere S, Cremers CW, 
Coucke PJ, Dhooge IJ. Association between bone mineral density 
and hearing loss in osteogenesis imperfecta. Laryngoscope. 2012 
Feb;122(2):401-8. PubMed PMID: 22252604. 
113. Kutilek S, Bayer M. Quantitative ultrasonometry of the 
calcaneus in children with osteogenesis imperfecta. J Paediatr 
Child Health. 2010 Oct;46(10):592-4. PubMed PMID: 20626576. 
114. Garnero P, Schott AM, Prockop D, Chevrel G. Bone turnover 
and type I collagen C-telopeptide isomerization in adult 
osteogenesis imperfecta: associations with collagen gene 
mutations. Bone. 2009 Mar;44(3):461-6. PubMed PMID: 
19071236. 
115. Roschger P, Fratzl-Zelman N, Misof BM, Glorieux FH, 
Klaushofer K, Rauch F. Evidence that abnormal high bone 
mineralization in growing children with osteogenesis imperfecta 
is not associated with specific collagen mutations. Calcif Tissue 
Int. 2008 Apr;82(4):263-70. PubMed PMID: 18311573. 
116. Rauch F, Land C, Cornibert S, Schoenau E, Glorieux FH. High 
and low density in the same bone: a study on children and 
adolescents with mild osteogenesis imperfecta. Bone. 2005 
Nov;37(5):634-41. PubMed PMID: 16112635. 
117. Kok DJ, Uiterwaal CS, Van Dongen AJ, Kramer PP, Pruijs HE, 
Engelbert RH, et al. The interaction between Sillence type and 
BMD in osteogenesis imperfecta. Calcif Tissue Int. 2003 
Nov;73(5):441-5. PubMed PMID: 12958692. 
118. Gatti D, Colapietro F, Fracassi E, Sartori E, Antoniazzi F, Braga 
V, et al. The volumetric bone density and cortical thickness in 
adult patients affected by osteogenesis imperfecta. J Clin 
Densitom. 2003 Summer;6(2):173-7. PubMed PMID: 12794240. 
119. Rauch F, Travers R, Parfitt AM, Glorieux FH. Static and 
dynamic bone histomorphometry in children with osteogenesis 
imperfecta. Bone. 2000 Jun;26(6):581-9. PubMed PMID: 
10831929. 
120. Cepollaro C, Gonnelli S, Pondrelli C, Montagnani A, Martini S, 
Bruni D, et al. Osteogenesis imperfecta: bone turnover, bone 
density, and ultrasound parameters. Calcif Tissue Int. 
1999;65(2):129-32. PubMed PMID: 10430645. 
121. Lund AM, Molgaard C, Muller J, Skovby F. Bone mineral 
content and collagen defects in osteogenesis imperfecta. Acta 
Paediatr. 1999 Oct;88(10):1083-8. PubMed PMID: 10565454. 
122. Miller ME, Hangartner TN. Bone density measurements by 
computed tomography in osteogenesis imperfecta type I. 
Osteoporos Int. 1999;9(5):427-32. PubMed PMID: 10550462. 
123. McCarthy EF, Earnest K, Rossiter K, Shapiro J. Bone 
histomorphometry in adults with type IA osteogenesis 
imperfecta. Clin Orthop Relat Res. 1997 Mar(336):254-62. 
PubMed PMID: 9060512. 
124. Jones SJ, Glorieux FH, Travers R, Boyde A. The microscopic 
structure of bone in normal children and patients with 
osteogenesis imperfecta: a survey using backscattered electron 
imaging. Calcif Tissue Int. 1999 Jan;64(1):8-17. PubMed PMID: 
9868277. 
125. Paterson CR, Mole PA. Bone density in osteogenesis 
imperfecta may well be normal. Postgrad Med J. 1994 
Feb;70(820):104-7. PubMed PMID: 8170878. Pubmed Central 
PMCID: 2397654. 
126. Nuti R, Righi G, Turchetti V, Martini G, Lepore C. Total body 
and regional analysis by dual-photon absorptiometry in 
  DANISH MEDICAL JOURNAL   49 
 
 
 
osteogenesis imperfecta. Ann N Y Acad Sci. 1988;543:180-5. 
PubMed PMID: 3265046. 
127. Kurtz D, Morrish K, Shapiro J. Vertebral bone mineral content 
in osteogenesis imperfecta. Calcif Tissue Int. 1985 Jan;37(1):14-8. 
PubMed PMID: 3922591. 
128. Ste-Marie LG, Charhon SA, Edouard C, Chapuy MC, Meunier 
PJ. Iliac bone histomorphometry in adults and children with 
osteogenesis imperfecta. J Clin Pathol. 1984 Oct;37(10):1081-9. 
PubMed PMID: 6490947. Pubmed Central PMCID: 498944. 
129. Baron R, Gertner JM, Lang R, Vignery A. Increased bone 
turnover with decreased bone formation by osteoblasts in 
children with osteogenesis imperfecta tarda. Pediatr Res. 1983 
Mar;17(3):204-7. PubMed PMID: 6835724. 
130. Pedersen U, Nielsen HE, Jensen KJ, Elbrond O, Hansen HH. 
Bone mineral content in osteogenesis imperfecta tarda and in 
otosclerosis. J Laryngol Otol. 1979 Jul;93(7):697-702. PubMed 
PMID: 469399. 
131. Nielsen HE, Pedersen U, Hansen HH, Elbrond O. Serum 
calcitonin and bone mineral content in patients with osteogenesis 
imperfecta. Acta Orthop Scand. 1979 Dec;50(6 Pt 1):639-43. 
PubMed PMID: 532592. 
132. Riley FC, Jowsey J, Brown DM. Osteogenesis imperfecta: 
morphologic and biochemical studies of connective tissue. Pediatr 
Res. 1973 Sep;7(9):757-68. PubMed PMID: 4744658. 
133. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas 
P, et al. Predictive value of BMD for hip and other fractures. J 
Bone Miner Res. 2005 Jul;20(7):1185-94. PubMed PMID: 
15940371. 
134. Cummings SR, Melton LJ. Epidemiology and outcomes of 
osteoporotic fractures. Lancet. 2002 May 18;359(9319):1761-7. 
PubMed PMID: 12049882. 
135. Binkley N, Adler R, Bilezikian JP. Osteoporosis diagnosis in 
men: the T-score controversy revisited. Current osteoporosis 
reports. 2014 Dec;12(4):403-9. PubMed PMID: 25255867. 
Pubmed Central PMCID: 4275049. 
136. Boudreaux M, Sibonga JD. Advanced Hip Analysis: Simple 
Geometric Measurements Predict Hip Fracture Beyond Bone 
Mineral Density. Texas Orthopaedic Journal. 2015;1(2):109-22. 
137. McKiernan FE, Berg RL, Linneman JG. The utility of BMD Z-
score diagnostic thresholds for secondary causes of osteoporosis. 
Osteoporos Int. 2011 Apr;22(4):1069-77. PubMed PMID: 
20533026. 
138. Wang Q, Seeman E. Skeletal growth and peak bone strength. 
Best Pract Res Clin Endocrinol Metab. 2008 Oct;22(5):687-700. 
PubMed PMID: 19028352. 
139. Beck TJ, Ruff CB, Warden KE, Scott WW, Jr., Rao GU. 
Predicting femoral neck strength from bone mineral data. A 
structural approach. Invest Radiol. 1990 Jan;25(1):6-18. PubMed 
PMID: 2298552. 
140. Folkestad L, Hansen S, Ejersted C, Hald JD, Langdahl B, Gram 
J, et al. Hip Structure Analysis in patients with Osteogenesis 
Imperfecta compared with age and sex matched healthy controls. 
Bone. 2011;Conference Publication:S240. 
141. Bala Y, Zebaze R, Seeman E. Role of cortical bone in bone 
fragility. Curr Opin Rheumatol. 2015 Jul;27(4):406-13. PubMed 
PMID: 26002033. 
142. Roux JP, Wegrzyn J, Arlot ME, Guyen O, Delmas PD, 
Chapurlat R, et al. Contribution of trabecular and cortical 
components to biomechanical behavior of human vertebrae: an 
ex vivo study. J Bone Miner Res. 2010 Feb;25(2):356-61. PubMed 
PMID: 19653808. 
143. Reyes C, Pottegard A, Schwarz P, Javaid MK, Van Staa TP, 
Cooper C, et al. Real-Life and RCT Participants: Alendronate Users 
Versus FITs' Trial Eligibility Criterion. Calcif Tissue Int. 2016 
Sep;99(3):243-9. PubMed PMID: 27099132. 
144. Pfeiffer BJ, Franklin CL, Hsieh FH, Bank RA, Phillips CL. Alpha 
2(I) collagen deficient oim mice have altered biomechanical 
integrity, collagen content, and collagen crosslinking of their 
thoracic aorta. Matrix Biol. 2005 Oct;24(7):451-8. PubMed PMID: 
16095890. 
145. Radunovic Z, Wekre LL, Steine K. Right ventricular and 
pulmonary arterial dimensions in adults with osteogenesis 
imperfecta. Am J Cardiol. 2012 Jun 15;109(12):1807-13. PubMed 
PMID: 22459302. Epub 2012/03/31. eng. 
146. Radunovic Z, Wekre LL, Diep LM, Steine K. Cardiovascular 
abnormalities in adults with osteogenesis imperfecta. Am Heart J. 
2011 Mar;161(3):523-9. PubMed PMID: 21392607. Epub 
2011/03/12. eng. 
147. Radunovic Z, Steine K. Prevalence of Cardiovascular Disease 
and Cardiac Symptoms: Left and Right Ventricular Function in 
Adults With Osteogenesis Imperfecta. Can J Cardiol. 2015 
Nov;31(11):1386-92. PubMed PMID: 26416541. 
148. Al-Senaidi KS, Ullah I, Javad H, Al-Khabori M, Al-Yaarubi S. 
Echocardiographic Evidence of Early Diastolic Dysfunction in 
Asymptomatic Children with Osteogenesis Imperfecta. Sultan 
Qaboos Univ Med J. 2015 Nov;15(4):e456-62. PubMed PMID: 
26629370. Pubmed Central PMCID: 4664088. 
149. Karamifar H, Ilkhanipoor H, Ajami G, Karamizadeh Z, 
Amirhakimi G, Shakiba AM. Cardiovascular involvement in 
children with osteogenesis imperfecta. Iranian journal of 
pediatrics. 2013 Oct;23(5):513-8. PubMed PMID: 24800009. 
Pubmed Central PMCID: 4006498. 
  DANISH MEDICAL JOURNAL   50 
 
 
 
150. Migliaccio S, Barbaro G, Fornari R, Di Lorenzo G, Celli M, 
Lubrano C, et al. Impairment of diastolic function in adult patients 
affected by osteogenesis imperfecta clinically asymptomatic for 
cardiac disease: casuality or causality? Int J Cardiol. 2009 Jan 
9;131(2):200-3. PubMed PMID: 18207586. 
151. Vetter U, Maierhofer B, Muller M, Lang D, Teller WM, 
Brenner R, et al. Osteogenesis imperfecta in childhood: cardiac 
and renal manifestations. Eur J Pediatr. 1989 Dec;149(3):184-7. 
PubMed PMID: 2693094. Epub 1989/12/01. eng. 
152. Kalath S, Tsipouras P, Silver FH. Increased aortic root 
stiffness associated with osteogenesis imperfecta. Ann Biomed 
Eng. 1987;15(1):91-9. PubMed PMID: 3578962. 
153. Hortop J, Tsipouras P, Hanley JA, Maron BJ, Shapiro JR. 
Cardiovascular involvement in osteogenesis imperfecta. 
Circulation. 1986 Jan;73(1):54-61. PubMed PMID: 3940669. 
154. White NJ, Winearls CG, Smith R. Cardiovascular 
abnormalities in osteogenesis imperfecta. Am Heart J. 1983 
Dec;106(6):1416-20. PubMed PMID: 6650365. 
155. Schjerning Olsen AM, Fosbol EL, Gislason GH. The impact of 
NSAID treatment on cardiovascular risk - insight from Danish 
observational data. Basic Clin Pharmacol Toxicol. 2014 
Aug;115(2):179-84. PubMed PMID: 24690187. 
156. Klouman M, Asberg A, Wideroe TE. [The blood pressure level 
in a Norwegian population--the significance of inheritance and 
lifestyle]. Tidsskr Nor Laegeforen. 2011 Jun 17;131(12):1185-9. 
PubMed PMID: 21694744. Blodtrykksniva i en norsk befolkning--
betydningen av arv og livsstil. 
157. Pouliot-Laforte A, Veilleux LN, Rauch F, Lemay M. Physical 
activity in youth with osteogenesis imperfecta type I. J 
Musculoskelet Neuronal Interact. 2015 Jun;15(2):171-6. PubMed 
PMID: 26032209. 
158. Palomo T, Glorieux FH, Schoenau E, Rauch F. Body 
Composition in Children and Adolescents with Osteogenesis 
Imperfecta. J Pediatr. 2016 Feb;169:232-7. PubMed PMID: 
26593106. 
159. Chen F, Guo R, Itoh S, Moreno L, Rosenthal E, Zappitelli T, et 
al. First mouse model for combined osteogenesis imperfecta and 
Ehlers-Danlos syndrome. J Bone Miner Res. 2014 Jun;29(6):1412-
23. PubMed PMID: 24443344. 
160. Cropp GJ, Myers DN. Physiological evidence of 
hypermetabolism in osteogenesis imperfecta. Pediatrics. 1972 
Mar;49(3):375-91. PubMed PMID: 5010466. 
161. Pehrsson K, Larsson S, Oden A, Nachemson A. Long-term 
follow-up of patients with untreated scoliosis. A study of 
mortality, causes of death, and symptoms. Spine. 1992 
Sep;17(9):1091-6. PubMed PMID: 1411763. 
162. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. 
Relationship between lung function impairment and incidence or 
recurrence of cardiovascular events in a middle-aged cohort. 
Thorax. 2008 Jul;63(7):599-605. PubMed PMID: 18245145. 
163. Braunwald E. The war against heart failure: the Lancet 
lecture. Lancet. 2015 Feb 28;385(9970):812-24. PubMed PMID: 
25467564. 
164. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. 
Ischemic mitral regurgitation: long-term outcome and prognostic 
implications with quantitative Doppler assessment. Circulation. 
2001 Apr 3;103(13):1759-64. PubMed PMID: 11282907. 
165. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton 
PK. Risk factors for congestive heart failure in US men and 
women: NHANES I epidemiologic follow-up study. Arch Intern 
Med. 2001 Apr 9;161(7):996-1002. PubMed PMID: 11295963. 
166. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart 
failure: treatment considerations for a dual epidemic. Circulation. 
2009 May 12;119(18):2516-25. PubMed PMID: 19433768. 
167. Wan SH, Vogel MW, Chen HH. Pre-clinical diastolic 
dysfunction. J Am Coll Cardiol. 2014 Feb 11;63(5):407-16. PubMed 
PMID: 24291270. Pubmed Central PMCID: 3934927. 
168. Kemp CD, Conte JV. The pathophysiology of heart failure. 
Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. PubMed PMID: 
22227365. 
169. Vaziri SM, Larson MG, Benjamin EJ, Levy D. 
Echocardiographic predictors of nonrheumatic atrial fibrillation. 
The Framingham Heart Study. Circulation. 1994 Feb;89(2):724-30. 
PubMed PMID: 8313561. 
170. Kumler T, Gislason GH, Kirk V, Bay M, Nielsen OW, Kober L, 
et al. Accuracy of a heart failure diagnosis in administrative 
registers. Eur J Heart Fail. 2008 Jul;10(7):658-60. PubMed PMID: 
18539522. 
171. Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY, et al. 
Prevalence of atrial fibrillation in the general population and in 
high-risk groups: the ECHOES study. Europace. 2012 
Nov;14(11):1553-9. PubMed PMID: 22490371. 
172. Carlson MD, Morrison RS. Study design, precision, and 
validity in observational studies. J Palliat Med. 2009 Jan;12(1):77-
82. PubMed PMID: 19284267. Pubmed Central PMCID: 2920077. 
173. Lynge E, Sandegaard JL, Rebolj M. The Danish National 
Patient Register. Scandinavian journal of public health. 2011 
Jul;39(7 Suppl):30-3. PubMed PMID: 21775347. 
174. Thygesen LC, Daasnes C, Thaulow I, Bronnum-Hansen H. 
Introduction to Danish (nationwide) registers on health and social 
issues: structure, access, legislation, and archiving. Scandinavian 
  DANISH MEDICAL JOURNAL   51 
 
 
 
journal of public health. 2011 Jul;39(7 Suppl):12-6. PubMed PMID: 
21898916. 
175. Thygesen LC, Ersboll AK. Danish population-based registers 
for public health and health-related welfare research: 
introduction to the supplement. Scandinavian journal of public 
health. 2011 Jul;39(7 Suppl):8-10. PubMed PMID: 21775344. 
176. Hansen S, Shanbhogue V, Folkestad L, Nielsen MM, Brixen K. 
Bone microarchitecture and estimated strength in 499 adult 
Danish women and men: a cross-sectional, population-based 
high-resolution peripheral quantitative computed tomographic 
study on peak bone structure. Calcif Tissue Int. 2014 
Mar;94(3):269-81. PubMed PMID: 24146226. 
177. Salas M, Hofman A, Stricker BH. Confounding by indication: 
an example of variation in the use of epidemiologic terminology. 
American journal of epidemiology. 1999 Jun 1;149(11):981-3. 
PubMed PMID: 10355372. 
178. Rizzoli R, Bonjour JP, Ferrari SL. Osteoporosis, genetics and 
hormones. J Mol Endocrinol. 2001 Apr;26(2):79-94. PubMed 
PMID: 11241160. 
179. Rauch F, Schoenau E. The developing bone: slave or master 
of its cells and molecules? Pediatr Res. 2001 Sep;50(3):309-14. 
PubMed PMID: 11518815. 
180. Masud T, Morris RO. Epidemiology of falls. Age Ageing. 2001 
Nov;30 Suppl 4:3-7. PubMed PMID: 11769786. 
181. Wagenseil JE, Mecham RP. Elastin in large artery stiffness 
and hypertension. J Cardiovasc Transl Res. 2012 Jun;5(3):264-73. 
PubMed PMID: 22290157. Pubmed Central PMCID: 3383658. 
182. Morgan AW, Pearson SB, Davies S, Gooi HC, Bird HA. Asthma 
and airways collapse in two heritable disorders of connective 
tissue. Ann Rheum Dis. 2007 Oct;66(10):1369-73. PubMed PMID: 
17412739. Pubmed Central PMCID: 1994284. 
183. Dahl JH, Folkestad L, Harsløf T, Brixen K, Langdahl B. 
Determinants of health related quality of life in adults with 
osteogenesis imperfecta. Bone Abstracts. 2016;5(43rd Annual 
European Calcified Tissue Society Congress):P436. 
184. Dahan-Oliel N, Oliel S, Tsimicalis A, Montpetit K, Rauch F, 
Dogba MJ. Quality of life in osteogenesis imperfecta: A mixed-
methods systematic review. Am J Med Genet A. 2016 
Jan;170(1):62-76. PubMed PMID: 26365089. 
185. Ablon J. Personality and stereotype in osteogenesis 
imperfecta: behavioral phenotype or response to life's hard 
challenges? Am J Med Genet A. 2003 Oct 15;122A(3):201-14. 
PubMed PMID: 12966520. 
186. Tsimicalis A, Denis-Larocque G, Michalovic A, Lepage C, 
Williams K, Yao TR, et al. The psychosocial experience of 
individuals living with osteogenesis imperfecta: a mixed-methods 
systematic review. Qual Life Res. 2016 Feb 19. PubMed PMID: 
26894269. 
 
 
